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BACKGROUND. Smear microscopy has a poor sensitivity, cannot identify 
drug resistance, and when followed up with culture tests it takes several 
weeks to obtain a result. Furthermore, sputum-scarce and smear negative 
tuberculosis is difficult to diagnose. The use of biological samples other than 
sputum such as blood, urine and bronchoalveolar lavage fluid, are thus 
increasingly being used for diagnostic purposes. However, there is a low 
yield of rapid diagnostic tools, and the use of recently released commercially 
available technologies for tuberculosis diagnosis requires clarification. 
AIMS/OBJECTIVES AND METHODOLOGY. Five-hundred tuberculosis 
suspects were sequentially recruited as part of a larger prospective parent 
study. Thus, where possible, blood, sputum, urine and bronchoalveolar 
lavage fluid samples were available for use in the current study. Blood 
samples were used to evaluate the following: i) treatment-related serial 
changes in the magnitude of antigen-specific IFN-y release assay (IGRA: T-
SPOT TB and QFT GIT) responses to a range of antigens (RD-l, HBHA and 
PPD) in active TB patients, ii) the comparison of same-day versus delayed 
enumeration of TB-specific T cell responses and iii) whether delayed sample 
processing with and without the use of T-Cell Xtend, a proprietary reagent for 
use with the T-SPOT.TB assay, impacts upon test accuracy in a clinical 
setting. Urine samples were used to evaluate the performance outcomes of 
the Clearview® urine LAM ELISA, and the diagnostic accuracy of urine LAM 
in HIV-infected patients stratified by CD4 T cell categories. The diagnostic 
utility of the Xpert® MTB/RIF Assay using bronchoalveolar lavage fluid was 
also evaluated. 
RESUL TS.IGRAs: There was poor agreement between changes 
(conversions/reversions) in peripheral quantitative T cell responses 
compared to culture status in active TB patients followed-up over a standard 
6-month treatment period. T-Cell Xtend-independent median ELISPOT 
counts (spot forming cells per million peripheral blood mononuclear cells) 
were significantly higher at day 1 versus day 0 (114 vs.l00; n=66;p=O.03); 











conversion/reversion rate was 4.55%. By contrast, counts on day 0 without T-
Cell Xtend versus day 1 'with T-Cell Xtend were similar (56 vs. 56;n=215), 
inter-time-point agreement between the results was 97.17%, and the 
conversion/ reversion rate was 2.83 %. These findings were independent of 
HIV status. Clearview Urine LAM ELISA: Urine-LAM positivity was 
associated with HIV positivity (p=O.OO7) and test sensitivity, although very 
low, was significantly higher in HIV-infected compared to uninfected 
patients (21 % versus 6%; p<O.OOl), and also in HIV-infected participants with 
a CD4 <200 versus >200 cells/mm3 (37% versus 0%; p = 0.003). Urine-LAM 
remained highly specific in all subgroups (95%-100%). 25% of smear-
negative but culture-positive HIV-infected patients with a CD4 <200 
cells/mm3 were positive for urine-LAM. MTB/RIF Gene Xpert: When using 
BAL fluid from patients with suspected TB, the Xpert MTB/RIF assay had a 
specificity of 97%. However, although the sensitivity (almost 60%) was 
higher than that of smear microscopy, this difference was not significant. 
CONCLUSIONS. IGRAs: IGRAs do not appear to be a useful monitoring 
tool of tuberculosis in a high burden setting. Regarding delayed processing 
of blood for use in the T-SPOT TB assay, there was high agreement between 
results when samples were processed immediately and after a 24-hour delay. 
However, although the use of T-Cell Xtend appeared to reduce the number 
of conversions/reversions this reduction was not statistically significant. 
Larger studies are required to clarify these findings. Clearview Urine LAM 
ELISA: The overall usefulness of urine-LAM in a high burden primary care 
setting is limited. However, smear-negative HIV-infected TB patients with a 
CD4 count<200 cells/mm3, who would otherwise have required further 
investigation, may benefit from the use of urine LAM as a rule-in test. 
Although sensitivity in this group was modest, these preliminary findings 
suggest that future and adequately powered studies in a primary care setting 
should specifically target TB suspects who have advanced HIV infection. 
MTB/RIF Gene Xpert: The user-friendliness and the rapidity of acquiring 
results makes the MTB/RIF Gene Xpert assay a promising test for the 
diagnosis of TB using bronchoalveolar lavage fluid. However, larger studies 
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INTRODUCTION, HYPOTHESIS AND SPECIFIC 
AIMS OF THE PROJECT 
There is an ongoing search for rapid, inexpensive, easy-to-use, highly 
sensitive and specific point-of-care (POC) tests for tuberculosis diagnosis. 
Technologies such as Interferon Gamma Release Assays (T-SPOT.TB and the 
QuantiFERON TB Gold-In Tube test), the Clearview® LAM ELISA, and the 
Xpert® MTBjRIF Assay require clarification, especially in high burden 
settings. An additional concern is the difficulty in diagnosing smear negative 
or sputum-scarce tuberculosis, as well as patients who are co-infected with 
the human immunodeficiency virus (HIV). 
The study hypothesis is that serial antigen-specific treatment-related 
response tracking and novel rapid diagnostic tests for use with alternative 
sampling (blood, urine and bronchoalveolar lavage) may be useful tools for 
the diagnosis and treatment-monitoring of tuberculosis in a high burden 
setting. 
The first aim of the study is to evaluate treatment-related serial changes in 
the magnitude of antigen-specific IFN-y responses to a range of antigens 
[RD-l (ESAT-6, CFP-I0 and TB 7.7), HBHA and PPD] in active TB patients on 
a 6-month course of anti-TB treatment. Secondly, we aim to investigate 
whether delayed blood sample processing with and without the use of T-Cell 
Xtend, a proprietary reagent for use with the T-SPOT.TB assay, impacts upon 
test accuracy of the assay. The third aim is to evaluate performance outcomes 
of the Clearview® LAM ELISA when using urine samples in HIV-infected 
and uninfected patients with suspected TB, and to determine the diagnostic 
accuracy of urine LAM in HIV-infected patients stratified by CD4 T cell 
categories. The final aim is to evaluate the diagnostic utility of the Xpert® 
MTBjRIF Assay in a group of pulmonary TB suspects, who are unable to 
expectorate sputum (sputum-scarce TB) or who are smear negative, using 













1.B. TUBERCULOSIS: CAUSE, DISEASE PRESENTATION AND 
EPIDEMIOLOGY 
Tuberculosis (TB) is a common, and often deadly, infectious disease that has 
been present in humans since ancient times (Zink et aI2001). TB, or 'tubercles 
bacillus', most commonly affects the lung-producing tubercles and, was 
discovered in the late 19th century by Dr Robert Koch. Mycobacterium 
tuberculosis (M.tb), is a pathogenic, rod-shaped bacillus responsible for the 
majority of cases of TB in humans (Malik & Godfrey-Faussett 2005). 
Humans are the only reservoir for M.tb, and about two billion people, or one 
third of the world's population, are currently infected with this infectious 
pathogen, and two to three million people die from the disease annually 
(Cardona et a12006; Corbett et a12003; Malik & Godfrey-Faussett 2005). M.tb 
is spread through the air (mode of transmission and pathogenesis are 
described in detail later), when people who have the disease sneeze, spit or 
cough. TB most commonly affects the lungs, where it is referred to as 
I pulmonary tuberculosis' I while the term I extra pulmonary tuberculosis' 
refers to TB in extra pulmonary sites such as the central nervous system (in 
meningitis), bones and joints (Pott's disease of the spine), the lymphatic 
system (scrofula of the neck), kidneys (urogenital TB) and skin (Golden & 
Vikram 2005). Miliary or disseminated TB, which is most common in young 
children and immunocompromised subjects, is a serious form of the disease. 
(Smith 2003) 
The classic signs and symptoms of pulmonary TB are a chronic cough of 
more than 2 to 3 weeks, chest pain and expectoration of blood or blood-











loss, chills, fever, night sweats, and the production of sputum that changes 
from mucoid to purulent (Kumar 2007). However, about 90% of individuals 
infected with M.tb have asymptomatic latent TB infection (LTBI). World 
Health Organisation (WHO) TB reports reveal that new infections occur at a 
rate of about one per second (WHO Fact sheet N° 104, 2007). Approximately 
one in ten latent infections eventually progress to active disease, which kills 
more than 50% of its victims if left untreated (Onyebujoh & Rook 2004). 
Other strains of Mycobacteria that commonly affect humans are 
Mycobacterium leprae (M.leprae) and Mycobacterium avium (M.avium). M.leprae 
is the causative agent of leprosy and M.avium causes a TB-like disease that is 
mostly prevalent in acquired immunodeficiency syndrome (AIDS) sufferers. 
Mycobacteria can also affect non-human hosts. The etiologic agent of TB in 
cows is Mycobacterium bovis (M.bovis). If humans ingest unpasteurised milk, 
they can be infected with M.bovis, which is most closely related to M.tb. 
(Thoen et al 2006) The Bacille Calmette Guerin (BCG) vaccine is a live vaccine 
against TB in humans and is derived from an attenuated (or weakened) 
strain of M.bovis (Hope & Villarreal-Ramos 2007). It was in 1921 that two 
French doctors -Camille Guerin and Albert Calmette- developed the BCG 
vaccine (Hawgood 2007), which was found to be the first genuine success in 
immunising against TB and is currently still the only partially successful 
vaccine that is used worldwide (Hope & Villarreal-Ramos 2007). However, 
the incidence of TB has been increasing since the 1980s, with sub-Saharan 
Africa and South-East Asia being the worst affected regions. 
In 2005 the rate of TB infection in the Western Cape region of South Africa 
was the highest in the world, with an annual incidence of 1037 cases per 100 
000 population (Cowley et al 2008). In 2007 there were an estimated 13.7 
million people with chronic active disease, 9.3 million newly infected cases, 
and 1.8 million deaths, mostly in developing countries (World Health 
Organization 2009). Although TB is less common in developed countries, 











infeclion if lheir immune systems are compromised due to the use of 
immunosuppressive drugs, other forms of subslance abuse (for example, 
~moking and alcoholism), and AIDS (Griffith & Kerr I Y96). Co-infection with 
human immunoddicil'ncy virub (HIV) i~ onl' of thl' many known ho~t factors 
lhat makl' pl'opll' more sU5Ceptibll' 10 TB inlL>clion and tlK' ri~ of TB infection 
levels has been direclly linked 10 the HlV I AIDS pandemic (\VHO f.acl sheet 
N° IO-t 2007). The above-mentioned faclors, coupled with the neglect of TB 
control programs, have contributed to the re~urgence of the epidemic 
(l,ldemarco & Castro 20IB). Furthermore, the emergence of multi- and 
extremely drug n~~istant (MDR and XDR, rl'bjX,'cti\'cly) I Il ha~ ex,lCerlJah:li 
Ihl' probloelll (OI1<.'da ('I aI201l1c). 
1.9. STRUCTURE AND 1\1ICRORIOlOGY 
M,I/1 i., ,1 non-motill', acid-fa~t, obligate aerolX' lhat ib rod-shajX'd. TlK, ro,.b 
are u~uaJly 1--l, um in knglh and 0.3-0,6 um in width (Figuroe 1.1, A) (Kubica 
& \\'aynoe 198-l,). 
IS 
Figure 1.1. (,-\) Scanninf, ,,[<'(tron micrograrh image of M.lb roos, ~nd IB) Lif,ht 











M.tb is an intracellular parasite, and its primary host cell is the macrophage. 
This bacterium has a very slow generation time (15-20 hours), which 
contributes to the chronic nature of TB. M. tb cannot be classified as Gram-
positive or -negative, because this pathogen does not possess the 
characteristics of either of these classes of bacteria. However, certain 
structural characteristics of Gram-positive bacteria are present (Brennan & 
Nikaido 1995). The common layers of the bacterial Gram-positive cell wall 
are the inner plasma membrane, consisting of a lipid bilayer, and a thick 
layer of peptidoglycan which surrounds it. Both of these layers are present in 
M.tb, but there are also additional layers (Figure 1.2.), making the cell wall of 
M. tb thick and also unique in its complex composition. 
A layer composed of arabinogalactan surrounds the peptidoglycan layer and 
the outermost layer is composed of mycolic acid. Thus, the core unit of the 
envelope is referred to as the mycolyl-AG-peptidoglycan complex (MAPc) 
(Brennan & Nikaido 1995). More than 60% of the cell wall is composed of 
complex lipids, which consist of three major components, namely, mycolic 
acids, Cord factor and wax-D. The mycolic acid layer is thick, hydrophobic 
and prevents disinfectants from entering the cell. Thus, when colonies are 
grown in vitro, there are distinctive chains of cells present in the smears. 
Cord factor is responsible for the distinctive s-shaped cords that are formed 
by these chains of cells and is most abundant in virulent strains of M.tb. 
Wax-D is present in the cell envelope and is associated with immunogenicity 
(Brennan & Nikaido 1995). 
The outer surface of M.tb also contains complex surface glycolipids, which 
are most likely involved in mediating interactions between the pathogen and 
specialised cell surface receptors on the surface of macrophages (Schlesinger 
1993). The mannose receptor (MR) is one of the many receptors present on 



















Figure 1.2. MynJbtlcleri"'" Ild,.·rcu/",is cell wa II ,[ru,[u re 
l.ip'lilri]binomil]1n~n (li\M). ~ majoT surface lipoglycall ,md virulence factor 
<ls~,,,iJkd with ,v1.lh, seTVe< ~s a liganJ for the manno~e receptor. LAM's 
rrin"lrl" function i, to inactivate m~crophages. which ,1l1ows for the 
dis,-<'mincltion ot mycob~cteria to other parts of the body, and to 'lCayenge 
oxid~tive r~Jic,ll~, which enable~ the bacteria to ~uryive (Ch,.1I1 el al 1<)91; 
Knutson el .II 1998). A~~ay~ u~ing antibodi.·s ~~"''Cific to 1 ,/\M <lntignl hi]\" 
been develo-peQ tn deled the prl,,,,,'nn' of L/\M TJl III inkctt',i illdivjdll~k 
I'he dda i Io'd I i It'r~ tun' rq""rd i ng til>' 1'';<.' (If LI\ M ilSS<1yS f,lT TB J iagl111~is will 










1.3. TRANSMISSION, PATHOGENESIS AND IMMUNE EVASION 
STRATEGIES 
M.tb interacts with the cells of the immune system. The innate immune 
response is the first line of defense against pathogen infection. It is an 
immediate, non-specific response, but the host does not receive long-lasting 
immunity. This long-lasting immunity is only conferred by the adaptive 
immune response, where memory T and B cells are involved (Janeway & 
Medzhitov 2002). Leukocytes (the most important cells of the innate immune 
system) include natural killer cells, mast cells and phagocytic cells such as 
macrophages, dendritic cells and neutrophils. Macrophages have been 
extensively studied and are known to be the most efficient phagocytes of the 
immune system. However, M.tb is able to evade the innate immune response 
and uses various evasion strategies that enable it to persist within 
macrophages (Clark-Curtiss & Haydel 2003). 
M.tb pathogenesis can generally be divided into five stages. Stage one 
occurs when droplet nuclei are inhaled. These droplet nuclei are expelled by 
active pulmonary TB sufferers during coughing, sneezing and also via any 
other form of contact with their sputum. Droplet nuclei containing the 
infectious organisms can r main suspended in the air for several hours and 
people who are in constant contact with active TB suffers are at an increased 
risk of being infected with the bacteria (Clark-Curtiss & HaydeI2003). 
When M.tb enters the alveolar passages, the first cells that the pathogen 
encounters are the resident alveolar macrophages. However, the 
macrophages are not activated and are thus unable to destroy the 
intracellular organisms (Prescott et al 2005). Pattern recognition receptors 
(these include toll-like receptors) are present on the cell surface of 
macrophages. There are distinct receptors that recognise and bind to specific 
pathogens. The specific binding of a pathogen by cell surface receptors 











extracellular particles and microorganisms. The macrophage mannose 
receptor, TLR-2 and complement receptor 3 (CR3) are a few of the receptors 
that are involved in the uptake of M.tb into macrophages (Ernst 1998; 
Schlesinger 1993). 
Generally, phagocytosis is initiated when bacteria bind to the host pattern 
recognition receptors. A signal cascade is initiated inside the cell which 
triggers the rearrangement of the cortical actin skeleton of the host cell, 
which is regulated by small Rho-dependent GTPases. The rearrangement of 
the actin cytoskeleton leads to the formation of pseudopods (invaginations of 
the plasma membrane) and the engulfment of the bacteria. These 
pseudopods fuse to form a phagosome. When most bacteria are 
phagocytosed, the phagosome fuses with an early endosome and acquire 
early endosomal proteins. Maturation into a late phagosome occurs after the 
exhange of material with late endosomes. The final step of phagosome 
maturation involves fusion with a lysosome to produce a phagolysosome. 
Lysosomal enzymes are released into the mature phagosome and toxic 
molecules (free radicals or reactive oxygen species) are produced (Aderem & 
Underhill 1999; Nathan & Shiloh 2000). However, research to date suggests 
that once M.tb has been phagocytosed, it evades the host's immune response 
by releasing virulence proteins that somehow inhibit the fusion of 
phagosomes into early endosomes within the macrophages, thereby 
preventing early endosomal maturation (Russell 2001). Hence, the formation 
of the phagolysosome cannot occur and there is no acidification of the 
phagosomal environment, which enables M.tb to survive within the 
macrophage. 
The exact mechanism whereby inhibition of phagosomal maturation occurs 
remains largely unknown, but it has been speculated that it is due to the 
modification of the phagosome membrane by a particular secreted protein, 
termed TACO (tryptophane aspartate-containing coat protein), which has 











thus the prolonged survival of M.tb in the intracellular environment (Ferrari 
et a11999; Gatfield & Pieters 2000). However, it is actually not clear whether 
the blocking of phagosomal maturation is absolutely vital for M.tb survival. 
The main point, though, is that M.tb is able to remain in the early 
phagosome, where it multiplies and grows (Russell 2001). 
The capsule of M.tb contains various polysaccharides, such as glucan, 
mannan and arabinomannan. Thus, M. tb has many other special 
mechanisms for cell entry. Besides binding indirectly via certain complement 
or Fc receptors, it can also bind directly to macrophage mannose receptors 
via the mannosylated glycolipid (LAM), as previously mentioned 
(Schlesinger 1993). The evasion tactic in the case of cell entry involves 
receptor selection. Binding to CR3 does not effectively stimulate the 
macrophage to the same extent as binding to other phagocytic receptors, 
because the production of reactive oxygen intermediates (ROls) by the host 
cell is reduced. M. tb interferes with the production of these ROls by 
bypassing the activation of respiratory burst and thus decreases cytotoxicity 
and cell cytotoxicity is also downregulated by compounds such as 
glycolipids and LAM. M.tb secretes a group of proteins known as the 
Antigen 85 complex. This complex is known to bind fibronectin, which may 
aid in the sheltering of bacteria from the cells of the immune system and 
prevent granuloma formation, but there is not enough evidence to prove 
this. 
The human toll-like receptor 2 (TLR-2) also plays a role in the uptake of M.tb 
(Noss et aI2(01). In previous studies it has been mentioned that Surfactant 
protein A (SP-A), a glycoprotein found on the surface of the alveolar 
passages, is able to upregulate the expression of the mannose receptor and 
therefore enhance the binding and uptake of M.tb by macrophages (Gaynor 
et al 1995). Ferguson and colleagues investigated another alveolar surface 
glycoprotein, surfactant protein D (SP-D). SP-D binds to lipoarabinomannan 











inhibit intracellular growth of M.tb within human macrophages by 
enhancing phagolysosome fusion (Ferguson et aI1999). 
The high lipid concentration in cell wall of M.tb results in resistance to 
antimicrobial agents, whereas the cord factor is known to be toxic to 
mammalian cells. However, the exact role of cord factor in M.tb virulence is 
unclear. Mycothiol is another compound that is secreted by M.tb and 
research to date suggests that it probably acts as an antioxidant for 
protection against toxic ROIs. KatG (catalase:peroxidase) is also an M.tb 
protein capable of detoxifying ROls (Ng et aI2004). 
Stage 2 of M.tb pathogenesis usually begins 7-21 days post-infection. The 
M.tb bacilli start to multiply within the naIve macrophages until the 
macrophages apoptose. Macrophages from the peripheral blood migrate to 
the site of infection and begin to phagocytose the bacteria. These 
macrophages are still not activated and cannot destroy the pathogen. 
During stage 3, T lymphocytes, which are constantly circulating in the blood, 
start to converge at the site of infection. This late stage of infection is referred 
to as acquired or adaptive immunity and is a more specific response, because 
it is only activated if the innate immune system fails to control infection 
(Orme 2004). Infected macrophages are able to migrate via tissue fluid to 
secondary lymphoid regions. The lymphocytes come into contact with the 
infected macrophages in secondary tissues, where bacterial antigen is then 
presented to either cytotoxic T cells or to helper T cells. Dendritic cells! 
which are also important phagocytes of the immune system, are also the 
most efficient antigen presenting cells and play a role in T cen activation in 
response to M.tb antigens. Dendritic cells are able to migrate and thus may 
also playa role in dissemination or spreading of infection in the body 
(Lipscomb & Masten 2002). Antigen presentation occurs via MHC class II 
receptors, on the surface of antigen presenting cells, to CD4 + T lymphocyte 
receptors, helper T cell pathways are activated to secrete cytokines, such as 











Tumour Necrosis Factor alpha (TNF-a) to destroy the intracellular pathogen 
through reactive oxygen and nitrogen intermediates (Romani et al1997). This 
response is referred to as the Thl (helper T cell 1) response. IFN-y is an 
important mediator of immunity and inflammation that and its key functions 
are mediated by cross-regulation of cellular responses to other cytokines 
(interleukin-2 and interleukin-12) and inflammatory factors. When antigens 
are presented via MHC class I receptors to CD 8+ T lymphocyte receptors, 
killer- or cytotoxic T cells directly kill the infected cells. In addition, long-
lasting immunity is conferred, because memory cells are generated, which, as 
the name implies, are long-lived cells that have undergone clonal expansion 
after encountering antigen (Prescott et al 2005). Therefore, a rapid immune 
response can be elicited if the pathogen is encountered in future. Interferon-
gamma release assays (IGRAs), which will be discussed in detail later, rely 
on the principle that sensitised T cells (effector memory cells) will rapidly 
produce IFN-y when they encounter the M.tb-specific antigens. By contrast, 
central memory T-cells are more likely to require several days in the presence 
of antigen before IFN-y is produced. 
As cellular mediated immunity builds up, the activated macrophages are 
thus capable of destroying M.tb and during this process granuloma 
formation takes place. Infected macrophages aggregate together in order to 
prevent further spread of the pathogen. T lymphocytes and other cells of the 
immune system surround the entire aggregation structure and release 
cytokines in order to activate the macrophages to destroy the bacteria. This 
entire fibrous structure is called a granuloma. The destruction of the M. tb 
bacilli results in the formation of the caseous, necrotic centre of the 
granuloma or tubercle (Houben et a12006; Nguyen & Pieters 2006). The M.tb 
bacilli are maintained in a steady, non-replicating viable state within the 
caseous centre of the granuloma. It has been postulated that this is due to the 
low oxygen and low pH environment that exists within the granulomatous 
centre. Therefore, some organisms enter into this state of dormancy and 
remain so for long periods of time. This state of infection is referred to as 











of the host immune system in the outcome of mycobacterial infection has 
been studied extensively for this state of infection. In a study performed by 
Dormans et aL 2004, the authors investigated the control of mycobacterial 
infections in humans and mice (Dormans et al 2004). It was found that the 
infections depend mainly on the macrophage activation, through the effect of 
Th1 type cytokines secreted by the infected marcrophages. IL-12 regulates 
the gamma-inteferon response and forms a feedback-loop to control 
infection (Romani et al 1997). Monocytes secrete IL-12 as part of a cellular-
mediated response in order to stimulate immature helper T cells to 
differentiate into Thl cells. The action of Th1 type cytokines thus causes 
inflammation, which may lead to the development of the tissue pathology 
associated with granulomas (Dormans et al 2004). Therefore, during this 
stage (stage 4), many activated macrophages can be found surrounding the 
tubercles (granulomas). 
It is important to emphasise that there is a difference between infection and 
disease. TB infection means that transmission has occurred (or in other 
words, M.tb is in the body), but the immune system is able to control the 
bacterial load. The problem arises when latent infections progress to the 
contagious active TB disea e. Progression to active TB typically occurs as a 
result of immune suppression, for example in people who become 
immunocompromised due to HIV infection, malnutrition, drug usage or any 
other factors that may cause extreme weakening of the immune system 
(Griffith & Kerr 1996). This is referred to as stage 5 of pathogenesis. For 
unknown reasons, the caseous centers of the granulomas liquify. M.tb is then 
able to mutiply rapidly extracellularly, because the liquid creates a 
favourable environment in which the bacilli can grow. The infection spreads 
out of the granulomatous tissue within the lungs (active pulmonary 
tuberculosis) or in secondary tissues (extrapulmonary tuberculosis). This 
person then has progressive active TB disease, which is symptomatic, highly 












1.4.1. The diagnosis of TB mostly relies on a combination of factors 
A complete medical evaluation of the individual suspected of having TB 
needs to be conducted, which includes recording the details of their medical 
history, and conducting a physical examination, a chest X-ray, 
microbiological examination (culturing of sputum or some other appropriate 
biological sample) and blood tests to seclude other diagnoses. The evaluation 
may include the tuberculin skin test (TST, also known as a Mantoux test), 
and in some cases even a surgical biopsy. Other details of the medical history 
include demographic risk factors for TB, prior exposure to TB, whether the 
patient's received TB treatment in the past, and whether there are any' other 
medical conditions that may increase the risk for TB disease, for example 
HIV infection. In the case of the physical examination, the physician's main 
objective is to assess the patient's general condition and observe other factors 
that may affect the treatment regimen. However, a physical examination 
alone cannot be used to confirm or rule out TB, because the only definitive 
way of diagnosing TB is by identifying M.tb in a biological sample (for 
example, sputum, cerebrospinal fluid, biopsied tissue, etc). However, the 
main problem is the difficulty in culturing this slow-growing bacterium in 
the laboratory (it may take 4 to 10 weeks for a positive blood or sputum 
culture). M.tb has historically been grown using Lowenstein-Jensen (LJ), 
Kirchner or Middlebrook (7H9 and 7HI0) media, but it takes up to 4-6 weeks 
to obtain visual colonies on these media (Drobniewski et al 2003). Even 
when using a more specialised form of Middlebrook media (7Hll), M.tb still 
takes at least 2 weeks to grow (Brennan & Nikaido 1995). If the patient is 
producing sputum, sputum smears and cultures are undertaken for acid-fast 
bacilli (AFB). The preferred method for microscopy is fluorescence 
microscopy (auramine-rhodamine staining), which has been shown to be 
more sensitive than the formerly used conventional method of Ziehl-Neelsen 











conclusive answer is obtained. However, new automated systems that are 
faster include the MB/BacT (2-3 weeks) (Brunello et al 1999), the BACTEC 
Mycobacterial Growth Indicator Tube (~13 days) (Diaz-Infantes et al 2000) 
and BACTEC 9000 (-10 days) (Pfyffer et al 1997). On average, 
the Microscopic-Observation Drug-Susceptibility (MODS) assay (Moore et al 
2006) takes only about 7 days to diagnose TB and is able to identify the 
presence of MDR TB much faster than conventional culture (Caviedes & 
Moore 2007). Thus, it has potential for assisting clinicians to help control the 
spread of infectious TB by diagnosing and treating the disease at an earlier 
stage. However, the specific limitations and benefits of MODs in clinical 
settings is that it is labour intensive and newer test developments are 
underway. Thus, the lengthy time to diagnosis, especially in high burden 
countries, using any of the above-mentioned culture testing options remains 
a limitation and there is an ongoing search for newer and novel rapid 
diagnostic tools that will help to significantly decrease the time-to-diagnosis 
gap. Without culture, any diagnosis made would be classified as 'presumed' 
or 'probable' TB by using X-rays or scans and/ or TST results. 
1.4.2. The Tuberculin Skin Test (TST) and the emergence of new 
technologies 
The interpretation of the TST depends on the individual's risk factors for 
infection such as exposure to other cases of TB (Pai & Menzies 2007b). 
Currently, LTBI is diagnosed in non-immunized subjects by a TST, which 
yields a delayed hypersensitivity type response to the M.tb-prepared extract 
of purified protein derivative (PPD). A major disadvantage of Tuberculin 
tests is false positives in the following instances: 1) if the patient has 
previously been immunised for TB, which is particularly the case in countries 
where routine BCG vaccination at birth is common (Rothel & Andersen 
2005),2) if the patient has past-cleared infection, or 3) if the patient is infected 
with environmental bacteria (Pai et al 2008b). Tuberculin tests also have the 











has malnutrition, Hodgkins lymphoma, sarcoidosis, or active TB disease (Pai 
& Menzies 2007b). 
Other laboratory methods are being developed and evaluated that offer the 
hope of cost-effective, rapid and more accurate TB testing. The Interferon 
release assays (I GRAs) are more specific markers of TB infection (Dheda et al 
2004b; Diel et al 2008; Pai et al 2008b). The detailed literature regarding the 
use of IGRAs for TB diagnosis will be reviewed later (Section 1.5). 
Furthermore, nucleic acid amplification tests (NAATs) have also emerged 
with the intended goal of enabling the rapid and accurate diagnosis of TB 
(Drobniewski et a12003; Ling et a12008). The detailed literature regarding the 
use of NAATs for TB diagnosis will be reviewed later (Section 1.6). 
1.4.3. Alternative sampling 
Another problem that clinicians are faced with, which has hugely 
contributed to the under-diagnosis of TB, is the difficulty of diagnosing 
sputum-scarce and smear-negative pulmonary TB (Gordin et a11989; Moore 
& Roper 2007). In patients who are unable to produce a sputum sample, 
common alternative sources for diagnosing pulmonary TB include 
performing sputum induction, bronchoscopies (with bronchoalveolar lavage, 
bronchial washings, and! or transbronchial biopsies), gastric washings, 
and fine-needle aspiration (trans-tracheal or -bronchial). In some cases, a 
more invasive technique is necessary, such as tissue biopsy. However, the 
low yield of rapid diagnostic tests for use with alternative sampling remains 
a problem. 
TB treatment is difficult to monitor as it requires long courses of multiple 
antibiotics. Furthermore, as mentioned previously, antibiotic resistance 
(MDR and XDR TB) is a growing problem. Prevention mainly relies on 
vaccination strategies and efficient screening programs. Thus, we cannot 











inexpensive diagnostic tests and the evaluation of existing tests, especially in 
the developing world. For the current study, we were particularly interested 
in using samples other than sputum (blood, urine and bronchoalveolar 
lavage fluid) to evaluate the use of IGRAs, the Clearview LAM assay, and 
MTB/RIF Gene Xpert assay, respectively, in a high burden clinical setting. 
1.5. INTERFERON-GAMMA RELEASE ASSAYS (IGRAs) 
1.5.1. What are IGRAs? 
Currently, there is no gold standard for diagnosing latent TB infection 
(LTBI). However, over the past decade, the development, validation and 
global recognition of antigen-specific interferon-gamma release assays 
(IGRAs) represents a 100-year change in the use of the traditional tuberculin 
skin test for the diagnosis of latent tuberculosis infection (LTBI) (Barnes 2001; 
Lalvani & Millington 2008; Pai et al 2008b), and have improved our 
understanding about TB in humans (Dheda et al 2009a; Pai et al 2006c; Pai & 
Menzies 2007b). IGRAs are based on the ability of the M.th region of 
difference 1 (RD1) antigens, early secretory antigen target 6 (ESAT-6) and 
culture filtrate protein 10 (CFP-IO), to stimulate host production of 
interferon-gamma. The T-SPOT.TB (Oxford Immunotec Ltd., London) and 
QuantiFERON-TB Gold (QFT-G) [Cellestis Ltd., Australia] assays are 
commercially available blood tests which use the M.th RDI antigens to 
identify the presence of TB by detecting the frequency of IFN-y-secreting 
CD4+ antigen-specific effector T cells in peripheral blood (Dheda et al 2009a; 
Dheda et al 2005) of infected individuals. Although both measure overnight 
«24 hours) IFN-y responses to the overlapping antigen-specific 
RDI peptides, these two IGRA tests are not equivalent (Ferrara et al 2006). 
The QFT -G is based on an ELISA format and detects the whole blood 
production of IFN-y (Mol & Koethe 2006; Todd 2006). QFT-G quantifies the 











assumption that LTBI test sensitivity should be at least as good as, or better 
than, sensitivity in active TB, investigators have used quantified TB exposure 
as a surrogate gold standard for LTBI. Using this strategy, several studies 
have shown test sensitivity between 78 and 100% when using both RD1 
antigens in either an ELISPOT or ELISA assay (Brock et al 2001; Chapman et 
al 2002; Lalvani et al 2001a). However, the optimal strategy that should be 
utilised to detect LTBI using IGRAs is controversial, especially due to the 
lack of sufficient prospective data. 
In 2006, a study by Wilkinson et al. (London) 16 LTBI patients receiving 
treatment were followed-up 2-6 weeks into treatment and at the end of 
treatment (12 weeks). Furthermore, an additional 17 subjects were recruited 
to determine the phenotype of the expanding T cell population in these L TBI 
patients. Briefly, PPD stimulated PBMCs were subjected to flow cytometry 
staining for CD4, CD45RO, IFN-y, CD38 and CD62L. The ELISPOT results 
showed that treatment of LTBI with isoniazid (INH) and rifampicin for 3 
months decreased the number of IFN-y-secreting T cells at the end of 
treatment, but not significantly (Wilkinson et aI2006). However, the fact that 
there were changes in the T cell responses early during the treatment of LTBI 
could be an indication of a possible surrogate marker of efficacy that cannot 
be dismissed and might be useful early during the early stages of treatment-
related clinical studies. Diagnosing and treating L TBI is a less important 
strategy in developing countries. In order to limit ongoing transmission, the 
main priority in the developing world is the diagnosis and treatment of large 
numbers of active TB cases. Currently, international guidelines mostly 
recommend the use of IGRAs for the diagnosis of L TBI, either alone (Mack et 
al 2009), or in conjunction with the TST (Dheda et al 2009a). One approach, as 
suggested by UK and Canadian guidelines, is to first perform a screening 
TST, and if the test is positive an IGRA can then be performed. However, this 
two-step approach relies on the assumption that the TST does not evoke 











Recently published data from our laboratory indicate that definite boosting 
of IFN-y responses occurs by day 7 after TST administration, and with other 
antigens by day 3 (van Zyl-Smit et al 2009). Thus, our findings suggest if a 
two-step strategy is used for IGRA testing, the IGRA should be performed by 
day 3 (i.e. at the time of reading of the TST). This approach is consistent with 
recent Canadian IGRA guidelines (Pai et aI2008a). 
1.5.3. Utility of IGRAs for the diagnosis of Active TB disease 
Timely diagnosis of active TB cases is essential for TB control. Isolation of 
M.tb can take up to 6 weeks and there is the risk of false negative culture 
results. Thus, an ideal test of active disease to enable clinicians to rule out a 
possible diagnosis is one that is rapid, highly specific and also has very few 
false-negatives, or in other words, is highly sensitive. The major limitations 
of current tests mostly arise from intra-patient immunogenetic differences 
that result in heterogeneous immune responses, and variability of antigen 
recognition according to the stage of the disease (Dheda et al 2007; 
Lyashchenko et aI1998). 
A study conducted in Korea, which is an area with a very high LTBI 
prevalence, showed that QFT-TB Gold and T-SPOT.TB have high sensitivity 
but reduced specificity for diagnosing patients with active TB (Kang et al 
2007). In a recently published meta-analysis of data from developed and 
developing countries, Diel and colleagues (Diel et a12010) reported that QFT-
TB GIT had a pooled specificity of almost 100% and sensitivity of 81 %, 
whereas T-SPOT.TB had a pooled specificity and sensitivity of 86% and 88%, 
respectively. In direct comparisons, the sensitivity of IGRAs surpassed that 
of tuberculin skin testing, and the authors concluded that IGRAs are superior 
to the TST for detecting confirmed active TB disease. However, it should be 
noted that although not precise, the IGRA and TST are the only available 
proxy markers of TB infection. Both tests are measures of T-cell priming and 











magnitude of exposure to M.tb (Dheda et a12009a; Pai et a12006c). However, 
exposure does not necessarily indicate the presence of potentially viable M.tb 
organisms in the tissue of individuals with LTBI, and there is a substantial 
amount of evidence for the TST, but not the IGRA, that treating individuals 
who test positive reduces the risk of possible subsequent development to 
active TB (Comstock 1978; Grzybowski et aI1975). 
A major drawback is that IGRAs cannot differentiate between active TB 
disease and LTBI (Dheda et al 2005; Lalvani 2007). Thus, IGRAs are not 
viewed as good rule-in tests. However, in individuals who are highly 
suspected of having active disease, but whose other diagnostic tests are 
negative, a positive IGRA result can help to support a presumed active TB 
diagnosis. Thus, in cases such as these, a positive result can be of value in 
initiating anti-TB treatment (Dheda et al 2005). A classic example of this 
scenario was reported by Richeldi and colleagues in the I Annals of Internal 
Medicine (Richeldi et al 2004). The authors described a case of MDR TB in an 
asymptomatic patient with a cavitating lesion that was detected on a CT scan 
(ie. highly suggestive a TB disease). The patients TST was found to be 
negative. However, an ELISPOT IGRA yielded a positive result. 
Thus, the question remains whether IGRAs can somehow be improved to 
accurately diagnose active disease. It is feasible to postulate that patients 
with a non TB diagnosis, for example cancer, should not have a high 
frequency of antigen-specific T cells at the site of disease. Therefore, it should 
be possible to diagnose active TB if there is a high frequency of M.tb-antigen-
specific T cells at the specific disease site. Indeed, quantitative antigen-
specific T-cell responses (using T-SPOT TB) have been shown to be accurate 
and useful for the diagnosis of pulmonary TB when using bronchoalveolar 
lavage (BAL) cells in both high and low-burden clinical settings (Dheda et al 
2009c; Jafari et al 2009). Recent work conducted by our laboratory (Lung 
Infection and Immunity Unit, Department of Medicine, University of Cape 
Town) suggests that although IGRAs may be useful for the 











current format of the assay, this diagnostic approach is not feasible in clinical 
practice (Cashmore et aI2010). However, is it perhaps possible to make use 
of the same approach using biological fluid obtained from other 
compartments? Although there is promising preliminary data from studies 
conducted by our group (Dheda et al 2009d) and other groups (Baba et al 
2008; Chegou et al 2008), it has been shown that IGRAs are not clinically 
useful for the diagnosis of pleural TB in high burden settings. The poor 
specificity reported in the above-mentioned studies, is most likely due to the 
migration of the M.th-specific T lymphocytes of non-TB patients, for example 
those with bacterial infection or cancer and other diseases, into the pleural 
compartment (Dheda et al 2009d). However, these findings may be different 
in a low burden setting. Preliminary data regarding the investigation of the 
clinical utility of IGRAs for the diagnosis of TB meningitis (TBM) are also 
encouraging (Thomas et al 2008). Moreover, we have recently found that T-
SPOT.TB is an accurate and useful clinical diagnostic tool for TBM (Patel et al 
2010). Thus, although IGRAs cannot be used to distinguish LTBI from active 
TB disease, they appear to be useful tools for the diagnosis of active TB when 
using cells from the site of disease (for example, cerebrospinal fluid and 
lung). 
1.5.4. Utility of IGRAs for the diagnosis of HIV-TB co-infeded patients 
TB is the most common opportunistic infection in HIV-infected individuals 
and it is challenging, especially in high burden countries, to accurately 
diagnose TB in this group (Dheda et al 2004a). An easy-to-use, rapid blood 
test that is highly accurate and specific would thus be a particularly useful 
diagnostic option in this group. There are limited data in low and high 
burden settings on the diagnostic utility of IGRAs in HIV-TB co-infected 
individuals. Studies in Italy and the UK, using less than 40 HIV-TB co-
infected subjects, found the overall range of the sensitivity and specificity of 
T-SPOT TB to be between 70-95% and 64-100%, respectively (Clark et a12007; 











Three studies conducted in a high burden setting (Africa) used either QFT-
GIT or an in-house ELISPOT assay to evaluate the sensitivity and specificity 
of the assay in HIV-TB co-infected subjects (Chapman et al 2002; Raby et al 
2008; Rangaka et al 2007). The sample size ranged from between 40-75 
individuals in each of the three studies, and IGRA sensitivity varied between 
74-100%. The ELISPOT performed better than the TST in an studies. 
However, an overall observation was that IGRA sensitivity decreased with 
advancing immune-suppression. Interestingly, two studies, namely the UK 
study conducted by Clark et al and the study conducted by Rangaka et al. in 
Africa, found that the IGRA:CD4 T cell count ratio in the study participants 
was useful in distinguishing LTBI from and active TB disease (Clark et al 
2007; Rangaka et al 2007). However, these were preliminary findings and a 
major limitation of IGRAs is the high rate of indeterminate results at very 
low CD4 T cell counts. Thus, further studies are required to determine the 
CD4 T cell count cut-point at which IGRA responses are attenuated. 
Furthermore, studies are required to evaluate whether IGRAs have 
incremental value over smear microscopy in HIV-TB co-infected patients. 
1.5.5. Utility of IGRAs for the monitoring of disease activity and efficacy 
of anti-tuberculosis treatment in high versus low burden settings 
Data evaluating active TB patients from high burden settings are limited, 
mostly using in-house/standard ELISPOT (Aiken et al 2006; Carrara et al 
2004; Ferrand et a12005; Lalvani et a12001a; Pathan et a12001; Wilkinson et al 
2006) and ELISA (AI-Attiyah et a12003; Turner et a12000) assays using ESAT-
6 or CFP-10 (or both) and/ or PPD as stimulants. Tuberculin purified protein 
derivative (PPD) is an immunological reagent that can be purchased for 
research purposes. The product is produced from virulent M.tb culture 
filtrates, and has been used as a stimulatory antigen in the ex vivo ELISPOT 
assays (Aiken et al 2006; Dheda et al 2009d; Hill et al 2005; van Zyl-Smit et al 
2009). 
Existing treatment-related data are discordant. Some studies report a failure 











treatment (Pai et al 2006d; Pai & Menzies 2007b). As previously described, 
the IGRAs rely on the principle that sensitised T cells (effector memory cells) 
will rapidly produce IFN-y when they encounter the M.tb-specific antigens. 
By contrast, central memory T -cells are more likely to require several days in 
the presence of antigen before IFN-y is produced. Therefore, incubation of 
whole blood or peripheral blood mononuclear cells (PBMCs) is for 24 hours 
(16-20 hours for T-SPOT.TB and16-24 hours for QFT-GIT). If longer 
incubation times are used it is possible for infection that has been treated, or 
resolved, to yield positive tests. This may explain the discordant results of 
studies that evaluated the change in IFN-y responses with anti-TB treatment 
(Dheda et al 2005). Studies that show substantially decreased IFN-y 
responses with treatment, used short incubation times (ELISPOT with < 24 
hours in all except one study) whilst those that showed equivalent or 
increasing responses all had considerably longer incubation times (3 or more 
days and usually 4 to 5 days) (Pai et aI2006a). 
The following table (table 1.1) outlines the longitudinal studies that have 
used IGRAs to monitor serial treatment-related responses in active TB adults 
on anti-TB treatment. The majority of the studies have been conducted in low 











Table 1.1. Summary of longitudinal studies that have that have used IGRAs to 
monitor serial treatment-related responses in active TB adults on anti-TB treatment. 
The study location, sample group details, as well as information on the longitudinal 
follow-up time points, and type of IGRA assays used, are displayed in the table. 
Study Stu dy location Study population (N) & Follow-up time points Type of assay and antigens 
(First author, journal, treatment status/details 
year) 
Al-attiyah, Ferns Imm and Kuwait N =15 confirmed cases of Baseline N=15, 2 months ELISA (6 days incubation); 
Med Micro, 2003 pulmonaryTB n=12, and 6 months n=7 recombinant ESAT-6 
expressed in E.coli 
Aiken, BMC Infectious The Gambia* 151 adults with active TB follow-upat12 months In-house EUSPOT assay 
Diseases, 2006. (sputum smear and culture overnight incubation with 
positive TB) were recruited ESAT-6,CFP-I0,PPD 
N =89 evalua ble, paired 
EUSPOT results for baseline 
recruitmentvs.12 months 
Bossard, Respiratory Geneva N=89 HIV negative subjects N=62atTO (2 weeks before TSPOTTB: 
Medicine, 2008. either treated for culture- treatment initiation), N=55 at ESAT-6andCFP-IO 
proven TB or having 6 months, and N=41 at6 
completed their treatment months post-treatment 
within the past 6 months, completion 
N=41 evaluable results at 0 
months, 6 months & 12 
months 
Carrara,CID,2004 Italy N =18 patients (enrolled from Time of diagnosis and 3 In vitro ELISPOT assay: 
a previous study) with months after they started ESAT-6,PPD 
microbiologically therapy 
confumedTB 
Dheda, J Inf, UK N=33 patients with culture Mean duration of T-SPOT.TB: 
2007 proven TB recruited: treatment=8.7 months ESAT6 and CFPlO 
Early phase (=4 months Early phase (=4 months of 
treatment; n=12) anti-TB treatment) & 
Continuation/late phase (>4 continuationjlatephase (>4 
monthsoftreatment or after months of treatment or after 
treatment treatment completion) 
completion, N~21) 
N =3 patients followed 
longitudinally 
Dominguez, Diagnostic Spain N=10HIV negative, Baseline (0 months), between T SPOT TB (ESAT 6 & CFP 
Microbiology and pulmonary TB patients 1 to 3 months of 10) and QFT GIT (ESAT 6, 
Infectious Disease, 2008 followed-up treatment, and after more than CFP 10 & TB 7.7) 
3 months 
Golletti et ai, IlMC Infect Uganda* N=12 active TB patients Followed-upat3 months and In-house overnight RD 
Dis, 2008 6 months post-treatment ELISPOTassay (ESAT-6, 
initiation CFP-10) 
Kobashi, Inter Med, 2008 Japan N =22 patients with active TB 6 months treatment, 3 years of QFT-TBGIT: 
follow-up ESAT6,CFPlO, TB7.7 
Lalvani,J Infect Dis, 2001 India"and UK N=50 patients with Culture N=50: 35 patients <1 month In-house ELlSPOT assay: 
positive TB recruited in India; treatmentor no treatment at ESA T6 and CFPl 0 
N=5 culture-confirmed the time of blood-draw; 15 &PPD 
TB patients were followed up patients at later time points in 
longitudinally in the UK treatment «1 year) 
N=5: longitudinal follow-up 
over 20 weeks of treatment 
Pathan, J Immunol,2001 London N =12: longitudinally Follow-up over 34 weeks of In-house ELlSPOT assay: 
tracked 12 patients on anti-TB treatment ESAT-6 
treatment 
Ribeiro, Set aI., IlMC Brazil N=58 active TB patients with Baseline, 16 and 24 weeks of T-SPOT. TB assay (using 
JnfectDis, 2009 T SPOT TB results at baseline, treatment frozenPBMCs): 
4 months and at treatment ESA T -6 & CFP-IO, note: they 
completion (6 months) displayed summated RD-l 
SFCs in the results section 
TurneretaL, TuberLung The Gambia* N =7 active Til patients 6 months treatment: follow-up In-house ELISA: 
Dis,2000. at9months PPD 











In 2006, Aiken and colleagues evaluated antigen-specific IFN-y responses to 
ESAT-6, CFP-l0 and PPD using an in-house ELISPOT assay (overnight 
incubation). The study group comprised 151 active TB patients (sputum 
smear and culture positivity was used as a reference standard for diagnosis) 
from The Gambia, who were on a standard 6-month course of anti-TB 
treatment. The patients were followed-up for a period of 12-months, and 
there were evaluable, paired ELISPOT results for 89/151 (59%) of the 
patients (Aiken et al 2006). The outcomes reported in their study were as 
follows: 96% of the patients who had evaluable, paired results completed 
treatment and were cured, 3 % defaulted from treatment, and treatment only 
failed (remained sputum positive) in 1 %. At 12 months, 55% were ELISPOT 
negative. Another study conducted in The Gambia used an in-house ELISA 
assay to longitudinally track the levels of IFN-y production in response to 
stimulation with PPD in 7 definite TB patients on a standard 6-month course 
of anti-TB treatment (Turner et al 2000). The patients were followed-up at 9 
months. However, the levels of IFN-y remained unchanged throughout the 
study. A treatment-related follow-up study conducted in another high 
burden setting (Uganda) used an in-house RDl ELISPOT assay to evaluate 
serial changes in antigen-specific T cell responses in 12 active TB patients at 3 
months and 6 months post-treatment initiation (Goletti et al 2008). Although 
responses decreased by end of treatment, the responses remained above the 
cut-point for positivity and here were no statistically significant changes 
observed over time. The median SFCs at diagnosis and after 3 and 6 months 
of therapy were 167, 103 and 100, respectively. 
In Kuwait, a study by AI-Attiyah et al. evaluated the use of an in-house 
ELISA (6-day stimulation assay using recombinant ESAT-6 expressed in 
Escherichia coli) to assess the responses of 15 confirmed cases of pulmonary 
TB patients on a standard course of therapy. However, there were only 
evaluable results for 12 of the subjects 2 months into treatment and 7 at 6 
months (treatment completion). Prior to treatment initiation, there were 13-
60% responders in the IFN-y assays. After 2 months of treatment, the 











patients had responded. In 2004, Carrara et al. conducted a study (in Italy) 
using an in-house ELISPOT assay (ESAT-6 and PPD) to evaluate treatment-
related responses in a group of 18 patients with microbiologically confirmed 
TB (Carrara et al 2004). The patients were on a standard 6-month course of 
treatment and their responses to ESAT -6 and PPD were assessed at the time 
of diagnosis (baseline, To) and 3 months after treatment was initiated (Tl). 
All patients had positive ELISPOT results at diagnosis. At 3 months, the 
responses to ESAT-6 peptides were still detectable only in 5 patients, who 
had an absence of clinical improvement after treatment completion. Another 
study using an in-house ELISPOT assay (ESAT-6 CFP-I0 and PPD) was 
conducted by Lalvani and colleagues in 2001, which evaluated treatment-
related data from India. The study, based in the United Kingdom (UK), 
assessed a group of 50 culture positive patients recruited in India. Only 5/50 
(10%) of these culture-confirmed TB patients were longitudinally followed-
up over 20 weeks of treatment. Eighty percent of these patients responded to 
;;::1 antigen, and many donors had high frequencies of T -cells that were 
specific for certain immune-dominant peptides. In contrast, of 40 mostly 
BCG-vaccinated, healthy UK adult residents, none responded to either 
antigen (Lalvani et al 2001a). Another study conducted in London (Pathan et 
al 2001) longitudinally tracked 12 patients (on anti-TB therapy) for a period 
of 34 weeks. Using an in-house ELISPOT assay, the investigators observed a 
decline in the overall frequency of ESAT -6 peptide-specific T cells (p::::0.005). 
Certain studies, such as the one published by Ferrand and colleagues in 2005 
(London) have focused on the comparison of ELISPOT assays, or more 
specifically, an in-house ELISPOT assay that uses overnight ESAT-6 
stimulation versus a 6-day stimulation assay. The aim of the study was to 
determine which type of assay provided the best indicator of a memory T-
cell response, and also to assess the relationship between ESAT -6 specific T-
cells and protective immunity (Ferrand et al 2005). In the overnight ELISPOT 
assay, the median IFN-y responses in all of the TB patients, irrespective of 
treatment status, were significantly higher than in the healthy BCG-











median IFN-y responses in the group who had completed treatment were 
higher than in the patients who were in the early phase of anti-TB treatment. 
Furthermore, the investigators found a considerable amount of variability in 
the degree of expansion of the ESAT -6 specific T -cells over the 6-day period 
in both groups. However, it was concluded that further studies were 
required to assess the phenomenon (Ferrand et al 2005). 
Although several studies have investigated the use of T -SPOT TB and QFT-
TB GIT using samples obtained from active TB patients on anti-TB therapy 
(Bosshard et al 2009; Dheda et al 2007; Dominguez et al 2009; Kobashi et al 
2008; Ribeiro et a12009), to our knowledge, there are currently no data from a 
high burden setting comparing T SPOT TB and QFT GIT results alongside 
PPD and HBHA responses to monitor treatment-related responses in active 
TB patients. 
The majority of the existing studies have only used the T-SPOT TB assay to 
monitor treatment-related responses in active TB patients from low burden 
settings. In 2007, a study entitled 'Interpretation of Mycobacterium 
tuberculosis antigen-specific IFN-y release assays (T-SPOT.TB) and factors 
that may modulate test results' was published by Dheda and colleagues in 
the UK (Dheda et a12007). A total of 33 patients with culture-proven TB were 
recruited. The mean duration of treatment was 8.7 months. A total of 12 
(36%) of the patients were in the early phase of treatment (~4 months), and 21 
were in the continuation/late phase of treatment completion (>4 months). 
Only 3 patients were followed longitudinally for the duration of the study. 
Significantly more patients in the early rather than the late phase had 
positive IGRA responses (10/12 (83%) vs. 4/21 (19%); p~0.01]. 17/21 (81 %) in 
the late phase or who had completed treatment were IGRA-negative, despite 
having robust antigen-specific recall proliferative responses. Furthermore, 
experiments using prolonged incubation (5 days vs. overnight), the addition 
of endotoxin, and different protein and peptide antigen preparations failed 
to elicit positive responses in these 17 IGRA-negative patients. The authors 











variation in laboratory protocols, the variability displayed in the results was 
more likely due to environmental or host factors. The T-SPOT TB responses 
were found to be persistently positive in the 3 patients (initially tested at 4 
months, 4 and 6 months after commencing treatment, and then again at 8, 18, 
and 18 months, respectively) who were followed longitudinally. 
In 2008, Bosshard et al. published a study detailing the treatment-related 
responses (T-SPOT TB: ESAT-6 and CFP-10) of active TB patients who were 
followed-up at the time of treatment completion (6 months) and 6 months 
after treatment completion. There were evaluable results for baseline (To: 2 
weeks before treatment initiation) versus 6-month follow-up (TE: treatment 
completion) versus 12-month follow-up (TE+6: 6 months after treatment 
completion) for 41 culture-proven TB patients. The mean spot forming cells 
(SFCs) were 75 at To, 46 at T E, and 33 at 12 T E+6, and the positive rates were 
98%,93% and 98%, respectively. The SFCs decreased significantly between To 
and TE, and 2 (6%) reversions occurred over the course of treatment. 
However, no reversions occurred between TE and the follow-up at 6 months 
post-treatment completion (TE+6). Of 6 patients (17%) with an increase in 
SFCs between To and T E, 5 had a favourable outcome at T E and T E + 6. 
(Bosshard et al 2009) Ribeiro and colleagues (Brazil) used T-SPOT TB to 
evaluate 58 active TB patients at baseline, 4 months and at treatment 
completion (6 months). The investigator's used summated RD-1 SFCs for 
their analyses. Their findings showed that the mean baseline ESAT-6, CFP-10 
and summated RD1 specific SFCs decreased from 43,41 and 84, respectively, 
to 23 (p=O.D1), 23 (p=0.18) and 47 (p=0.02) at completion of 6 months of 
treatment. Furthermore, only 10% of subjects with a reactive test at baseline 
reverted to negative at treatment completion. However, for the entire study, 
frozen PBMCs were used in the T -SPOT TB assays. The overall sensitivity of 
the T-SPOT TB assay, as measured by baseline reactivity of the frozen 











A study conducted in Japan (Kobashi et a12007) evaluating the utility of QFT 
TB GIT (ESAT6, CFPI0, TB7.7 antigens), used samples obtained from 22 
patients with active TB followed up at 6 months and 3 years after treatment 
completion. The investigators found that the positive rate of QFT test results 
decreased by 50% at treatment completion, and thereafter, although the 
positive rate of results decreased 45% six months later (even after treatment 
was completed). Two years post treatment completion, the responses 
decreased slightly to 41 %, and one later (ie. 3 years post-treatment 
completion) the responses had decreased further, but not significantly, to 
36%. 
To our knowledge, there is only one study from a low burden setting (Spain) 
that has used both the T SPOT TB and QFT TB GIT tests to monitor 
treatment-related responses in a group of active TB patients (Dominguez et 
aI2009). Only ten HIV-uninfected, pulmonary TB patients were followed up 
over 6 months of anti-TB treatment. Samples were collected from the patients 
at the beginning of treatment, between 1-3 months of treatment, and after 
more than 3 months of treatment. Furthermore, the study was mostly 
focused on the sensitivity and specificity of the assays. The sensitivities of T-
SPOT TB and QFT -GIT for the patients at the beginning of treatment were 
83.3% and 69.4%, respectively. During treatment, the sensitivity decreased to 
69.8% for T-SPOT.TB and 48.8% for QFT-GIT. When compared with the 
values during treatment, the responses to the specific antigens increased 
significantly after treatment completion. However, the main finding was that 
the T-SPOT.TB test was more sensitive in diagnosing active TB than the QFT 
TB GIT. (Dominguez et al 2009) 
In summary, studies from low burden countries generally show rapidly 
declining IGRA responses, whereas those from high burden countries show 
highly inconsistent changes that range from minimal to modest. These 
observations are more likely to be due to biological factors and perhaps other 
factors such as residual post-treatment, persistent infection, re-infection or 











factors. Another possibility is that there is possible maintenance of a 
circulating pool of effector memory T-cells. The diagnostic utility of IGRAs 
may be improved if they can be shown to be good proxy markers of disease 
activity. 
1.5.6. Can we do better? 
The key question throughout the IGRA literature is "Can we do better?" 
(Arend et al 2000; Lalvani & Millington 2008; Menzies 2008; Pai & Menzies 
2007a). One approach that has been utilised to increase the diagnostic 
accuracy of T Cell-based ELISPOT and ELISA assays is to incorporate 
additional antigens of established high specificity (Liu et al 2004), because it 
has been hypothesised that assays that use cocktails of antigens may 
overcome the existing problem of heterogeneous immune responses 
(Houghton et al 2002). In this study by Houghton and colleagues, genomic 
expression libraries from M.tb were screened with sera from TB patients or 
rabbit anti-serum to M.tb. By doing so the authors identified novel antigens, 
namely Mtbll (also known as CFP-IO), Mtb8, and Mtb48, which were used 
in an ELISA to detect specific antibodies to M.tb. These 3 proteins, together 
with a previously tested 38-kDa protein associated with active TB disease, 
were also produced as a genetically fused poly-protein, and tested with two 
additional antigens (DPEP, or MPT32) and Mtb81, using sera from 
pulmonary and extra-pulmonary TB patients, TB patients co-infected with 
HIV, and patients with PPD positive and negative statuses with no evidence 
of disease. The authors discovered that in samples from HIV -negative 
individuals, the ELISA detected antibodies in more than 80% of smear 
positive subjects and ~60% smear negative subjects, with a high specificity 
(98%), and the antigen combination detected a significant number of HIV ITB 
co-infections and extra-pulmonary infections. Thus, their data suggests that 
the use of multiple antigens can be used to develop a highly sensitive test for 
M.tb antibody detection. In another recent study, Dosanjh and colleagues 











to create the 'ELISpotPLUS assay', which was shown to have significantly 
improved sensitivity compared to that of the standard ELISPOT test 
(Dosanjh et al 2008). In another study, the use of novel antigen Rv2645 in 
QFT-GIT significantly improved the sensitivity of the assay in diagnosing 
active TB cases without compromising the assay's specificity (Harada et al 
2008). Heparin Binding Haemaglutinin (HBHA) is another TB-specific 
antigen that appears to be promising for immuno-diagnosis. HBHA, which is 
a 28-kDa methylated surface-exposed mycobacterial protein antigen that is 
involved in mediating the interaction of M.th with the host (Delogu et al 
2006; Menozzi et al 1996) and may playa role in the protection against 
extra pulmonary dissemination of M. tb into alveolar epithelial cells (Pethe et 
al 2001; Shin et al 2006), has also been used in IGRA studies (Dheda et al 
2009c). Furthermore, HBHA is referred to as a latency antigen (Hougardy et 
al 2007). Evidence has emerged showing that cells from individuals with 
LTBI release IFN-y in response to HBHA, whereas cells from patients do not 
(Temmerman et al 2004). 
It is evident that further studies are urgently required to evaluate alternative 
testing platforms and to investigate the incorporation of additional novel 
antigens (for example, HBHA) of established high specificity. Furthermore, a 
useful approach would be to evaluate different biomarker readouts, for 
example, IFN-y-inducible protein (IP-I0), Monocyte Chemotactic Protein 1 
(MCP-l) and IL-1 receptor antagonist (IL-1RA), for the rapid diagnosis of TB 











1.6. LIPOARABINOMANNAN (LAM) ASSAYS 
1.6.1. Urine lipoarabinomannan for diagnosis of tuberculosis 
The use of urine for TB diagnostic purposes is increasingly becoming an 
attractive test option, because it is a convenient, easily obtainable biological 
fluid that can be transported, processed and stored without much hassle. 
Almost half a century ago (late 1950s/ early 1960s), scientists postulated that 
M.tb bacilli would be present in the urine of active pulmonary TB patients. 
However, the use of urine specimens in routine diagnosis of active 
pulmonary TB is currently not recommended, mainly due to the poor clinical 
utility of conventional TB diagnostics when applied to urine samples. Thus, 
the development of novel tools to detect mycobacteria i  the urine of TB-
infected individuals, such as tests that utilise mycobacterial 
lipoarabinomannan (LAM) and urine mycobacterial deoxyribonucleic acid 
(DNA) have provided a promising way forward from using conventional TB 
diagnostics. (Peter et a12010) 
The recognition of the urgent need for the development of novel and 
improved technologies for detecting TB in urine was mainly spurred on by 
the release of two large retrospective urine diagnostic reviews (Mortier et al 
1996; Nour et a12007), which both reported that the yield of urine smear and 
culture was very low «2%), but the yield of urine culture improved 
significantly, by approximately 39-fold (>77%), in HIV-infected patients in 
the stages of advanced immune-suppression. Moreover, recent reports reveal 
that the sensitivity of urine smear and the low incremental yield of urine 
M.tb culture «5%), compared to sputum smear microcopy or culture, 
remains a problem in HIV-infected and -uninfected TB patients 











1.6.2. Performance outcomes of urine LAM in clinical studies 
Studies by Daffe and Draper, and Lee et al. suggest that LAM is specific for 
mycobacteria (Daffe & Draper 1998; Lee et al 1996). Our recently published 
urine LAM findings (please refer to chapter 4: urine LAM specificity of 95 
100%) are consistent with the high specificities reported in two other recent 
studies (Lawn et a12009; Shah et aI2009). However, these findings contradict 
earlier data from other studies showing poor urine LAM specificity (83-89%) 
(Daley et al 2009; Mutetwa et al 2009; Reither et al 2009). The low specificity 
displayed in these early studies could have been due to due to undiagnosed 
occult TB disease, contamination of the sample by environmental 
mycobacteria or other bacteria, or possibly even nonbacterial contamination. 
Indeed, recent studies have revealed that several species of bacteria, and 
even some fungi, possess LAM-like glycolipids in their cell walls. 
Interestingly, we have found that anti-LAM polyclonal antibodies cross-react 
with various micro-organisms found in the normal mouth flora of non-TB 
patients (Dheda et al 2010a). 
The very first tests for the detection of LAM antigen in urine, namely, a basic 
LAM ELISA and a dipstick test, were designed and evaluated almost a 
decade ago (Hamasur et aI2001). The Clearview-TB® LAM ELISA (Inverness 
Medical Innovations, Waltham, Massachusetts, USA), is the most recently 
developed urine LAM test, and is based on the earlier developmental studies 
(Hamasur et a12001; Tessema et aI2001). Moreover, the Clearview-TB® LAM 
ELISA supersedes a pre-commercial prototype (MTB LAM ELISA Test®, 
Chemogen, Portland, USA) that was first tested 5 years ago in Tanzania 
(Boehme et aI2005). In the evaluation of this pre-commercial prototype (MTB 
LAM), Boehme and colleagues reported a sensitivity of 80.3% and a 
specificity of 99% (Boehme et aI2005). Although the high sensitivity reported 
by Boehme et al. is promising, several recently published studies have 
reported very low sensitivities (ranging between 13-51 %) in unselected TB 











suggesting that the urine LAM assay has little clinical utility in this particular 
sub-group of patients. Furthermore, the accurate diagnosis of TB in HIV-
infected patients, particularly those with advanced immune-suppression, is 
difficult. Studies in HIV /TB co-infected patients are of particular importance, 
because these patients suffer from increased rates of extra-pulmonary TB, 
often with atypical presentations. However, the use of standard tests is not 
feasible, and there is an urgent need to evaluate rapid tools such as the 
Clearview-TB® LAM ELISA. 
Recent studies have shown that urine LAM may have diagnostic value in 
HIV-infected (Lawn et a12009; Mutetwa et a12009; Reither et a12009; Shah et 
a12009) suspects but not in those who are HIV uninfected (Daley et aI2009). 
Moreover, the Clearview TB ELISA has shown strong performance in 
detecting TB in individuals co-infected with HIV. The aim of the study 
conducted by Shah et al. was to evaluate the diagnostic accuracy of the 
Clearview LAM ELISA for TB in hospitalised patients in a high HIV 
prevalence setting. Thus, the authors conducted a nested cohort study of 499 
South African TB suspects who were inpatients, and the majority of these 
were co-infected subjects (84.6% HIV-infected). In the confirmed TB cases, 
the sensitivity of the urine LAM ELISA was suboptimal (59%, 95% CI). 
Interestingly, the urine LAM positivity in the smear-negative TB patients, in 
particular, was also poor (56%). However, the sensitivity improved to 71 % in 
patients with a CD4 cell count of 50-100 cells/mP. The sensitivity was even 
further improved to 85% in patients who were in the most advanced stages 
of immune-suppression (CD4 cell counts<50 cells/m13). It was suggested that 
the improved sensitivity was related to a high antigen burden and 
disseminated disease, because the investigators observed that HIV positivity, 
and positive sputum smear and mycobacterial blood culture were all factors 
associated with LAM positivity. The overall conclusion was that urine LAM 
in combination with sputum smear miscroscopy is an attractive test option in 











We have also postulated that the Clearview® LAM ELISA may be a useful 
rapid tool for TB diagnosis in HIV-infected TB suspects from primary care 
facilities in a high burden setting. The detailed evaluation of the performance 
outcomes of our study using the Clearview® urine LAM ELISA are contained 
in chapter 4. This work, along with sputum- LAM data generated during the 
course of the parent study, has recently been published (Dheda et aI2010a). 
Other studies have also investigated the utility of LAM ELISA using samples 
other than urine. 
1.6.3. Clinical utility of lipoarabinomannan ELISA using biological 
samples other than urine 
Although most studies have evaluated the diagnostic utility of LAM-ELISA 
using urine, several studies have investigated urine LAM using various 
specimens, including cerebrospinal fluid (CSF) (Patel et al 2010), pleural fluid 
(Dheda et al 2009b), and serum (Sada et al 1990). Furthermore, besides our 
study (Dheda et al 2010a), sputum has also been used in another LAM 
detection study(Pereira Arias-Bouda et al 2000). In the study conducted in a 
resource-poor high HIV prevalence setting by Patel and colleagues, it was 
shown that the detection of LAM may be a promising tool for the diagnosis 
of TB meningitis (TBM) (Patel et al 2010). In a collaborative effort between 
our laboratory and Patel and colleagues, a larger prospective study 
evaluating LAM antigen detection in CSF, yielded promising results and has 
recently been completed (V. Patel and K. Dheda; personalcommunication). 
In pleural fluid, LAM has been shown to be of no diagnostic use (Dheda et al 
2009b). Furthermore, detection of LAM in sputum (and induced sputum) has 












1.6.4. Future directions for urine-based diagnostics 
Given the advantages of using urine as a diagnostic sample, coupled with the 
fact that several host and organism-related metabolites and proteins are 
likely to be found in urine, there is much promise for the identification of 
signature molecules that may be helpful for TB diagnosis. The use of 
proteomic and metabolomic technologies for screening urine may be a 
promising tool to detectTB-specific protein signatures. Other approaches 
using urine include gas chromatography spectrometry for the 
characterisation of TB-specific volatile organic compounds. Urine nucleic 
acid amplification tests (NAATs) such as such as loop-mediated isothermal 











1.7. NUCLEIC ACID AMPLIFICATION TESTS (NAATs) 
1.7.1. NAATs for the diagnosis of TB 
NAATs such as Polymerase Chain Reaction (PCR) are radically changing the 
detection of infectious pathogens such as M.tb. As previously mentioned, 
currently used conventional tools such as smear microscopy have a very low 
sensitivity and culture results are available only after several weeks. Hence, 
better efforts to control TB require more rapid and accurate diagnostic tests. 
NAATs have been developed to address these issues, because amplification 
technology offers the potential for the rapid diagnosis of TB (within a few 
hours of sample receipt) with a high degree of sensitivity and specificity 
(Ling et al 2008; Pai & Ling 2008). 
A summary of the commercially available nucleic acid amplification tests 
(NAATs) for tuberculosis is shown in table 1.2. Two of the commercial tests, 
namely Roche Amplicor® MTB (Roche Molecular Systems Branchburg, New 
Jersey) and the Amplified M.tuberculosis Direct® Test (AMDT; Gen-Probe 
Inc. San Diedo, California), have been approved by the US Food and Drug 
Administration (FDA) for testing of smear-positive sputum samples in 
diagnostic laboratories. Moreover, the Gen-Probe has also received FDA 
approval for use on smear-negative sputum samples. Other manufacturers 
have developed molecular assays for rapid TB diagnosis that utilise other 
amplification methods such as strand-displacement amplification (SDA) 
technology (Hellyer et al 1996) and ligase chain reactions (OIConnor et al 
2000; Rantakokko-Jalava et al 2001). While the Amplicor® MTB (Roche 
Molecular Systems Branchburg, New Jersey) and Cobas® Amplicor (Roche 
Molecular Systems Mannheim, Germany) have been in existence for quite 
some time, the BD-ProbeTec ET (a newly improved version of the BD-
ProbeTec Direct SDA technology) and Loop-mediated Isothermal 
Amplification (LAMP) tests (Boehme et al 2007) are relatively new. In 2009, 











which is now also available in other parts of the world. The Xpert® 
MTB/RIF Assay is on-demand molecular test for simultaneous detection of 
M.tb and RIF resistance. This is the only system that delivers answers directly 
(TB or no TB) from unprocessed samples by combining on-board preparation 
of the sample with real-time PCR in less than 2 hours (Cepheid 2009). 
Table 1.2. Summary of commercially available nucleic add amplification tests 
(NAATs) for tuberculosis 
NAAT MethodfPrinciple Manufacturer 
Amplified M.tuberculosis Transcription-mediated amplification of Gen-Probe Inc. San Diedo, 
Direct® Test (AMDT) rRNA transcripts, with product detection California 
performed via chemiluminescence 
Roche Amplicor® MTB PCR amplification of 16s rRNA, with Roche Molecular Systems 
product detection performed via colorimetric Branchburg, New Jersey 
detection 
Cobas® Amplicor PCR amplification of 16s rRNA Roche Molecular Systems 
Mannheim, Germany 
Abbott LCx® assay* Ligase chain reaction amplification of Abbott Laboratoroies, Illinois 
38kDa protein 
BD-ProbeTec Direct Strand Displacement Amplification Becton-Dickinson Diagnostic 
And the BD-ProbeTec ET (SDA) technology for the direct, Systems Sparks, Maryland 
qualitative detection of 16s rRNA and 
the M.tb insertion sequence IS6110 
Xpert® MTBjRIF Semi-quantitative nested real-time PCR Cepheid, Sunnyvale, 
in-vitro diagnostic test for the detection 
California 
of M.th complex DNA, and rifampicin-
resistance 
associated mutations of the rpoB gene 
Loop-mediated Isothermal Isothermal amplification and visual Eiken Chemical Co. Ud.,Japan 
Amplification (LAMP) read-out with ultra violet fluorescence 











1.7.2. In-house versus commercial NAATs 
In a meta-analysis by Flores et al., the authors reviewed data from 65 
published studies on in-house NAATs for pulmonary TB. The main objective 
was to determine factors associated with the heterogeneity in test accuracy, 
and to evaluate the higher accuracy estimates of accuracy in studies that 
evaluated in-house PCR for the diagnosis of pulmonary TB. The confounding 
factors that contribute to heterogeneity in test accuracy are not well 
characterised, and it is difficult to address the issue in individual studies. The 
variability displayed among in-house NAATs may be due to the several 
factors, namely, differences in study design, or differences in laboratory 
techniques and assay characteristics, for example, the method of sample 
preparation (DNA extraction), the amplification step, and the method of 
detection used. Thus, increasing the power of analyses by combining data 
from multiple studies is a useful method which may enable researchers to 
identify the sources of heterogeneity in study findings. In their meta-
analysis, Flores and colleagues reported that the use of [56110 as an 
amplification target, and the use of nested PCR methods appeared to 
enhance test accuracy, and suggested the inclusion of these elements in PCR 
protocols. Their analyses also suggested that the methods used for DNA 
extraction and detection were not critical. However, a potential limitation of 
targeting [56110 is that certain strains from different parts of the world lack 
this insertion sequence (Das et al 1995).Thus, a possible solution may be to 
use multiple targets. However, the meta-analysis revealed that that multiplex 
PCR failed to increase the diagnostic accuracy of in-house assays. At the 
time, the overall sensitivity and specificity of in-house assays could not be 
adequately summarised due to the significant amounts of heterogeneity in 
the results. However, several years later, studies determined that in-house 
NAAT sensitivities have been found to vary to some extent based on the 
bacillary load in the specimen. Compared to higher sensitivities (85-90%) in 
smear-positive samples, sensitivities range from 50-60% in smear-negative 











Commercial NAATs have been shown to give more consistent results 
compared to in-house assays, and several meta-analyses have evaluated the 
accuracy of commercial NAATs in pulmonary and extra-pulmonary TB 
(Daley et al 2007; Pai et al 2004; Pai et al 2003; Piersimoni & Scarparo 2003; 
Sarmiento et al 2003). Overall, the majority of studies evaluating commercial 
NAATs have reported high and consistent specificity (95-100%), but low and 
varied sensitivity (33-96%) (Ling et al 2008; Pai et al 2004; Pai et al 2003; 
Piersimoni & Scarparo 2003). Furthermore, when comparing smear negative 
and smear positive TB, studies have shown that sensitivity is lower in smear-
negative TB (Greco et al 2006; Pai et al 2004; Pai et al 2003; Piersimoni & 
Scarparo 2003). Sarmiento et al. conducted a meta-analysis on the use of 
commercial NAATs for smear negative TB, and found that the sensitivity 
estimates were low and variable in this group (Sarmiento et al 2003). If the 
sensitivity of commercial NAATs, especially in smear negative TB, can be 
improved, this group of patients are most likely to benefit from the use of 
NAATs, because a faster diagnosis can lead to earlier treatment initiation if a 
result is positive. 
1.7.3. Extra-pulmonary TB poses a diagnostic challenge 
The lack of a diagnostic gold standard remains one of the biggest obstacles 
for evaluating new diagnostics, especially in HIV-infected patients and 
extrapulmonary TB. In cases of suspected extra pulmonary TB, rapid 
and accurate diagnosis is important, because, as previously emphasised, 
conventional methods of detecting AFB have many limitations. As 
mentioned earlier, the majority of studies evaluating commercial NAATs 
have reported high and consistent specificity, but low and varied sensitivity 
in both pulmonary and extra-pulmonary TB. However, given the 
paucibacillary nature of extra-pulmonary disease, it is particularly difficult to 
diagnose extra-pulmonary TB (Pai & Ling 2008). Although several meta-
analyses have investigated the use of NAATs in studies that have used 
cerebrospinal fluid (Pai et al 2003), pleural fluid (Pai et al 2004) and lymph 











none of the commercial NAATs are FDA-approved for use in extra-
pulmonary samples. Overall due to the low sensitivity of the test, it is 
suggested that NAATs should be used in combination with the conventional 
methods and further research is required to improve the sensitivity of 
NAATS for extra-pulmonary (Ling et aI2008). 
1.7.4. NAATs for the diagnosis of active pulmonary TB using BAL fluid 
Using various in-house PCR assays, several studies have demonstrated that 
PCR is more sensitive than smear microscopy in detecting M. tb in the BAL 
fluid of sputum-scarce or smear negative patients with active pulmonary TB 
(Chen et al 2002; Liam et al 1998; Tueller et al 2005). A study conducted in 
Taiwan by Chen et al. found that when compared to smear, the sensitivity 
and specificity of an in-house NAAT in the BAL fluid of smear negative, 
pulmonary TB patients was 36% and 96%, respectively (PPV=94% and 
NPV=45%) (Chen et al 2002). Liam et al. (Malaysia) found that an in-house 
NAAT had a positivity rate of 80.9% (55/68) compared with lower smear 
and culture positivity rates of 8.8% and 7.4%, respectively, for detecting M.tb 
in BAL fluid of smear negative active pulmonary TB patients (Liam et al 
1998). A study conducted by Tueller and colleagues (Switzerland) used an in-
house NAAT in an investigation of 71 patients who had smear negative or 
sputum-scarce TB. BAL fluid (smear or M.tb complex-PCR) allowed an 
accurate rapid diagnosis in 10 (59%) out of 17 sputum smear negative 
patients, and 49 (91 %) out of 54 patients who could not produce sputum 
(sputum-scarce TB). In all of these studies it was evident that the combined 
use of BAL fluid smear and M.tb NAAT had a good diagnostic yield in 
sputum-scarce or smear-negative TB. 
1.7.5. Future NAAT research directions 
Studies need to be conducted to evaluate the performance outcomes of 
commercial NAATs in different geographical settings, especially in high 











example, the Xpert MTB/RIF assay is available in the private sector at R980 
(US $130) per test (Pathcare). However, the potential benefits may outweigh 
the cost when considering the rapidity of assay (result can be obtained in 
under 2 hours) and that RIF resistance can is detected simultaneously. A key 
study, conducted by Helb and colleagues (Helb et al 2009), who performed 
the first analysis of the Cepheid Gene Xpert System's MTB/RIF assay (using 
sputum samples obtained from 107 consecutively enrolled Vietnamese 
patients suspected of having TB), has been referred to in more detail in 
chapter 5 (pp.112 and 123). Furthermore, promising data on the analytic 
sensitivity, analytic specificity, and dynamic range for the new Xpert 
MTB/RIF assay has recently been published (Blakemore et al 2010). Seventy 
nine M.th isolates, including 42 drug-susceptible and 37 RIF-resistant isolates, 
containing 13 different rpoB mutations or combinations of mutations were 
used to test the sensitivity of the new Xpert MTB/RIF assay. Assay 
specificity was tested using 89 non-tuberculous bacteria, fungi and viruses. 
The assay correctly identified all 79 M.th isolates (ie. 100% sensitivity) and 
correctly excluded all 89 non TB isolates (ie. 100% specificity). Furthermore, 
RIF resistance was detected in all of the RIF-resistant isolates and in none of 
the drug-susceptible isolates. The dynamic range of the assay was also 
assessed by conducting spiking experiments (concentration range of 102 to 
107 CFU of M.th into non TB samples) which showed a log-linear relationship 
between Tc (cyde threshold) and inputCFU over the entire range.(Blakemore 
et a12010) 
The above-mentioned data is very promising. However, due to the issue of 
smear negative and sputum-scarce TB, and the difficulty of diagnosing extra-
pulmonary TB, we cannot over-emphasise that research is also needed to 
enhance the sensitivity of NAATs using biological fluids other than sputum. 
Furthermore, the lack of a diagnostic gold standard remains a serious 













The Use of a Range of Antigens in the Serial Evaluation of Antigen-
specific Quantitative T Cell Responses of Active tuberculosis Patients on a 
Course of Anti-tuberculous Therapy 
2.1. INTRODUCTION 
To date, the T-SPOT.TB test and similar in-house ELISPOT tests have 
reported sensitivities of 83-97% in active TB subjects (Goletti et al 2006; 
Lalvani et al 2001a; Meier et al 2005; Pathan et al 2001; Ribeiro et al 2009; 
Wilkinson et al 2005). Disease activity studies are required for providing 
clues about clinically important changes, which may be important in the 
management of disease monitoring. More specifically, good biomarkers for 
tuberculosis disease activity, cure and relapse are required because they may 
have an important role in providing validated surrogate endpoints, which 
can be used to enhance feasibility and thus accelerate the evaluation of new 
drugs, vaccines and other therapies. However, data on IGRAs as a promising 
marker of disease activity is conflicting (Dheda et a12005; Pai et a12006a; Pai 
et al 2006d; Pai & Menzies 2007b). Moreover, the role of T-SPOT.TB in 
monitoring response to TB treatment is not well-established and responses to 
treatment studies are controversial. 
Longitudinal data from high burden settings are limited, mostly using in-
house/ standard ELISPOT and ELISA assays (as discussed in the literature 
review, chapter 1 section 1.5.5) and to our knowledge, there are currently no 
data from a high burden setting comparing T SPOT TB and QFT GIT results 
alongside PPD and HBHA responses in a group of active TB patients on a 
course of anti-TB therapy. There is only one other study that has used both 
the T SPOT.TB and QFT-GIT tests to monitor treatment-related responses in 
active TB patients (Dominguez et al 2009), and the study was conducted in a 











studies that have assessed the potential utility of IGRAs for monitoring 
treatment efficacy, we evaluated the frequency and magnitude of antigen-
specific IFN-y-secreting T cells responses, in patients with active TB receiving 
a 6-month course of anti-TB therapy, using a range of antigens, namely RDl 
antigens ESAT-6 and CFP-I0 (T SPOT.TB), ESAT-6, CFP-I0 and TB7.7 (QFT-
GIT), PPD (ELISPOT), and HBHA (ELISPOT). We also evaluated the 
relationship between the RDl SFC counts/million PBMCs and markers of 
disease activity at baseline and 2 months post-treatment initiation, and at 











2.2. AIM AND OBJECTIVE(S) 
Aim: 
The main purpose of this section of the study was to evaluate treatment-
related serial changes in the magnitude of antigen-specific IFN-y responses to 
a range of antigens [RD-l (ESAT-6, CFP-I0 and TB 7.7), HBHA and PPD] in 
active TB patients on a 6-month course of anti-TB treatment. 
Objectives 
1. What is the frequency and magnitude of IGRA (T-SPOT.TB and QFT 
TB GIT) RDI responses at serial time points during anti-TB treatment 
(baseline versus 2 months post-treatment initiation, and versus 
treatment completion at 6 months)? 
2. Is there agreement between the changes in RDI antigen-specific 
quantitative T cell responses and changes in culture and smear status 
at 2 months? 
3. Is there agreement between the changes in RDI antigen-specific 
quantitative T cell responses and changes in culture and smear status 
at treatment completion (6 months)? 
4. What is the frequency and magnitude of PPD and HBHA responses at 
serial time points during anti-TB treatment (baseline versus 2 months 












2.3. MATERIALS AND METHODS 
2.5.1. Clinical recruitment 
The subjects for this study were recruited as part of a larger prospective 
parent study involving the evaluation of the utility and interpretation of 
antigen-specific T cell interferon gamma release (IGRA) assays in a high 
incidence tuberculosis and HIV setting in South Africa (SAIGRA). The 
sample recruitment sites, namely, Langa Clinic (Langa), Chapel Street Clinic 
(Woodstock), and Ikwezi Clinic (Lwandle) operate within the Cape Town 
Metro Region. Blood samples from five hundred sequentially recruited adult 
TB suspects from Cape Town (South Africa) were collected and processed at 
the Lung Infection and Immunity Unit Laboratory. The study flow diagram 
is shown in figure 2.1. 
500 TS suspects recruited from Cape Town, South Africa 
~ 
Chest X ray, HIV testing, smear and culture testing, blood samples (0 months): 2xlOmi 










(follow-up samples taken 
at 2 & 6 months) 
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.. store cells in RLT buffer: for possible future use in 
RT-PCR 
.. store supernatants for protein analysis: for possible 








LTBI Non LTBI 
.. Perform IGRAs for 500 TB suspects at 0 months (baseline). After overnight stimulation with RDI 
antigens, PPD and HBHA, collect supernatants and store for later analysis. 
** Only know whether subject has definite TB at 2 months (ie. culture and smear results confirmed). Invite 
ali definite and probable TB subjects to return for follow-ups (2 &. 6 months). 
Figure 2.1. Study flow for the investigation of the use of a range of antigens 
in the serial evaluation of antigen-specific quantitative T cell responses of 











Ethical approval was obtained from the University of Cape Town Health 
Sciences Faculty Research Ethics Committee and all subjects signed informed 
consent prior to entering the study. A detailed questionnaire was completed 
by each participant and all underwent clinical, radiological, and laboratory 
evaluation. 
2.5.2. Laboratory methods 
Blood (~20ml) was drawn from all TB suspects at baseline (0 months) into 
lithium-heparin tubes (BD Europe) and transported to the laboratory within 
3-4 hours where peripheral blood mononuclear cells (PBMCs) were isolated 
from -10ml blood (within 8 hours of venipuncture) for use in the T-
SPOT®.TB assays. The remaining 10ml was used in a different experimental 
set-up (chapter 2). An additiona13ml of blood was collected as follows: 1 mL 
of blood was drawn directly into each of 3 QuantiFERON®-TB Gold-IT 
blood collection tubes, namely, a Nil control tube (grey cap), TB antigen tube 
(red cape) and Mitogen control tube (purple cap). 
Individuals were diagnosed based on detailed patient characterisation 
criteria, as shown below. The characterisation was performed by a clinician 
blinded to the IFN gamma release assay (IGRA) results. 
1. Definite TB: A clinical presentation compatible with TB with at least 1 
positive culture (from any specimen) for M.tb with response to anti-TB 
therapy (Wilson et aI2006). 
2. Probable TB: A clinical-radiological picture highly suggestive of TB 
and! or anti-TB treatment initiated by the attending clinician based on 
clinical suspension, but not meeting the above-mentioned criteria for 
definite TB. 
3. Non-TB: no evidence of TB based on smear microscopy and culture, 











or without an alternative diagnosis being established on patient follow-
up. 
4. Indeterminate TBjuncertain diagnosis: either the culture or chest x-
ray results (or both) were unavailable, and the patient was lost to 
follow-up or transferred to another centre, thus making it impossible to 
confidently rule-out or rule-in TB. These patients were excluded from 
the analysis. 
The definite and probable TB patients were invited to return for follow-up 
sessions at 2 months and 6 months. However, the patients were ambulatory. 
Thus, it was anticipated that a certain percentage of patients would be lost to 
follow-up if they transferred to other clinics, interrupted treatment during 
the course of their therapy, or opted out of the study for various other 
reasons. 
For all subjects, blood was collected between 2 weeks and 1 day prior to the 
possible initiation of TB therapy (0 months, baseline) and once diagnosed as 
definite or probable TB, blood was collected during follow-up (2 months 
andj or 6 months) from those who returned. Thus, the current study 
comprised a group of active TB patients on a 6-month course of anti-TB 
therapy who were assessed at baseline and followed-up, if possible, at 2 
months of treatment and at completion of treatment at 6 months. 
2.5.2.1. Isolation of peripheral blood mononuclear cells (PBMCs) for 
use in the T SPOT. TB assay 
Blood (~10ml) was centrifuged in the collection tube at 1800rpm for 15 
minutes. After centrifugation, the layer of plasma was removed with a 
Corning® Disposable Pasteur Pipette (Sigma-Aldrich) prior to carefully 











PBMCs) above the red blood cell pellet to a 15ml conical centrifuge tube. The 
volume was made up to 10ml with Ix phosphate buffered saline (PBS, pH 7.2 
lOX liquid, GIBCO®, Invitrogen), layered on top of 3-4 ml Ficoll-Paque™ 
(Sigma-Aldrich) in a new 15ml conical centrifuge tube, and centrifuged at 
1800 rpm for 25 min at room temperature, with no brake. After ficon-density 
centrifugation, the further condensed and separated PBMC layer was 
collected and transferred, using a pipette, to a clean 15ml conical tube. Two 
wash steps were performed as follows: 1) for the first wash step, the volume 
was made up to 10ml with PBS and the sample was centrifuged at 600xg for 
10 min at room temperature and no brake, and 2) after decanting the 
supernatant, the cell pellet was re-suspended by making the volume up to 
10ml with PBS prior to centrifuging at 350xg for 7 min at room temperature 
and no brake. After the second wash, the cell pellet was re-suspended in Iml 
of pre-warmed AIM-V medium (37°C for use with T-SPOT.TB.) [Adcock 
Ingram Scientific Group]. A 1:10 staining dilution was made by mixing 10ul 
of the re-suspended cells with 90 f.ll Turk's blood counting fluid. 10 ul of the 
stained cell suspension was loaded onto an Improved Neubauer 
haemocytometer, and the lymphocytes were manually counted using a light 
microscope (20x magnification). The ruled area of the haemocytometer 
consists of several, large 1 mm2 squares (4x4 grids) and the volume of each 
grid is 10-4ml (O.lp.l). Thus, the total number of cells per ml was calculated by 
using the following formula: 
COlllltsmi = total founts x 10' x srunpl(l dilution 
Ilumb(ll' of 4:\4 grills COlllltNI 
A Iml aliquot of the final cell suspension was made at a concentration of 












2.5.2.2. The ELISPOT (T-SPOT.TB) assay 
The T SPOT.TB test was performed following the manufacturer's 
recommendations (T-SPOT®.TB [package insert] 2008), as follows: The assay 
requires four wells of the 8-well strip to be used for each patient sample. Two 
of the wells are for the TB-specific antigens (1 wen for RDl antigen Panel 
A/ESAT-6, and a second well for RD1 antigen Panel B/CFP-10). A Positive 
Control well containing phytohaemagglutinin (PHA, a known polyclonal 
activator) is required as a test for PBMC functionality, and a well for the Nil 
Control (AIM-V medium) is also required to identify non-specific cell 
activation. It is recommended that the samples are arranged vertically on the 
plate (ie. 2 patient samples can thus be run on an 8-well strip of the 96-well 
micro-titre plate. Each well on the strip is pre-coated with a mouse 
monoclonal antibody to the cytokine interferon gamma). For the purpose of 
the current evaluation, wells containing PPD and HBHA were also included. 
The PPD (Statens Serum Institut, Copenhagen, Denmark) was used at a 
working concentration of 20J.tg/mL, and the HBHA at a working 
concentration of lOOJ.tg/mL (derived from optimisation experiments). Thus, for 
each patient, PBMCs were stimulated in each well of the 8-well test strip by 
medium alone (as nil control), phytohemagglutinin (as positive control), 2 
main peptide panels containing the antigens ESAT-6, CFP-I0, and an 
additional 2 peptide panels containing PPD (in duplicate) and HBHA (in 
duplicate). 
Thus, the assay was conducted by seeding the PBMCs at a final concentration 
of 250,000 PBMCs per T SPOT well (ie. 100ul of the 2.5xl06 cells/rnl cell 
suspension into each well), and adding 50 J.tl of the relevant antigens and 
controls to the wells (according to the above-mentioned layout). The plate 
was incubated at 37°C in a C02 incubator for 16-24 hours. After the 
overnight incubation, the antigen-driven culture supernatants were collected 
in clean, labelled l.5ml microfuge tubes and stored in cryogenic boxes at -











lxl-'I:\S. fhe plate was gently, but thoroughly, t.:lpped on.:l cie.:ln p.:lper towei 
to remove exress FBS from the wells prior to adding 5(Jul of mnjug.lte 
solution to ('~ck wdl (for cilch 8-well ~trip, ,1 conjugate solution w~s m,'dc by 
adding 2.5 ~d 1 SPOT TB kit conjugate, equilibrated to room temperahHe 
prior to use, to 497.5 ~d lxrBS). The plate wab il1cubated at <1 "C for 1 hour. 
The conjugate was dbciUded and the plate was washed, as previoubly 
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The antigen-specific T cell responses were scored using an automated AID 
ELISPOT plate reader (AID Autoimmun Diagnostika GmbH) at the Institute 
of Infectious Diseases and Molecular Medicine (Department of Medicine, 
University of Cape Town). The results were interpreted according to 
manufacturer's instructions as follows: A typical result would be expected to 
have few or no spots in the Nil Control and greater than 20 spots in the 
Positive Control. The test result is considered 'Reactive' if either or both of 
Panel A or Panel B respond, according to the following criteria: 
1) Where the Nil Control has 0 - 5 spots and (Panel A or Panel B spot 
count) - (Nil Control spot count) ;;::: 6. 
2) Where the Nil Control has 6 - 10 spots and (Panel A or Panel B spot 
count) ;;::: 2x (Nil Control spot count). 
The test result is considered 'Non reactive' if the above criteria are not met 
and the Positive Control is valid. Typically, the Positive Control spot count 
should be ;;::: 20 or show saturation (too numerous to count). Where the 
Positive Control spot count is < 20 spots, it should be considered as 
'Indeterminate', unless either Panel A or Panel B are 'Reactive', in which case 
the result is valid. Where the Nil Control has 0 - 5 spots and (Panel A or 
Panel B spot count) - (Nil Control spot count) = 5 - 7, this may be considered 
as a II grey area" and should be considered in conjunction with all available 
clinical information. In this case, it may be necessary to re-test the individual. 
Please refer to figure 2.3, which shows examples of a T SPOT TB result in a 
patient who is not infected with M.tb (figure 2.3 A) and a patient with M.tb 
infection (figure 2.3 B). 
The SFCs for each RD-l antigen were calculated using the above-mentioned 
criteria. However, for the purpose of graphical representation, the ESAT-6 
and CFP-IO spot counts were summated using the spot count of the antigen 
that yielded the most spots (for example, if the ESAT-6 count was 20 and the 
CFP-IO count was 8, then the ESAT-6 count would be used to represent the 











forming cells (SI Cs) per millial [~t;MCs. [he nklnuf.,('tur('r (OxfmJ 
lmmunolec Ltd, London) sets the ('ut-nd fnr I'o"itivity ilt;,., 6 sl'"t" pl'f well 
cont,linine; 2511,IXlO PBMC~. which thu~ tTanslated into ;;:, 21 SI'Cs/rnilli(ln 
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I-igure 2.3. An ~'Jmpk of.l T SI'OI-IB test result in" ,u1i" ct cLlssifi",\ as 'not 
miette, \ witl, M .rb' (1\), ""d d 'U t,e(' l cla %ihed ~> '])If('Cl~ d w,th M.tl!' (H). 
2.5.2.3. Quantil :J:<:RON-TIl Gold In-Tube (QFT-TB G IT) 
This QFT-TB CIT test was performed according to the manuiacturer's 
instructions (QuantiI'ERON:!,-TB Gold In-Tube jPackage Insertl 20(7), as 
follows: 3ml of blnod was cnlIected from each p.trtinp~nt into :1 tub<-'s of 1 
ml «ach (Nil Contrni. Positi\'e Control, ,mJ l"B-sp(~iii(' .,ntie;ens). 
Immedi~tely after venepuncture (wh tube wus vi~oruus[y shaken up and 
downiO times tn ('nsure the' thorout;h mixint; of the bl,x,,-{ with tlw tube's 
cuntents. Upun arrival at lh« lung Infection and Immunity Laboratory 
(within 3-'\ hours nf venepuncture, as previously mentioned), tlw (21']' tulws 
were shaken again and immedi~k[y incub.,tcd ~t :17"C in un upTit;ht 
position. Ait(,,- 16-24 hours 01 incubation, the QFT tubes were centrifuged for 
'15 minutes ut 3O(XI RCT (g). in order to separal:\> the plasma from the cells, 
und the QFT tu bes were then stored at 4°C for use in the enzyme linked 











Thu~. the amount of IfN-y released was measured by ELISA. Brieilv. the 
plnsmLl from the b,ltched tubes (stored for Ll maximum of 2-:\ weeks) was 
tpnsfern'" to L~ml minofuf," tu\x·s. Ih· s.-.,.TIll'les ,md QFT-GIT hLiSA kit 
reilgl'nts. except £o( the Conjugilll' 100X Con("ellh"iltl'. were brought to n~>Ul 
tempt'ralllrl', At il'ilSt bO mjnute~ wa~ allowed for the l'<:lui libration ~ll'p. and 
during' this time, the [LISA kit test strip!' for the standards and samples were 
rrermed. The kit's freeze dried standard was rrerared by recolL~tituting 
'",ith deioniM·d 0r distilled water with the volume indicMed 0'1 the' label of 
the ~tLlndard vial (rr~'0n~titllti0n \'olume of the klt stLlnd,nd differs bdw''''n 
batch,'~) to product' a >ll,llltion wIth a final cOll<'enh:ati0r1 of K.O lUjmL. I he 
standard w~s used to rroduce ~ 1:1 dilution s~'ries llf IFN-y in Grel1' Diluent 
(contains no(m~l mouse sc(Um Jnd c~Sl'in), ~s dericted ill figuw 2.<1, 
r or tripli<ote ,tond" rdo: 
K'I<t,ndord 
(3,OIU/ml) 
" __ ' , ,,_, 7O~1 7O~1 
" - ,-" .. . ~---~.... . .?~.~., -. t..J • •. _'-; .. _._/,. 4_..:~_ 
DII""n' 






S,. nd.rd 3 
(O.15llJ/ml) 
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Fih'Ur~ 2.4. Prep"mtion of the kit sl~nd~I<ls fur '-'-"'-' in the l.hl,mtiFEROK Guld-In 
lube ass~y 
nil' heeze-drieJ kit Conjugate lOOX Conc"ntrate wa~ pn'pared b, 
H'u>l1stituting the ('oncentrate with 1l,3mL dl'ionised or distilled water and 
mixing gently. \Vorking strength conjugate was prepared from the solution 
by diluting the required amount of reconstituted conjugale in Green Diluent 











T~ble 2.1. Guideli,...:~ for the I'rCl'aratipn of the QrT-GIT kit Cnnj"83t" IIlUX 
Conn'ntratl' 
N"rnb~r uf strips V "Iurne of Coni ug"te lOOX C()n<~T\tr ~t~ h,1) V ul "me "f GrL'~n Dj]u~nt (m I) , W " , 
" 1j , W ' .0 
.. _. ... , 2" 2.3 
----------f---- .. _-- .-
" 
~ .' 0 
... -- :)5 J5 
- --, ~n '" , . , 4" , 4.5 -_ .. _ .. --- --
11.1 "f' 5.0 ._--_ .. -
" "" "." 
" "' ".0 . -_.-
The plate layout wa~ prepared acronling to the template shown in figure 2.5. 
The plasma ~amples were thoroughly mixed prior to proceeding with the 
assay. SOJ-Ii of freshly prepared working ~trength conjugate was auded to the 
appropriate ULI5A wells using a multi-channel pipette prior to adding 50J-ll 
of the plasma sample~ to the appropriate wells. Par the standard wells, 5() J-Il 
each "f the <;t,mdnrds 1-4 weTe added in h'i!'1 ic,ltc 
- - -
Row 1 2 3 4 5 b 7 8 9 10 11 
- ,' -A IN lA 1M <;1 <;1 51 13N l nA 13M 21N 21A 
B 2N 2A "1 51 52 52 "N 14A 14M 22N 221\ 
C 3N 31\ 3M 53 S3 53 1SN 151\ 15M 2::\N 2::1A 
-
~N 0 4N 4A "1 54 " 54 16N 161\ 16M 24A - . . -.-
L Sr\ I 5A 5M 'IN 9A %1 17N 17/\ 17:\-1 25N 25A , , 
I 6N' j 6A 
._. .. _- . 
1- 6M ION lOA lOr-. 1 IhN IRA 11l:\-1 26N i 26A 
G iN 7A iM llN llA! 11:\-1 19N 19A 19M 27N ZlA 
H 8~ RA 8M 12N 12A! 12:\1 20N ,",' 20:\1 28N 2Jj" , 
- - - - - -
Figure 2.5. Flail' 1,1yO"t templatc used for the Qu,mtifERO:\ Gold-In Tub<> 1.I.JSA 





















The conjugate and plasma samples/ standards were thoroughly mixed for 1 
minute using a micro-plate shaker. After mixing, the plate was covered with 
the lid and incubated at room temperature in a dark draw for 2 hours. 
During this incubation step, working strength wash buffer was prepared as 
follows: one part Wash Buffer 20X Concentrate was diluted with 19 parts 
deionised or distilled water and mixed. Thus, after incubation, the wells were 
washed 6-7 times, with 5 seconds in between each wash cycle, using 400pl of 
Ix working strength wash buffer. The plate was tapped face down on 
absorbent towel and 100 pI of Enzyme Substrate Solution 
(tertamethylbenzadine) was added to each well. The plate was covered with 
the lid and incubated at room temperature in a dark drawer for 30 minutes. 
The reaction was stopped by adding 50 pI Enzyme Stopping Solution 
(contains sulfuric acid) to the wells. The plate was read immediately after 
stopping the reaction (Anthos Labtec HT3 ELISA plate reader set on 450nm 
filter and 620nm-650nm reference filter). 
The results were calculated using the manufacturer's analysis software. The 
software was used to conduct a quality control assessment of the assay, 
generate a standard curve and provide the Nil control, Antigen and Mitogen 
control results for each sample by using the OD values. For analysis 
purposes, the Nil control result was subtracted from the mitogen control and 
the antigen-stimulated sample result to obtain the final QFT-GIT read-out 
and a result for each subject. The cut-off value for a positive test was ~ 0.35 
IU/mL of IFN-y in the sample after simultaneous stimulation with the 
specific antigens. A result was considered as indeterminate if the positive 
control was less that 0.5 IU / mL and the antigen-stimulated sample negative. 
2.5.2.4. Definition of IGRA conversions and reversions 
The conventional method, as used by the manufacturer, defines an IGRA 
conversion as a change from a negative to positive result relative to the cut-











to the cut-point) (Pai & O'Brien 2007). The conventional method was thus 
utilised during the analysis stage when the results were interpreted. 
2.5.3. Statistical Analyses 
Analysis was performed using the Wilcoxon matched pairs test when 
comparing two non-parametric data sets and the Friedman test was applied 
for comparison of results when more than two data sets were involved. The 
McNemar test was utilised to evaluate whether there was agreement 
between the antigen-specific quantitative T cell responses and culture and 
smear conversion/ reversion at 2 months, and treatment completion at 6 
months. The risk factors for change were evaluated using the relevant non-












The definite and probable TB patients were invited to donate blood at 2 and 6 
months. Only 42/269 (16%) were available for 2-month follow-up. The 
remainder, 227/269 (84%), were not available for follow-up due to the 
following reasons: 20 transferred to another clinic, 5 moved to another town, 
2 were lost to an unrelated trial (REMOX) at the clinic, 1 was untraceable 
(occupation: seaman), 2 were convicted of crimes (unable to follow-up in 
jail), 3 died, 9 interrupted their treatment course, 17 probable TB patients 
returned but had no follow-up notes/no entry, 5 untraceable/lost folders, 3 
refused to return (opted out of study), 160 did not return (unknown, no 
reason recorded on the database). We deal with a hugely migrant population 
and presume that the patients transferred to other clinics or defaulted 
treatment. There is no regional or national monitoring system in place to 
track such patients. 
Only 21/42 (50%) patients who returned at 2 months donated blood at 6 
months. The breakdown of the remainder (50%) who did not return to 
donate blood at 6 months was as follows: 2 died, 5 interrupted their 
treatment course, 1 was pregnant, 4 moved to another clinic or town, 6 
refused to return (opted out of study), and 3 were not contactable. 
Furthermore, there were only 17/21 (81 %) that were evaluable for 6-month 
follow-up, because 4 were excluded due to logistical reasons (4 ELISPOT 
results unavailable due to development errors). Moreover, due to other 
minor logistical reasons that arose during the course of the study (for 
example, HBHA availability), and the exclusion of indeterminate results, the 
analysis was divided into different subsets based on the evaluable results. 
Please refer to table 2.2 for a summary of the evaluable subsets. There was no 
systematic distribution of the groups analysed with respect to clinical 











The evaluation of the subset with the largest number of patients (baseline vs. 
2-month follow-up, n=42) was considered as the main analysis. However, 
detailed analyses were conducted for an of the subsets 
Table 2.2. Summary table of the evaluable subsets for the investigation of the use of 
a range of antigens in the serial evaluation of antigen-specific quantitative T cell 
responses of active TB patients on a course of anti-tuberculous therapy. 
o months (baseline) vs. 2-month follow-up Sample size (n) 
T SPOT (RD1) 42 
EUSPOT (PPD) 42 
EUSPOT (HBHA) 21· 
QFT GIT (RD1 & TB77.7) 28" 
o months (baseline) vs. 2-month follow-up vs. 6-month follow-up Sample size (n) 
T SPOT (RD1) 17# 
EUSPOT (PPD) 17 
ELiSPOT (HBHA) 13## 
QFT GIT (RD1 & TB7.7) 12¥ 
* 21/42 no HBHA available at the time of conducting the HBHA ELISPOT 
** 14/28 excluded due to an indeterminate QFT -GIT result either at baseline or 2 months. 
# Only 21/42 (50%) patients who returned at 2 months donated blood at 6 months. 
Furthermore, there are only 17/21 (81 %) evaluable results for the 6-month follow-up 
patients, because 4 were excluded due to logistical reasons (4 ELISPOT results 
unavailable due to development errors). 
## 4/17 no HBHA available at the time of conducting the HBHA ELISPOT 
¥ 5/17 excluded due to an indeterminate QFT-GIT result either at baseline, 2months or 6 
months. 
The clinical and demographic characteristics of the patients who returned to 
donate blood at 2 months is shown in table 2.3 (n=42). Statistical analyses 
used to compare the clinical and demographic characteristics of the 21/42 
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2.6.1. The frequency and magnitude of IGRA (T SPOT TB and QFT TB 
GIT) RD1 responses at serial time points during anti-TB treatment 
2.6.1.1. TSPOTTB 
The median T SPOT TB assay spot counts for baseline (0 months) versus 2-
month follow-up (figure 2.6 A) remained above the cut-point for positivity, 
and were not found to be significantly different (86 vs. 98, respectively; n=42; 
p=0.641). After 2-months of treatment, 26% (11/42) subjects showed a change 
across the cut-point (6 converted and 5 reverted). Furthermore, there were no 
significant differences between those who converted and those who reverted 
(refer to table 2.4 for the comparison of the relevant clinical and demographic 
characteristics of the T SPOT converters vs. reverters). 
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o months (baselne) 2-month follow-up 
n=17 
88 
6-rmnlh allow-up 2-monlh follow-up 
n=42 
p=O.641 Friedman test p=O.368 
Figure 2.6. Quantitative antigen-specific IFN-gamma responses, in active TB patients on a six-month 
course of anti-TB therapy, to RD-l antigens: (A) T SPOT.TB: summated results for ESAT-6 and CFP-IO 
at 0 months (baseline) and at 2 months post-treatment initiation [n=42], and (B) 0 months (baseline), 2 
months post-treatment initiation and at treatment completion (6 months) [n=17]. The medians for the T 
SPOT.TB assay are indicated as horizontal solid lines and the cut-points (24 SFCs/million PBMCs) are 











Table 2.4. Comparison of clinical and demographic characteristics of the T SPOT 
converters versus reverters. 
Characteristic T SPOT conversion T SPOT reversion p-value 
N(%) N(%) 
Sex 0.265 
Male 6 (100) 3 (60) 
Female 0(0) 2 (40) 
Race 0.877 
Black African 3 (50) 5 (100) 
Coloured 3 (SO) 0(0) 
HIV status 0.151 
HIV infected 1 (17) 4 (80) 
HIV uninfected 5 (83) 1 (20) 
Previous TB 0.589 
Yes 3 (50) 3 (60) 
No 3 (50) 2(40) 
Other diseases 0.964 
Yes 0(0) 0(0) 
No 6 (100) 5 (100) 
Current smoker 0.603 
Yes 3 (50) 1 (20) 
No 3 (50) 4 (80) 
On chronic medication 0.964 
Yes 0(0) 0(0) 
No 6 (100) 5 (100) 
Assessing the results of the subset of patients who returned for both the 2-
and 6-month follow-up (figure 2.6 B) revealed similar findings when 
compared to the 2-month follow-up data. The medians were above the cut-
point for positivity and that there was no significant change in the median 
spot counts (80 vs. 96 vs. 88, respectively; n=17; Friedman test p-
value=0.368). By the end of treatment, 41 % (7/17) subjects showed a change 
across the cut-point (4 converted and 3 reverted), and there were no 
significant differences between those who converted and those who reverted 












The median IFN-y levels (IU/ml) for the baseline (0 months) versus 2-month 
follow-up (figure 2.7 A) were above the QFT cut-point for positivity and 
were not significantly different (4 vs. 3, respectively; n=28; p=0.737). Only 
11 % (3/28) subjects showed a change across the cut-point (2 converted and 1 
reverted). 
A. B. 
o rmnlhs (baseline) 2 rmnlh follow-up 
n=12 
6 rmnlh follow-up 
n=28 
p=O.737 Friedman test p=O.034 
Figure 2.7. Quantitative antigen-specific IFN-gamma responses, in active TB patients on a six-
month course of anti-TB therapy, to RD-l antigens: (A) QFT-GIT (ESAT-6, CFP-I0, TB7.7) results 
at 0 months (baseline) and at 2 months post-treatment initiation [n=28], and (B) 0 months 
(baseline), 2 months post-treatment initiation and at treatment completion (6 months) [n=12]. The 
medians for the QFT-GIT assay are indicated as horizontal solid lines and the cut-points (0.35 
IU I ml) are indicated as horizontal dotted lines. 
Assessing the results of the subset of patients who returned for both the 2-
and 6-month follow-up (figure 2.7 B) revealed that there was no change in 
the median IFN-y levels, which remained above the cut-point for positivity of 
0.35 IU/ml, at baseline VS. 2-month follow-up (4 vs. 4, respectively; n=12; p-











was a significant decrease in the median IFN-y levels to below the cut-point 
for positivity of 0.35 If ml (n=12; Friedman test p-value=0.034). 
2.6.2. Evaluation of the risk factors for change in the RDt ELISPOT (T 
SPOT TB) and QFf -GIT results vs. culture and smear results 
Although there were no significant changes in the median spot counts (T 
SPOT TB) and QFT levels (QFT-GIT), as shown in the previous figures, the 
changes in the RDI responses over the course of treatment were not affected 
by confounding factors such as a history of previous TB, smoking, HIV 
infection, other diseases (for example, diabetes, hypertension and epilepsy) 
or the use of chronic medication. 
An evaluation of the possible risk factors for change (confounders) in the RD-
1 (T SPOT TB and QFT -GIT) responses at baseline vs. 2-month follow-up, 
along with the corresponding changes in culture and smear results, are 











Table 2.5. Risk factors for change in the RDl ELISPOT (T SPOT TB) results vs. 
culture and smear results 
Change No change Change No change Change No change 
Characteristic inTSPOT inT SPOT 
p-
in culture in culture 
p-
in smear in smear 
value value 
result result result result result result 
N(%) N(%) N(%) N(%) N(%) N(%) 
Sex 0.375 0.332 
Male 2(18.2) 10 (32.3) 8 (36.4) 4 (22.2) 4 (23.5) 8 (34.8) 
Female 9 (81.8) 21 (67.8) 14 (63.6) 14 (77.8) 13 (76.5) 15 (65.2) 
Race 0.272 0.130 
Black African 8 (72.7) 27 (87.1) 20 (90.9) 13 (72.2) 13 (76.5) 20 (87) 
Coloured 3 (27.3) 4 (12.9) 2 (9.1) 5 (27.8) 4 (23.5) 3 (13) 
Previous TB 0.268 0.604 
Yes 6 (54.5) 11 (35.5) 8 (36.4) 8 (44.4) 6 (35.3) 10 (43.5) 
No 5 (45.5) 20 (64.5) 14 (63.6) 10 (55.6) 11 (64.7) 13 (56.5) 
Current smoker 0.105 0.436 
Yes 4 (36.4) 20 (64.5) 12 (54.5) 12 (66.7) 10 (58.8) 14 (60.9) 
No 7 (63.6) 11 (35.5) 10 (45.5) 6 (33.3) 7(41.2) 9 (39.1) 
HIV status 0.103 0.379 
HIV infected :5 (45.5) 6 (20) 6 (28.6) 3 (16.7) 3 (17.6) 6 (27.3) 
HIV uninfected 6 (54.5) 24 (80) 15 (71.4) 15 (83.3) 14 (82.4) 16 (72.7) 
Other diseases 0.558 0.832 
Yes 0(0) 4 (12.9) 2 (9.1) 2 (11.1) 1 (5.9) 3 (13) 
No 11 (100) 27 (87.1) 20 (90.0) 16 (88.9) 16 (94.1) 20 (87) 
On chronic 0.955 0.433 
medication 
Yes 
1 (9.1) 3 (9.7) 1 (4.5) 2 (11.1) 1 (5.9) 2 (8.7) 
No 




















Table 2.6. Risk factors for change in the QFT GIT results vs. culture and smear 
results 
Change No change Change No change Change No change 
Characteristic inQFf inQFf 
p-
in culture in culture 
p-
in smear in smear 
value value 
result result result result result result 
N(%) N(%) N(%) N(%) N(%) N(%) 
Sex 0.602 0.659 
Male 3 (50.0) 18 (81.8) 10 (76.9) 9 (69.2) 11 (78.6) 9 (69.2) 
Female 3 (SO.O) 4 (18.2) 3 (23.1) 4 (30.8) 3 (21.4) 4 (30.8) 
Race 0.523 0.430 
Black African 2 (66.7) 21 (84.0) 11 (84.6) 10 (76.9) 11 (50.0) 11 (50.0) 
Coloured 1 (33.3) 4 (0.16) 2 (15.4) 3 (23.1) 11 (50.0) 11 (50.0) 
Previous TB 0.936 0.701 
Yes 2 (66.7) 11 (44.0) 6 (46.2) 5 (38.5) 5 (35.7) 7 (53.8) 
No 1 (33.3) 14 (56.0) 7 (53.8) 8 (61.5) 9 (64.3) 6 (46.2) 
Current smoker 0.322 0.443 
Yes 3 (23.1) 15 (1.0) 8 (61.5) 9 (69.2) 9 (64.3) 9(69.2) 
No 10 (76.9) 0(0.0) 5 (38.5) 4 (30.8) 5(35.7) 4 (30.8) 
HIV status 0.589 0.354 
HIV infected 0(0) 4 (16.7) 0(0) 2 (15.4) 1 (7.1) 2 (16.7) 
HI V uninfected 3 (100.0) 20 (83.3) 12 (100.0) 11 (84.6) 13 (92.9) 10 (83.3) 
Other diseases 0.534 0.565 
Yes 0(0) 2 (8.0) 0(0) 2 (15.4) 1 (7.1) 1 (7.7) 
No 3 (100) 23 (92.0) 13 (100) 11 (84.6) 13 (92.9) 12 (92.3) 
On chronic 0.750 0.458 
medication 
Yes 
1 (33.3) 2 (8.0) 1 (7.7) 2 (15.4) 1 (7.1) 1 (7.7) 
No 
2 (66.6) 2.1 (92.0) 12 (92.3) 11 (84.6) 13 (92.9) 12 (92.3) 
2.6.2.1. Changes at 2 months 
Please refer to table 2.7. The differences between the changes in T SPOT 
results vs. changes in culture and smear status from baseline to 2-months 
were statistically significant (McNemar test p-values of 0.011 and 0.023, 
respectively), and the differences between the changes in QFT GIT results vs. 




















statistically significant (McNemar test p-values of 0.035 and 0.054, 
respectively). 
Table 2.7. Summary table of the McNemar test results used to assess whether there 
was agreement between the changes in IGRA and culture and smear changes 
(conversions/reversions) in TB patients after 2 months of treatment. Significant 
McNemar test p-values (::;;0.05) denote that there is poor agreement between the 
changes in the RDl antigen-specific quantitative T cell responses (T SPOT TB and 
QFT-GIT) and the changes in culture and smear status at 2 months of treatment. 
McNemar test 
N of Valid 
Cases 
Changes in T SPOT vs. Changes in Culture from baseline to 2 months 40# 
Changes in T SPOT vs. Changes in Smear from baseline to 2 months 40# 
Changes in QFf-GIT vs. Changes in Culture from baseline to 2 months 26¥ 
Changes in QFf-GIT vs. Changes in Smear from baseline to 2 months 27¥¥ 
# Total N=42: no culture result for 2142; # Total N=42: no smear result for 2/42; 
¥ Total N=28: no culture result for 2128; W Total N=28: no smear result for 1128. 







The T SPOT TB findings at treatment completion (6 months) were similar to 
the trends displayed at 2-month follow-up. However, there was agreement 
between the changes in the QFT-GIT results and changes in culture and 
smear status at treatment completion (6 months). Please refer to table 2.8 
below, which shows that the difference between the changes in QFT -GIT 
results vs. changes in culture and smear status from 2 months to 6 months, 
and baseline to 6 months, were not statistically significant. 
Table 2.B. Summary table of the McNemar test results used to assess whether there 
was agreement between the changes (conversion/reversion) in QFT-GIT results and 
culture and smear results in TB patients at treatment completion (6 months). 
McNemar test 




Changes in QFr-GIT vs. Changes in Culture from baseline to 6 months 10 1.000 











2.6.3. The frequency and magnitude of PPD and HBHA ELISPOT 
responses at serial time points during anti-TB treatment 
2.6.3.1. PPD 
The median PPD spot counts for baseline (0 months) versus 2-month follow-
up (figure 2.8 A) remained above the cut-point for positivity, and were not 
significantly different (86 vs. 88, respectively; n=42; p=0.530). As shown in 
figure 2.8 B, the median spot counts at baseline vs. 2-month follow-up vs. 6-
month follow-up remained above the cut-point for positivity and there was a 
trend of increasing median spot counts (34, 93 and 118, respectively). 
However, the difference between these median spot counts was not 
statistically significant; n=17; Friedman test p-value=O. 101). 
A. B. 
118 
o months (baseline) 2-month follow-up o months (baseline) 2-month follow-up &month follow-up 
n:::42 n=17 
p=0.530 Friedman test p=0.101 
Figure 2.8. Quantitative antigen-specific IFN-gamma responses, in active TB patients on a six-month course of 
anti-TB therapy, to PPD antigen: (A) PPD ELISPOT results at 0 months (baseline) and at 2 months post-
treatment initiation [n=42], and (B) 0 months (baseline), 2 months post-treatment initiation and at treatment 
completion (6 months) [n=l7]. The medians for the PPD ELISPOT assay are indicated as horizontal solid lines 











2.6.3.2. Heparin-binding haemaglutinin (HBHA) 
The median HBHA spot counts for baseline (0 months) versus 2-month 
follow-up (figure 2.9 A) remained below the cut-point for positivity, and 
were not significantly different (6 vs. 10, respectively; n=21; p=O.755). As 
shown in figure 2.9 B, the median spot counts at baseline vs. 2-month follow-
up vs. 6-month follow-up remained below the cut-point for positivity (6 vs. 
10 vs. 10, respectively) and there was no significant change in the median 
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Friedman test p=0.430 
Figure 2.9. Quantitative antigen-specific IFN-gamma responses, in active TB patients on a six-month 
course of anti-TB therapy, to HBHA antigen: (A) HBHA ELISPOT results at 0 months (baseline) and at 2 
months post-treatment initiation [n=21], and (B) 0 months (baseline), 2 months post-treatment initiation 
and at treatment completion (6 months) [n=13]. The medians for the PPD ELISPOT assay are indicated as 












Overall, our results do not support the use of IGRAs as an early surrogate 
marker for treatment response in patients on anti-TB treatment. There was 
poor agreement between the changes in antigen-specific peripheral 
quantitative T cell responses and changes in sputum smear and culture 
status at 2 months and at treatment completion (6 months), irrespective of 
the use of a range of antigens (RD1, PPD and HBHA). 
As previously mentioned (please refer to chapter 1, section 1.5.5) existing TB 
treatment-related study data are conflicting. Several studies have provided 
data that support the hypothesis that anti-TB treatment leads to a decreased 
antigen burden, and in turn, a diminished frequency of circulating antigen-
specific T lymphocytes (Carrara et al 2004; Dheda et al 2007; Lalvani et al 
2001b; Pathan et al 2001; Ribeiro et al 2009). Paradoxically, in our study, the 
median T SPOT TB and PPD ELISPOT spot counts remained above the cut-
point for positivity (24 SFCs/million PBMCs). Furthermore, although there 
was no significant difference between the median spot counts over the course 
of anti-TB treatment, there was an increased frequency of circulating antigen-
specific T lymphocytes from baseline to 2 months, and at treatment 
completion at 6 months. How do we explain this increase in median spot 
counts despite the fact that these patients are on anti-TB treatment? An 
increased frequency of circulating antigen-specific T lymphocytes could be 
an indication of re-infection or a high burden of disease with slow decay in T 
cell responses. There may be a genetic patient-specific differential effect of 
the variability in pattern recognition receptors for immunogenic RD-l 
epitopes, and perhaps an effect of CD4+ regulatory T cells (Dosanjh et al 
2008; Lalvani et al 2001a), thus resulting in higher or lower T cell counts in 
some active TB patients. 
Our findings are consistent with those of several previous studies, which 
demonstrated persistently high or positive RD-l-specific test results, even 











(Ferrand et al 2005; Ulrichs et al 2000a; Ulrichs et al 2000b). Furthermore, 
available data suggest that serial IGRA conversion rates may be much higher 
in high-burden settings compared with low-burden settings (Pai & O'Brien 
2007). However, there are limited data from high burden settings. A study of 
LTBI-treated Health-care workers (HCWs) in India found that at 6-month 
follow-up, the subjects had persistently positive IGRA reponses (Pai et al 
2006a). Furthermore, only one study evaluated serial IGRA responses over 
18 months (Pai et al 2006b). However, prospective studies are required in 
HCWs from high-burden settings, to determine the predictive value of 
IGRAs for active disease and for the evaluation of serial treatment-related 
responses over the course of anti-TB treatment. A treatment-related study in 
another high burden setting (The Gambia), showed that the levels of IFN-y 
production in response to PPD (n=7) remained above the cut-point for 
positivity and unchanged throughout the study (6 months of treatment and 
follow-up at 9 months) (Turner et al 2000). Serial frequencies of antigen-
specific T cell treatment-related responses (in-house ELISPOT assay) in 
Ugandan active TB patients were also persistently high 3-12 months after 
treatment completion (Goletti et al 2008). The median PPD ELISPOT 
responses also remained above the cut-point for positivity in our study. 
Furthermore, we found that the median T SPOT TB and PPD ELISPOT spot 
counts were quite similar (T -SPOT TB and PPD ELISPOT median 
SFCs/million PBMCs at baseline vs. 2-month follow up were 86 vs. 98 and 86 
vs. 88, respectively). 
The significant decrease in QFT -GIT responses at 6-month follow-up 
suggests that this test may be a helpful treatment-related response indicator 
closer to the end of treatment completion. However, it is unclear why this 
decrease was not seen at 6-months when using the T-SPOT.TB and PPD 
ELISPOT assays. Besides the two assays having different properties (QFT 
measures IFN-y responses in whole blood, whereas T-SPOT TB and PPD 
ELISPOT measures responses in PBMCs), this difference could perhaps have 
been due to Type I error (attrition bias/loss-to follow-up). Furthermore, we 











driving immunosuppressive regulatory T cells or inhibitory pathways 
(Dheda et al 2009c; Guyot-Revol et al 2006). 
As outlined in the literature review (p. 31), and in contrast to RD-l antigens, 
it has been found that cells from individuals with LTBI release IFN-y in 
response to HBHA, whereas cells from definite TB patients do not 
(Temmerman et al 2004). However, in our study HBHA appeared to have 
poor discriminatory value. Further studies are needed to explain these 
findings, because the regulatory T cell profile, which may be involved in 
modulating HBHA responses, may be different in high burden countries and 
when compared with RD-l antigen responses. 
Investigations using genomic, proteomic and suspension array technologies 
are required to find new biomarkers that may be useful for tracking disease 
activity (Dheda et a12010b; Walzl et aI2008). Indeed, an essential role of IFN-
y in response to infection with M.th is the activation of macrophages. In 
delayed hypersensitivity reactions to tuberculin PPD, IFN-y has been found 
to induce downstream chemokines such as IFN-y inducible protein (IP-I0 or 
CXCLI0), monokine-inducible protein (MIP or CXCL9), and monocyte 
chemo-attractant protein 2 (MCP-2) (Kaplan et al 1987). Also, studies have 
reported the presence of these IFN-y inducible chemokines in the plasma 
(Ruhwald et al 2007) and pleural effusions (Okamoto et al 2005) of TB 
patients. These markers require further evaluation in serial time-point 
studies in active TB patients. Clearly, IGRAs do not fulfil this requirement. 
Further studies using different biomarkers, and alternative antigens, are 
required to clarify the issue. 
The rapid diagnosis of active pulmonary cases is important for TB control 
and there is a great need for novel immunotherapeutic interventions. 
However, evaluating these interventions is problematic, because it takes 
several years to complete treatment evaluation studies (Perkins et al 2006). 
Thus, it would be beneficial if a rapid proxy marker could be used as a 











patient is likely to relapse after treatment. However, quantitative T cell 
assays are unlikely to fulfil the promise created by earlier studies. 
A limitation of the study is that, due to quantitative chest X-ray scores being 
unavailable at the time of analysis, we were unable to assess whether the 
extent of disease (disease chronicity) accounted for some of the changes 
observed. Nevertheless, irrespective of specific antigens (RDl, PPD, HBHA), 
culture remains one of the best treatment monitoring tools. Larger 
longitudinal studies with long-term patient follow-up and using different 
antigens are now required to determine the utility of various antigen-specific 













Delayed Enumeration of TB-spedfic T Cell Responses and the Evaluation 
of T Cell Xtend 
3.1. INTRODUCTION 
During the initial stages (recruitment of the first 100/500 subjects), it became 
evident that a major drawback of the enzyme-linked immunospot (ELISPOT) 
interferon gamma release assay (T-SPOT®.TB) is that sample processing must 
be started within 8 hours of the blood-draw. This imposes logistical 
limitations when sample transport takes longer than expected or dispatch to 
the laboratory is delayed (not uncommon for peripheral clinics or when 
patients are seen in the afternoon), and may increase labour costs if a 
technician is required to process samples after normal working hours. 
Furthermore, batching of samples over 48 to 72 hours is not possible. The 
manufacturer of T-SPOT®.TB (Oxf rd Immunotec Ltd.) recently introduced a 
proprietary reagent, T-Cell Xtend, which has been designed to allow for the 
delayed processing of blood samples without a reduction in test accuracy. 
According to the manufacturer's package insert, T-Cell Xtend™ is an 
antibody complex directed against specific cell surface antigens on human 
blood cells. This proprietary antibody complex enables the cross-linking of 
red blood cells with selected white cells. The selected cells form a pellet when 
applied to density gradient centrifugation, thus allowing the removal of cells 
that may confound ELISPOT T helper cell 1 (Thl) responses [T-Cell Xtend™ 
mechanism of action, Oxford Immunotec Ltd. 2009]. Flexibility in sample 
processing may improve test utility of the quantitative antigen-specific T-cell 
assay (T-SPOT®.TB). Thus, it would be advantageous if blood could be 
processed the day after it is drawn without compromising assay 
performance. Moreover, there are limited data comparing TB-specific 











times (Meier et al 2005). The current study was thus designed and 
incorporated for the remainder of the T-SPOT®.TB evaluation. 
The main purpose of this component of the study was to investigate the 
effect of delayed processing on test accuracy in a clinical setting. 
Accordingly, blood samples were processed immediately (day 0) and at 
different times after receipt of the sample [~ 24 hours (day 1) or ~ 32 hours 
(day 2)] with and 'without the addition of T-Cell Xtend™. We hypothesised 
that delayed sample processing of blood for use in the T SPOT TB assay 
impacts upon test accuracy of the assay, and that the use of T-Cell Xtend™ 
allows for the delayed processing of blood for up to 32 hours for use in the T 












To investigate whether delayed sample processing 'with and without the use 












3.3. MATERIALS AND METHODS 
3.3.1. Clinical recruitment 
The subjects for the current study were recruited as part of the SAIGRA 
prospective cohort parent study (please refer to chapter 2 for the sample 
recruitment site details). After ~10ml blood was assigned for use in the 
treatment-related study (chapter 2) and various unrelated ongoing studies, 
the remainder of the sample was available for use in the current study, in 
which blood samples from 363 sequentially recruited adult TB suspects and 
patients on treatment, from Cape Town, South Africa, were processed at two 
study sites, namely, the Lung Infection and Immunity Unit (main study site) 
and Biotec Laboratories South Africa Ltd. The study flow diagram is shown 
in figure 3.1. 












paired results Day 0 
withoutTCX'" vs. day 
o with TCX 
20 sequ entially recru ited 
subjects: 
Group1: Group2: Group3: 
3-way serial analysis Day 
o withoutTCX vs. day 1 




paired results Day 0 
withoutTCX vs. day 
1 (24-26 hours) 
withoutTCX 
The relevant statistical analyses were used to evaluate the following: 
• Inter-lime point agreement between ELiSPOT results for each group 
• The number of conversions/reversions 
195 sequentially 
recruited subjects: 
paired results Day 0 
withoutTCX vs. day 1 
(24-26 hours) with 
TCX, and 20 paired 
results from the 3-way 
serial analysis (n=215t ) 
12 sequentially 
recruited subjects: 
paired results Day 0 
withoutTCX vs. day 2 
(32 hours) with rcx 
303 evaluable, paired T SPOT results, and 60 patient samples excluded [19 indeterminate ELiSPOT resuns, 18 inadequate PBMC yield 
(either for day 0, 1 or 2), 23 other (4 development error, 3 incubator malfunction, 16 administrative errors on case record forms)]. 
Due to logistical and sample constraints, the study was conducted in a step-wise fashion by conducting a preliminaryloptimisation phase in 
a small group of sequentially recruited subjects, followed by a validation phase in a larger number of subjects who were 
sequentially recrutted for each of the three main study protocol groups 
TCX:T-Cell Xtend 
t For group 2, 159/215 samples were processed at the main study site (Lung Infection and Immunity Untt), and 56/215 samples were 
processed at another site (Biotec Laboratories South Africa Ltd, Cape Town). When these 56 samples were excluded from the analysis the 
conclusions remained unchanged. Thus, analysis at a different site did not impact on the findings presented. In any event both technicians 
were experienced and trained. 
Figure 3.1. Study flow diagram for the investigation of the delayed enumeration of 











conducted using two phases, namely, a preliminary/optimisation phase and a 
validation phase. 
Consecutive unselected patients were recruited and there was equal 
distribution of the sub-groups analysed with respect to clinical background 
or HIV status. Ethical approval was obtained from the University of Cape 
Town Health Sciences Faculty Research Ethics Committee and the 
Committee for Human Research, University of Stellenbosch, Tygerberg. All 
subjects signed informed consent prior to entering the study. 
3.3.2. Laboratory methods 
Blood (-20m!) was drawn from all participants into lithium-heparin tubes 
(BD Europe) and transported to the laboratory within 3-4 hours where 
peripheral blood mononuclear cells (PBMCs) were isolated from -10m! 
blood for the treatment-related study (chapter 1) and other unrelated studies. 
The remainder of the sample (-5-10m!) was used for the current study, in 
which blood was processed at different times (as shown in figure 3.1, p.77) 
for use in the T-SPOT®.TB assay. For all samples, the blood was stored at 
room temperature (18-25°C) during transport and was assayed within 8 
hours of venipuncture (ie. on the day of blood collection as recommended by 
the manufacturer of the T-SPOT.TB assay). 
3.3.2.1. Isolation of peripheral blood mononuclear cells: 
The blood sample for use in the current study (5m!) was transferred from the 
lithium-heparin tube (BD Bioscience, South Africa) to a 15m! conical 
centrifuge tube, directly diluted 1:1 with 1x phosphate buffered saline (ie. 
excluding the initial centrifugation step, as described in chapter 2, in which 











top of 3-4 ml l'icoll_raquc''lM Thereafter, the steps were conduded ,l~ 
previously tk>f.Cribed (plea"", refer to chapter 2, pp.50-53). 
3.3.2_2. The use of T Cell Xlend 
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Figure 3.2. Sim plifif'<l flow diagram showing how I-Cell Xknd should be 











3.3.2.3. The ELISPOT (T-SPOT.TB) assay 
The T-SPOT.TB assay was conducted according to the manufacturer's 
instructions (T-SPOT®.TB [package insert] 2008), as previously described 
(chapter 1). However, the well layout was as follows: panel A (ESAT-6), 
panel B (CFP-10), positive control (PHA) and negative control (AIM-V 
medium). Thus, the T SPOT TB assay was conducted by seeding the PBMCs 
at a final concentration of 250,000 PBMCs per wen (ie. 100ul of the 2.5x106 
cells/ml cell suspension into each well), and adding 50 III of the relevant 
antigens and controls to the T SPOT wells (according to the above-mentioned 
well layout). The antigen-specific T cell responses were scored and the test 
results were interpreted accordingly (as previously described in chapter 1). 
3.3.3. A preliminary/optimisation phase was conducted to investigate the 
following: 
1) To evaluate whether T-Cell Xtend impacted upon spot counts, 
independent of time delay, paired samples from a group of 10 sequentially 
recruited subjects were processed on day 0 with and without T-Cell Xtend. An 
intra-assay variance control was also included in this part of the analysis, and 
a within-operator variability experiment was performed. 
2) To gain a preliminary idea of the overall effect of T-Cell Xtend on delayed 
processing, serial testing (by means of a 3-way analysis) on day 0 without T-
Cell Xtend, day 1 without T-Cell Xtend and day 1 'with T-Cell Xtend was 
conducted in a group of 20 sequentially recruited subjects. Given the 
logistical constraints and the limited amount of blood sample it was not 
possible to perform the detailed 3-way serial analysis (with and without T-Cell 
Xtend) on all samples for the entire duration of the study. Therefore, after this 
optimisation phase only 2-way comparisons were performed in the 











3.3.4. For the validation phase the cohort was divided into three study 
protocol groups: 
Group 1) To evaluate whether delayed processing at ~ 24 hours 
(independent of T-Cell Xtend) impacted upon the results, paired samples, 
from 66 sequentially recruited subjects, were processed "without T-Cell Xtend 
on day 0 and day 1. 
Group 2) To evaluate whether delayed processing ~ 24 hours (with the 
addition of T-Cell Xtend) impacted upon the results, paired samples from 195 
sequentially recruited subjects were processed on day 0 without T-Cell Xtend 
and day 1 with T-Cell Xtend. Also, the day 0 without T-Cell Xtend vs. day 1 
with T-Cell Xtend results for the 20 subjects that formed part of the 
optimisation phase (3-way analysis) were included in group 2. Hence, there 
were a total of 215 evaluable results for this part of the analysis. 
Group 3) To assess whether processing of blood could be delayed for up to 
32 hours, paired samples (from a group of 12 sequentially recruited subjects), 
were processed on day 0 without T-Cell Xtend and on day 2 'with T-Cell Xtend. 
The baseline (day 0) sample was processed immediately upon arrival at the 
laboratory. The samples for delayed processing [a delay of either ~24 hours 
after receipt (day 1) or ~32 hours after receipt (day 2)] were stored at room 
temperature in an upright position in a dark drawer and processed in the 3 
main study protocol groups, at the relevant time-point, with or without the 
addition of T-Cell Xtend. The groups were sequentially recruited to answer 











3.3.5. Definition of conversions and reversions 
Conversions and reversions were defined in 2 ways: 
(i) Based on data from van Zyl-Smit and colleagues (van Zyl-Smit et al 2009), 
conversions were defined as an increase in interferon gamma (lFN-y) 
response from below 6 spots to above 9 spots (greater than or equal to 3 spots 
on either side of the manufacturer's cut-point of 24 SFCs/million PBMCs), 
and reversions were defined as a decrease in lFN-gamma response from 
above 9 spots to below 6 spots. 
(ii) The conventional method, as used by the manufacturer, defines an lGRA 
conversion as a change from a negative to positive result relative to the cut-
point, and a reversion as a change from a positive to negative result relative 
to the cut-point) (Pai & O'Brien 2007). Method (i) was used for the analysis of 
the current study. However, method (ii) was also taken into account. 
3.3.6. Statistical Analyses 
Analysis was performed using the Wilcoxon matched pairs test when 
comparing two non-parametric data sets. Fischer's exact testing was used to 
determine the significance levels when comparing concordance and the 
Friedman test was applied for comparison of results when more than two 
data sets were involved. A detailed comparison was required to evaluate 
whether the use of T-Cell Xtend enabled processing without reducing test 
accuracy. Taking into account that there were 66 subjects in group 1 and 215 
subjects in group 2, the number of conversions and reversions across the 
groups were compared using the Wilcoxon Signed Ranks test (Mann-












3.4.1. Clinical and demographic information 
The participants were predominantly male (236/363; 65%) and the median 
age was 33 (range 18-83) years. HIV testing was performed in 85% (307/363) 
of participants. Of those who were tested, 78 % (240/307) were HIV negative. 
Thirty percent of the participants were patients receiving anti-TB treatment 
and the remainder were unselected TB suspects. The ELISPOT results for 
60/363 (17%) were unavailable: 19 were indeterminate, 18 had an inadequate 
PBMC yield (either for day 0, 1 or 2) so the assay could not be performed, 4 
failed due to plate development errors, 3 were invalid due to an incubator 
malfunction and there were irreconcilable administrative errors on the case 
record forms for 16 subjects. Thus, a total of 303/363 (83%) subjects yielded 
evaluable ELISPOT results and could therefore be included in the analysis 
(please refer to the study flow diagram, figure 3.1 on p.77). 
3.4.2. OPTIMISATION PHASE: 
3.4.2.1. T-Cell Xtend independent of delay did not impact on test results 
at baseline (day 0) 
The median spot counts for day 0 with T-Cell Xtend vs. day 0 without T-cell 
Xtend were not significantly different (46 vs.49; p=0.94; n=10, figure 3.3) and 
there were no conversions or reversions (changes across the cut-point). 
An intra-assay variance control was included which showed that intra-test 
variability was minimal (figure 3.4), and a within-operator variability 
experiment also showed that variability was minimaL Please refer to the raw 






























dayO (without T-Cell Xtend) day 0 (with T-Cell Xtend) 
Figure 3.3. Summated response to ESAT -6 and CFP-l0: day 0 without T-Cell Xtend 
vs. day 0 with T-Cell Xtend. The medians are indicated as horizontal solid lines and 
the cut-point (24 SFCs/million PBMCs) is indicated as a horizontal dotted line. 
sample 1.3 sample 1.4 
Figure 3.4. One sample was split into 6 (1.1-1.6), processed in parallel by the study 
operator, and seeded at a final concentration of 250000 PBMCs per well. Intra-test 
variability was found to be minimal [average summated spot count =4.8 (values 











Table 3.1. A within-operator variability experiment showed that variability was 
minimal. 
Technician Technician Technician 
1 2 3 
19 and 16 19 and 17 18 and 23 
ESAT-6 spot count (in duplicate) Average: Average: Average: 
18 18 21 
17 and 11 16 and 14 19 and 18 
CFP-I0 spot count (in duplicate) Average: Average: Average: 
14 15 18 
Positive control spot count (in duplicate) 
Too Too Too 
numerous numerous numerous to 
to count to count count 
Negative control spot count (in duplicate) 0 0 0 
3.4.2.2. Three-way serial analysis: 
Ihere were no significant differences between the median spot counts for 
day 0 without I-Cell Xtend vs. day 1 without I-Cell Xtend vs. day 1 with I-Cell 
Xtend (70, 66 and 56, respectively; n=20; Friedman statistic= 0.46; p-value= 
0.80, figure 3.5). 
One subject reverted across the cut-point on day 1 without I-Cell Xtend, but 
with the addition of I -Cell Xtend this reversion did not occur (table 3.2 box 






















III 450 0 
:::IE 400 











day 0 (without T-Cell Xtend) day 1 (without T-Cell Xtend) day 1 (with T-Cell Xtend) 
Figure 3.5. Summated response to ESAT-6 and CFP-I0 on day 0 without T-Cell 
Xtend vs. day 1 without T-Cell Xtend vs. day 1 with T-Cell Xtend (n=20). The 
medians are indicated as horizontal solid lines and the cut-point (24 SFCs/million 











Table 3.2: Agreement between serial T-SPOT®.TB results with and without T-Cell 
Xtend [agreement= the sum of those who remained T-SPOT positive (;:,::24 
SFCs/million PBMCs) and those who remained I-SPOT negative «24 SFCs/million 
PBMCs) divided by the total sample size]. 
A.'" A 1. Day 1 without T-Cell Xtend A 2. Day 1 with T-Cell Xtend 
T-SPOT+ T-SPOT - T-SPOT+ T-SPOT -
Day 0 without 
T-CeliXtend T-SPOT+ 13 1 14 0 
T-SPOT - 0 6 0 6 
s....."'* Day 1 without T-Cell Xtend 
T-SPOT+ T-SPOT -
Day 0 without 
T-SPOT+ T-CellXtend 49 1 
T-SPOT - 2 14 
~*::4I::* Day 1 with T-Cell Xtend 
Day 0 without 
T-SPOT+ T-SPOT -
T-Cell Xtend T-SPOT+ 142 3 
T-SPOT· 3 67 
~*::t:*:It: Day 2 with T-Cell Xtend 
T-SPOT+ T-SPOT -
Day 0 without 
T-SPOT+ 10 1 T-CeliXtend 
T-SPOT - 0 1 
* Box Ai and A2 = the agreement between results for the 3-way analysis of the same sample (day 0 
without T-Cell Xtend, day 1 without T-Cell Xtend and day 1 with T-Cell Xtend; n=20). 
** Box B = the agreement between paired T-SPOT results for day 0 and day 1 (both without T-Cell 
Xtend; n=66) 
*** Box C = the agreement between paired T-SPOT results for day 0 withoutT-Cell Xtend and day 1 
with T-Cell Xtend. Box C excludes the 3 converters/reverters who fall within the borderline zone; hence 
for the purpose of calculating inter-time-point agreement, the corrected sample size total is n=215 
minus 3=212. 
**** Box D = the agreement between paired T-SPOT results for day 0 without T-Cell Xtend and day 2 











3.4.3. V ALIDATION PHASE 
3.4.3.1. Delayed processing (~24 hours) without T-Cell Xtend resulted in 
significant changes in ELISPOT results 
The median spot counts on day 1 without T-Cell Xtend were found to be 
significantly higher than day 0 without T-Cell Xtend (114 vs.l00; p=O.03; n=66; 
figure 3.6 A). Inter-time-point agreement between the results was 95.45 % 
(table 3.2 box B, p.87), and 4.54 % subjects showed conversion or reversion 
across the cut-point (figure 3.6 B). These results were similar when the HIV 
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d.,o IMIhclll T -cen lOend,l d!IIJ 1 IUIhllllt T -CelllOeneil 
Figure 3.6. Summated response to ESAT-6 and CFP-10 on day 0 vs. day 1 (both 
without T-Cell Xtend). A line graph of each individual's summated response is 
shown in figure A (n=66). For the whole group, 2 conversions and 1 reversion 











Zyl-Smit et a12009) and were thus all considered to be true conversions/reversions 
(B). The medians are indicated as horizontal solid lines and the cut-point (24 
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Figures 3.7. Summated response to ESAT-6 and CFP-IO on day 0 vs. day 1 (both 
without T-Cell Xtend): response of the HIV negative subjects only (n=51; A) and the 
HIV positive group (n=15; B). The medians are indicated as horizontal solid lines 
and the cut-point (24 SFCs/million PBMCs) is indicated as a horizontal dotted line. 
3.4.3.2. Delayed processing (~24 hours) with T-Cell Xtend maintained a 
high level of inter-time-point agreement, but the number of 
conversions/reversions was not significantly reduced 
The median spot counts were the same at day 0 without T-Cell Xtend vs. day 1 
'with T-Cell Xtend (56 vs 56; n=215; p= 0.42; figure 3.8 A). When processing 
was delayed for ~24 hours with the addition of T-Cell Xtend, a total of 4 
subjects crossed the cut-off from positive to negative (reverters), but 2 of 
these fall within the 'borderline zone' and were thus not considered to be 











positive (converters), but 1/5 fell within the 'borderline zone' and was thus 
not considered to be a true converter. Thus, agreement between the results 
was 97.17% (table 3.2 box C, p.87) and the conversion/ reversion rate was 
2.83 % (the summated IFN-y responses of the 4 true converters and 2 true 
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Figure 3.8. Summated response to ESAT-6 and CFP-IO on day 0 without T-Cell 
Xtend vs. day 1 with T-Cell Xtend. A line graph of each individual's summated 
response is shown in figure A (n==215). For the whole group, a total of 9 
conversions/reversions occurred. However, 3 of the 9 conversions/reversions fall 
within the 'borderline zone' (van Zyl-Smit et al2009). Hence, only 6 (4 conversions 
and 2 reversions) were considered to be true conversions/reversions (B). The 
medians are indicated as horizontal solid lines and the cut-point (24 SFCs/million 
PBMCs) is indicated as a horizontal dotted line. 
The difference between the number of conversions/reversions for group 1 
(day 0 without T-Cell Xtend and day 1 'without T-Cell Xtend) vs. group 2 (day 0 
'without T-Cell Xtend vs. day 1 with T-Cell Xtend) was not statistically 












































_0 IlIIiIhoLil T -Cellxtend) 
Hillneaom.e 
dll!ll 11111i1h T-Cell Xlendl 
Hllln"ll_" 
dIllJI'll jailhllilt T-Cell lOend) 
HlVplIlIIit;"e 
dllll'1 jailhT -Cell Xlelld! 
HlVpllllilive 
Figure 3.9. Summated response to ESAT-6 and CFP-I0 on day 0 without T-Cell 
Xtend vs. day 1 with T-Cell Xtend: response of the subjects who had a negative HIV 
test result (n=115/159; A) and the HIV positive group (n=37/159; B). HIV results for 
7/159 subjects were unknown. The medians are indicated as horizontal solid lines 
and the cut-point (24 SFCs/million PBMCs) is indicated as a horizontal dotted line. 
3.4.3.3. Delayed processing for up to 32 hours with T-Cell Xtend resulted 
in high inter-lime-point agreement, but the number of 
conversions/reversions was not significantly reduced 
The median spot counts were not significantly different in samples processed 
on day 0 -without T-Cell Xtend vs. day 2 with T-Cell Xtend (96 and 106; n=12; 
figure 3.10). Inter time-point agreement between the results was 92% (table 






















== 2DD 'E 2DD -III 
U 
~ 11D 
96 106 1DD 
DL ___ ~====::::::::::::==;;;:;;:;;;;,_---- n= 12 
d iI¥ D (wittlalJl: T-Cell Iterld, dll,2 (With T-Cell Iterld) 
Figure 3.10. Summated response to ESAT-6 and CFP-IO on day 0 without T-Cell 
Xtend vs. day 2 with T-Cell Xtend (n=12). The medians are indicated as horizontal 
solid lines and the cut-point (24 SFCs/million PBMCs) is indicated as a horizontal 
dotted line. 
3.4.4. Individually scored RDl antigen-specific spot counts 
For all groups, a similar pattern was seen when the data was analysed using 
the individually scored RD1 antigen-specific spot counts compared to the 
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Figure 3.11. Group 1 (delayed processing at ~ 24 hours, independent of T-Cell 
Xtend): The median SFCs/million PBMCs for the summated RDl antigen responses 
were 100 vs. 114, respectively, n==66, p==0.03 (as shown previously). A similar trend 
was seen when the results were displayed using (A) the individually scored 
SFCs/million PBMCs for ESAT-6, and (B) the individually scored SFCs/million 







~ c ~ 
~ ! II. 
II. e e 
'" 
~ 
1 li <> 
;! ... Q. 
:i ... 0 
w .!! .e .. .. .. .. c 
li 8-... .. .. .. .. co: co: 
Figure 3.12. Group 2 (delayed processing ~ 24 hours, with the addition of T-Cell 
Xtend): There were no significant differences between the median SFCs/million 
PBMCs for the summated RDI responses (56 vs. 56, respectively, n==215, p==0.42 (as 
shown previously), and a similar pattern was seen when the when the results were 
displayed using (A) the individually scored SFCs/million PBMCs for ESAT-6, and 












The main aim of this study was to investigate whether delayed sample 
processing with and without the use of T-Cell Xtend impacted upon the 
accuracy of the T-SPOT®.TB assay. This study is of practical relevance, 
because if samples could be batched over a period of 1-2 days, the utility of 
the assay would be improved and costs reduced through avoidance of after-
hours sample processing. 
During the analysis phase of the study, the SFCs for each antigen were 
individually scored, and then compared to the summated spot count. Thus, 
we are certain that the overall principal findings are not affected by using the 
summated SFC scores. Other studies have also used summated RDl values 
to perform their analyses. For example, Bosshard and colleagues (Respiratory 
Medicine, 2009) reported SFC values as [highest SFC value of ESAT-6 or 
CFP-I0 antigen - SFC value of negative control] (Bosshard et al 2009) and 
there are several others (Dheda et al 2009c; Lalvani et al 200la). The main 
advantage of this approach, g ven the large amount of data and graphs, is 
that it is less confusing and improves readability and understanding of the 
data. Using a combined antigen-specific readout (i.e. highest spot count) did 
not impact on the conclusions compared to using the SFCs for each antigen. 
It was shown that splitting the data by antigen made little difference. 
When analysing the summated results, at first glance, the addition of T-Cell 
Xtend appeared to maintain a high level of accuracy when processing was 
delayed. However, from a clinical point of view, a categorical change in the 
result (the number of conversions and reversions) is a more meaningful 
measure of the effect of T-Cell Xtend. There was a high agreement between 
ELISPOT results despite a processing delay of over 24 hours and the use of T-











4.54% to 2.83%. However, this reduction was not statistically significant. This 
may be due to type II error and using a larger sample size may have 
demonstrated a significant difference. Nevertheless, in the serial analysis 
using the same sample (day 0 without T-Cell Xtend vs. day 1 without T-Cell 
Xtend vs. day 1 'with T-Cell Xtend), even though the median spot counts were 
not significantly different, with the addition of T-Cell Xtend, all reversions 
were eliminated. 
Conversions and reversions have been defined in this study in accordance 
with recent findings, which show that an increase in IFN-y response from 
below 6 spots to above 9 spots (3 spots on either side of the cut-point) 
accounts for + / - 95 % of the within-subject variability for the T -SPOT. TB 
assay, and values within this 'borderline zone' are not considered to be true 
conversions/reversions (van Zyl-Smit et al 2009). This evidence-based 
definition is more robust compared to the conventional definition (IGRA 
conversion= change from a negative to positive result relative to the cut-
point and reversion= change from a positive to negative result relative to the 
cut-point) (Pai & O'Brien 2007). Using the evidence-based definition, 
although there were 9 conversions/reversions (figure 3.8 A), 3 of them were 
within the 'borderline zone'. Thus, there were only 6 true 
conversions/reversions (figure 3.8 B) and the conversion/reversion rate was 
2.83%. Nevertheless, whichever definition is used (conventional vs. evidence-
based), the addition of T-Cell Xtend did not significantly reduce the number 
conversions/reversions (namely, 4.55% vs. 2.83% as defined by van Zyl-Smit 
et al (van Zyl-Smit et al 2009) or 4.55% vs. 4.19% as defined by the 
conventional definition). 
An important question that needs to be answered, though, is what is the 
exact mechanism of action of T-Cell Xtend and how do we explain an 
increase in spot counts despite storage of blood under hypoxic conditions, 











processing on T cell counts is complex and poorly understood. Furthermore, 
given the proprietary nature of the product, the exact mechanism by which 
T-Cell Xtend works remains unclear. Delayed processing may reduce the 
frequency of the T cell marker CD127 (Higgins et a12005), reduce plasma IL-
7 levels (Read et al 2006), and increase the frequency of granulocytes that 
have T cell inhibitory properties (McKenna et al 2008). Indeed, recently 
released information from Oxford Immunotec Ltd. has confirmed that the 
selected white cells that are removed by T-Cell Xtend are in fact granulocytes 
(Oxford Immunotec Ltd 2009). 
It is also possible that other immunosuppressive cells or pathways (T 
regulatory cells or cells producing IL-l0, TGF-~, IL-4 and IL-9) are impacted 
upon by delayed processing. There may be a patient-specific differential 
effect of these factors as delayed processing may result in higher T cell counts 
in some patients, whilst in others the counts are reduced. Further studies are 
needed to clarify this issue. Nevertheless, delayed processing without T-Cell 
Xtend, but not with it, paradoxically resulted in significantly higher spot 
counts (100 vs. 114 in the whole group and 116 vs. 144 SFCs/million PBMCs 
in HIV uninfected patients). Although this may be related to sample size, we 
hypothesise that, in addition to granulocytes, potentially immuno-
stimulatory cells, for example Thl regulatory cells (Koch et al 2009), may 
drive responses during delayed processing. Further studies are now required 
to delineate these pathways, which appear, based on our results, to be 
independent of HIV status. The effect of a greater processing delay on spot 
counts, and alternative methods to preserve cellular integrity and function 
are also required to further improve the utility of the assay. A limitation of 
the study is that, due to resource constraints and limited sample volume, a 
small sample number was used for the day 2 analysis and the assays could 
not simultaneously be conducted in the absence and the presence of T-Cell 
Xtend. Furthermore, these data pertain to samples obtained in a high burden 












Clinical Utility of the Clearview-TB®-ELISA Lipoarabinomannan Assay 
Using Urine Samples from HIV -infected tuberculosis Patients 
4.1. INTRODUCTION 
The clinical utility of the Clearview-TB®-ELISA (Inverness Medical 
Innovations, USA), a standardised and commercially available 
lipoarabinomannan (LAM) antigen-detection assay designed for TB 
diagnostic testing, requires clarification. As previously mentioned, currently 
used tools such as smear microscopy have a very low sensitivity and culture 
testing takes several weeks (Pai et al 2006c). Moreover, newer technologies 
such as the T cell assays are not useful as rule-in tests for the diagnosis of 
active TB in adults (Dheda et al 2009a) and molecular assays such as NAAT 
are not widely available in high burden settings (Pai et al2006c). Thus, there 
is an ongoing search for a rapid point-of-care (POC) test (Pai et a12009). 
Urine is a sterile and easily obtainable biological fluid that can be assayed. 
Hence, this test option is appealing, especially if it can be used for diagnosing 
TB in patients who are sputum-scarce, and even children. Furthermore, a 
dipstick-friendly prototype of the test has also been developed and is 
currently undergoing validation testing for use as a POC test. 
Although it is known that LAM may be useful in HIV-infected patients 
(Lawn et al 2009; Shah et al 2009) the precise sub-groups that may benefit 
from this test in a high burden primary care setting remains unknown. Most 
TB cases present to and are diagnosed in primary care facilities. Existing data . 
about the performance outcomes of the urine MTB ELISA Test® (Chemogen) 
in a primary care setting is limited (Reither et al 2009) and urgent 
clarification about the utility of the urine Clearview® LAM ELISA is required. 











stratified by CD4 count in unselected TB suspects from a primary care 
setting. Previous studies that have stratified the outcome of the LAM test 
result by CD4 count are limited (Lawn et al 2009; Shah et a12009). Thus, the 
aim of the study was to evaluate performance outcomes using the Clearview-
TB® LAM ELISA on urine samples from TB suspects recruited at primary 
care facilities in a high burden setting, and to determine the diagnostic 












4.2. HYPOTHESIS AND AIMS: 
Hypothesis: 
The Clearview® LAM ELISA may be a useful rapid tool for tuberculosis 
diagnosis in HIV-infected TB suspects attending primary care facilities in a 
high burden setting. 
Aims: 
1. To evaluate performance outcomes of the Clearview® LAM ELISA 
when using urine samples in HIV -infected and uninfected patients 
with suspected TB. 
2. To determine the diagnostic accuracy of urine LAM in HIV-infected 











4.3. MATERIALS AND METHODS 
4.3.1. Participants and study design 
Five-hundred TB suspects were consecutively recruited from primary care 
facilities (as mentioned in Chapters 2 and 3), which operate within the Cape 
Town Metro Region (South Africa). Clinical, physical and demographic 
information was recorded for each subject on detailed case record forms. All 
subjects signed informed consent and the study was approved by the 
University of Cape Town Human Research Ethics Committee. After 
appropriate counselling an HIV test was conducted and for the participants 
who were HIV-infected, a CD4 count was also determined. Blood, saliva, 
sputum and urine samples were collected from each subject and transported 
to the Lung Infection and Immunity Unit within 3-4 hours for further testing. 
For the current study, the urine samples were required for LAM detection 
testing. LAM detection testing was also conducted on the sputum samples. 
However, only the urine data is reported in this dissertation, please refer to 
our published manuscript for the full comprehensive study (Dheda et al 
2010a). 
Two sputum samples were collected for routine fluorescence smear 
microscopy after centrifugation, and these samples underwent culture 
testing for M.tb (BACTEC MGIT 960, BD Diagnostics, USA). Standard chest 
radiography and a urine dipstick test (UriCHECK 9, RapiMed Diagnostics, 
South Africa) were conducted to assess for proteinuria and leukocytosis. 
Based on the clinical, microbiological and radiological findings, and the 
overall impression of the attending physician, each patient was allocated to 
one of four diagnostic categories (outlined in chapter 2, pp.50-53) by the 
study investigator, who was blinded to the LAM results. In order to avoid 
incorporation bias, the LAM ELISA results were not taken into account when 











diagnosis were considered as indeterminate and were thus excluded from 
the analysis. TB treatment was at the discretion of the attending physician. 
4.3.2. Laboratory methods: 
4.3.2.1. Detection of LAM in urine samples using the Clearview-TB®-
ELISA 
The urine samples, which were collected in sterile containers, were processed 
according to the manufacturer's instructions (Clearview TB ELISA [Package 
Insert]. Inverness Medical Innovations 2009). Briefly, a l.5ml aliquot of each 
unprocessed urine specimen was collected and stored at -80°e. A further 8-
10ml of the remainder of the urine was heated to 95-100oC for half an hour in 
a water bath, cooled to room temperature and then centrifuged at 3000rpm 
for 15 minutes. After centrifugation, 2xl.5ml aliquots of the supernatants 
were collected and frozen at -80° prior to batching for LAM-ELISA testing. 
The supernatants were thawed within 2-3 weeks of storage, and further 
processed according to the manufacturer's instructions. Briefly, the samples, 
along with the LAM antigen detection kit reagents were left to equilibrate to 
room temperature. The samples and controls (1 positive control and 1 
negative control) were carefully mixed by inverting the tubes several times 
without creating air bubbles. 1001J,1 of the positive control, negative control 
and patient samples were added into the appropriately labelled duplicate 
wells of the Clearview TB® LAM-ELISA kit plate. A new pipette tip was 
used for each sample. The plate was then sealed with the self-adhesive film 
and incubated at 20-25°C for 60 minutes. Immediately after the 60 minute 
incubation, the adhesive film was removed and the contents of the wells 
were decanted by shaking into a collection basin and then firmly tapping the 
plate on a paper towel several times to remove any residual contents from 
the wells. The first manual wash steps was performed with a pre-prepared 
wash solution by carefully adding 2501J,1 of the solution to each well and 
vigorously shaking the solution from the wells into a collection basin prior to 











repeating 3-4 times. After the first wash step, 100~1 horse radish peroxidase 
(HRP) conjugate was added to each well in the same order and at the same 
rate that the samples were added. The plate was promptly covered with self-
adhesive sealing tape and incubated at 20-25°C for 60 minutes. After 
incubation the self-adhesive tape was removed and the HRP conjugate 
decanted into a collection basin. Another wash step was performed (as 
described above). After this second wash step, 100~1 of chromogenic 
substrate solution, tetramethylybenzidene (TMB), was added to each well in 
the same order and at the same rate that the samples were added. The plate 
was covered with adhesive film and incubated at 20-25°C for 15 minutes. 
After the 15 minute incubation, the adhesive tape was removed and 100~1 
stop solution (1 molar sulfuric acid) was added in the same order and at the 
same rate that the TMB was added. The plate was shaken gently to mix the 
reagents and read immediately after development (Anthos Labtec HT3 
ELISA plate reader set on 450nm). Duplicate positive and negative controls 
were performed with each run, and the results were determined as the 
average of duplicate optical density (OD) readings for each sample minus 
[the average negative control OD reading plus 0.1]. Please refer to figure 4.1 
for a summary flow diagram of the procedure. 
4.3.2.2. Interpretation of the results 
A cut-off value of zero was used for negative and positive results. A result 
was considered as negative when the average sample OD was less than the 
cut-off value, and positive when the average sample OD was greater than or 
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4.4.1. Clinical and demographic information 
Sixty (12%) of the participants were excluded from further analysis because 
their TB status could not be reliably determined (see TB case definitions, 
chapter 2, pp.47-48). Thus, there were 440 evaluable subjects. Please refer to 
figure 4.2, which is a study flow diagram of the recruitment that includes the 
sample numbers stratified by patient subgroups, smear microscopy, HIV 
status and CD4 T cell count. 
T8 suspects recruited 
N=SOO 
I 
I I I I 
DefiniteT8 
NonTB Probable TB" 
No diagnosis 
(culture pos) 
N=l72 N= 121 
possible"" 
N=141 N=60 
I I I 
Smear pas: 92 Smear pos: 0 Smearpos: 0 
Smear neg: 49 Smear neg: 112 Smear neg: 121 
Unavailable: 6 
Urine LAM pas: 11 Urine LAM pos: 1 Urine LAM pas: 3 
Urine LAM neg: 118 Urine LAM neg: 110 Urine LAM neg: 118 
Unavailable: 6 Unavailable: 1 Unavailable: 6 
HIV pos: 44 HIVpos:41 HIV pas: 3S 
C04<200: 20 CD4<2oo: 18 C04<2OO: 23 
C04C:!2OO: 19 CD4c:!200: 20 C04 c:! 200: 11 
unavailable: 5 unavailable: 3 unavailable: 1 
HIV neg: 80 HIV neg: 109 HIVneg: 78 
Refused: 12 Refused: 17 Refused: 13 
Unavailable: 5 Unavailable: 5 Unavailable: 1 
Figure 4.2. Flow chart of patients recruited to the study stratified by patient 
subgroup, smear microscopy, HIV status, and CD4 T cell count. 
The clinical and demographic information of the 440 evaluable TB suspects is 
shown in table 4.1. The participants were predominantly male (291/440; 
66.1 %) and the median age was 41 (range 18-84) years. HIV results were 
available for 90% (398/440) of participants, because 42 refused an HIV test 
and there were unknown results/no results for 11 subjects. Of those who 











infected. However, only 111/123 (90%) of these infected subjects had 
available results for CD4 count. The median CD4 count in this group was 177 
cells/mm3. 
Table 4.1. Clinical and demographic information of the 440 evaluable TB suspects 




Positive** Negative .... 
(%) (%1 
Total TB suspects included 440 (100) 120 (27.3) 267 (60.7) 
Age, mean (SD) 41(12) 38(10) 42 (13) 0.0006 
Sex 
Male 291(66.1) 61(21) 195 (67) 
Female 149 (33.9) 59 (39.6) 72 (48.3) <0.001 
Race 
Black 314 (71.4) 97 (30.9) 178(56.7) 
Mixed ancestry (Coloured) 118 (26.8) 22 (18.6) 82 (69.5) 
Caucasian 8 (1.8) 1 (12.5) 7 (87.5) 0.015 
Weight in Kg, mean (SD) (n=410)* 61.2 (11.9) 58.3 (10.1) 62.0 (12.2) 0.005 
PreviousTB 
Yes 161 (36.6) 46 (28.6) 101 (62.7) 
No 279 (63.4) 74 (26.5) 166(59.5) 0.924 
Current Smoker (n= 437)* 
Yes 252 (57.3) 55 (21.8) 170(67.5) 
No 185 (42.0) 65 (35.1) 95 (51.4) 0.001 
Urine protein (n= 384)* 
+ 32 (7.3) 13(40.6) 18(56.3) 
++ 15 (3.4) 4(26.7) 10 (66.7) 
+++ 3(0.7) 0(0) 3 (100) 
negative 334(75.9) 91 (27.2) 210(62.9} 0.362 
CD4count, median (cells!mm3) - 177 - -
(n:::l11)* 
* Irreconcilable ambiguity on the request form precluding processing of sample, or patient consented 
but did not tum up for the test. 
** Excludes 42 (9.5%) patients who refused HIV testing and 11 (2.5%) patients who had no data. 
4.4.2. Sensitivity, specificity of urine LAM versus smear microscopy in 
different categories of TB suspects, and the association of urine 
LAM with HIV status and urine protein 
The sensitivity and specificity of urine LAM alone, smear microscopy alone, 












I Definite HIV positive 
and non TB All HIV Negative HIV Positive CD4 <200 cellsl 
groups III 
only SIms. 6pec. 6ens. 6pBC. 6Bns. 6pec. 6ens. spec. 
(9S%ci) (9S%CI) (9S%CI) (9S%CI) (9S%CI) (9S%CI) (95%CI) (95%CII 
Sputum smear 
65 100 72' 99 49' 100 37" 100 
(57, 72) (98,100) {51, 51} (95, 100) (35,53) (91,100) (19. 59) (82, 100) 
Urine LAM 
13 99 a# 99 21# 100 37 95 
(8, 19) (97, 100) (3, 14) (95, i00) {11,35) {91, 100) (19,59) (84,99) 
I 
Sputum smear 68 99 72 100 58 100 53"" 100 I 
and/or urine LAM (60,75) (97,100) (61,81) (97,100) (43,72) (91,100) (32,73) (83,100) 
PPV NPV PPV NPV PPV NPV PPV NPV 
(95%CI) (95% Cll (95%CI) (95%CI) (95%CI) (95%CI) (95%CI) (95%CI) 
Sputum smear 
100 78 98 83 100 65 100 60 
(95,100) (72,83) (91,100) (76,88) (85,100) (53,76) (65,100) (42,75) 
I 94 59 83 59 100 55 78 76 
Urine LAM 
(74.99) (53,64) (44.97) (52.66) (70,100) (43.65) (45.94) (63.86) 
Sputum smear 99 79 100 83 100 69 100 67 
Olnd/or urine LAM (94,100) (73.84) (94,100) (76,88) (87.100) (57.80) (72.100) (48,81 ) 
% of sputum 8.6 0 17.6 25.4 
smear neg 
CJ c:J ~ 
.•.. f ::"'';'''. ;" :::::::::::. . 
definite TB I ::::.:.::< ( .:,;.;.:,:,;,;. 




*p=O.OO1; #p=<o.ool; **p=O.07 
Pie chart segments represent percentages of patients that were smear positive (shaded) smear negative 
(non-shaded) and urine LAM positive but smear negative (speckled). 
Figure 4.3. The sensitivity, specificity (including 95% confidence intervals (%); top 
panel of table) and positive and negative predictive value (middle panel of table) of 
smear-microscopy alone, urine LAM alone, and a combination of urine LAM and 
smear-microscopy (using culture-positivity as a reference standard). The bottom 
panel of the table shows the test sensitivity in smear negative culture positive TB 
patients. For sensitivity calculations the definite TB group (n=141) was used. 
Specificity calculations were performed using the non-TB group (n=l72) as a 
reference. 
In the unselected TB patients, HIV co-infected patients and those who had a 
CD4 count <200 cells/mm3, smear microscopy had a sensitivity of 65%, 49% 
and 37%, respectively. By contrast, there were comparative sensitivities for 
urine LAM in the same groups (13%, 21 % and 37%, respectively). Whilst the 











immune paresis (HIV-infected vs. HIV-uninfected and CD4<200 vs. 
CD4~200), the sensitivity of urine LAM increased significantly (Figure 2; 
p<0.003). Except for patients who had a CD4 count <200 cells/mm3, smear 
miscroscopy was significantly more sensitive than urine LAM in all of the 
other groups where sensitivities were equivalent. However, in this group of 
patients with the CD4 count <200 cells/mm3 the urine LAM assay and smear 
microscopy appeared to identify different patients. In this group of TB 
patients with advanced HIV a combination of urine LAM and smear 
microscopy showed a sensitivity of 53 % compared to the lower sensitivity 
(37%) for smear-microscopy alone. However, this additive value of urine 
LAM did not reach statistical significance (p=0.07). Comparitive 
multivariable Receiver Operating Characteristic (ROC) curve analysis could 
not be performed because of the smaller number of HIV-infected patients in 
the sub-group with a CD4 count <200 cells/mm3. Collectively, 25% of HIV-
infected smear negative TB patients with a CD4 count < 200 cells/mm3 had a 
positive urine LAM test. In the smear negative culture positive group, a 
significantly greater percentage of patients with CD4 count <200 cells/mm3 
were urine LAM positive compared to those with CD4 count ~200 cells/ mm3 
(p = 0.003). 
Using the non-TB group as a reference, the specificity of urine LAM and 
smear miscroscopy in the different subgroups is shown in figure 4.3. There 
was high specificity for urine LAM (95 to 100%) in all subgroups but 
specificity was comparatively lowest in the advanced HIV (CD4<200 
cells/mm3) subgroup. However, this was not statistically different from 
other subgroups). 
As shown in figure 4.3, urine LAM positivity was significantly higher in 
HIV-infected subjects versus those not infected with HIV (21 % vs. 6%, 
respectively; p<O.OO1) and in those with a CD4 count <200 cells/mm3 versus 
~200 cells/mm3 (37% vs. 0%, respectively; p=0.003). In the univariable 











positivity (odds ratio=4.75; p=O.002), but inversely associated with low 
weight (odds ratio=O.94; p=O.Ol) and previous TB (odds ratio=O.09; p=O.02). 
In contrast, in the multivariable analysis, there was an independent 
association between LAM positivity and HIV-infected status (odds ratio=3.2; 
p=O.04) and LAM positivity and lack of previous TB (odds ratio=O.09; 
p=O.02). 
In the culture positive HIV-infected TB patients (n=36) there was no 
significant difference in the LAM positivity between the proportion of 












Due to the poor sensitivities (13% and 21 %, respectively) of the Clearview 
TB® LAM ELISA in unselected HIV-infected and uninfected suspects from a 
high burden primary care setting, urine LAM seems to have limited clinical 
utility. However, because the specificity of the assay in the diagnostically 
challenging smear negative/ culture positive group (n=19) with a CD4 count 
<200 cells/mm3 was high (95% specificity and 37% sensitivity), urine LAM 
may possibly be deemed as a reasonable rule-in test for active TB within this 
sub-group. Thus, even though the sensitivity in this sub-group is low, the 
high specificity, reasonable cost of the kit, rapid generation of results within 
a day (potentially even faster if the LAM urine strip can be validated and 
commercialised as a POC test), the lack of alternative rapid test options and 
the continuous diagnostic conundrum presented by this particular sub-group 
of patients, makes urine LAM an attractive test option. Moreover, established 
PCR-based TB tests such as NAAT have a high specificity and a low 
sensitivity (-30%) within a similar range when used clinically as rule-in tests 
for extra-pulmonary TB (Alvarado-Esquivel et al 2009). 
Other studies have shown that urine LAM sensitivity in smear negative TB 
patients varied between 28%-56% when using the pre-commercial version 
(Lawn et a12009; Reither et a12009; Shah et aI2009). However, as previously 
mentioned, urine LAM outcomes stratified by CD4 count were not available 
in two of these studies, and specificity was suboptimal in both (Mutetwa et al 
2009; Reither et al 2009). Thus, there are no existing data about urine LAM 
outcomes in specific CD4 categories in patients who present to primary care 
clinics with suspected TB. Given the availability of rapid HIV testing, and 
POC CD4 tests in the near-future, if additional studies confirm our findings 
there is potential to develop an algorithm where patients who usually 
present the existing clinical TB diagnostic conundrum (smear negative, HIV 
positive and a CD4 count <200 cells per mm3) may be ideal candidates for the . 











specific sub-group that should now be focused on in future studies in order 
to clarify the diagnostic utility of the urine LAM assay in these patients. 
The high specificity of the urine LAM assay, even though it was lower in 
patients with advanced HIV, was similar to that of two other studies (Lawn 
et al 2009; Shah et al 2009). The first study was conducted in hospitalised TB 
patients in a high HIV prevalence setting (Shah et al 2009) and the second 
study involved individuals being screened for TB prior to antiretroviral 
therapy (Lawn et al 2009). Similarly, the high specificity in these studies also 
contrasts with the poorer specificity (~88 %) in other studies (Daley et al 2009; 
Mutetwa et al 2009; Reither et al 2009). This phenomenon may possibly be 
explained by undiagnosed occult TB disease, which in turn may even justify 
the lower specificity in the patients with advanced HIV in our study. 
Furthermore, possible detection of antigen from LTBI subjects, the presence 
of environmental pathogens or contamination by non-bacterial species (for 
example, Candida) may also be plausible explanations. The non-bacterial 
species situation may be possible given our findings that several organisms, 
including Candida species, cross-react with the polyclonal LAM antibodies 
within the assay (Dheda et al 2010a). However, in our study urine was 
collected at the clinic in sterile containers, but the collection methods used in 
the other studies have never been clearly described. 
As previously mentioned, the urine Clearview® LAM ELISA used in this 
study is the current commercially-available version. Although the polyclonal 
antibody used in this ELISA is the same as the one used in the pre-
commercial MTB LAM ELISA, there are differences in the manufacturing 
technology and protocols used. It is unlikely that these differences make the 
different versions incomparable, but this possibility cannot be dismissed 
given that several technical factors may impact on ELISA test performance 
(Sittampalam et al1996). 
A limitation of this study is the low number of HIV-infected definite TB cases 











However, this is the first study to stratify LAM-related outcomes by CD4 
count in unselected TB suspects from a primary care setting. Although urine 
LAM used in conjunction with smear miscroscopy may be more sensitive 
that smear microscopy alone in patients with low CD4 counts, the differences 
between the two were not statistically significant (ie. urine LAM + smear 
miscroscopy vs. only smear miscroscopy; p=O.07). However, this could be 
due to type II error and the low sample numbers in the low CD4 subgroup. 
Larger studies are required to recruit a sufficient number of patients with 
smear negative definite TB and HI V-infection (with a low CD4 count) in 
order to achieve reliable performance outcome estimates. However, given 
that it was not possible to clearly evaluate the outcomes in this particular 












Diagnostic Utility of the Xpert® MTBfRIF Assay using Bronchoalveolar 
Lavage Fluid 
5.1. INTRODUCTION 
One of the many problems that clinicians are faced with when working with 
tuberculosis cases is the diagnosis of sputum-scarce and smear-negative TB, 
because the yield of existing rapid diagnostic tools is low, and it is 
challenging to obtain representative biological samples. 
As outlined earlier (please refer to chapter 1, section 1.7), existing NAAT 
platforms for the detection of M.tb are technically demanding and labour-
intensive (Vaneechoutte & Van Eldere 1997), and problems of sensitivity 
remain. NAATs have a sensitivity of ~40% in smear negative pulmonary TB) 
(Ling et a12008). Thus, a more sensitive, user-friendly test option, such as the 
Xpert® MTBjRIF Assay (Cepheid 2009), would be very useful. 
Helb and colleagues performed the first analysis of the Cepheid Gene Xpert 
System's MTBjRIF assay. They evaluated the diagnostic utility of the system 
using sputum samples and showed that it was highly sensitive and simple-
to-use (Helb et al 2009). However, in sputum-scarce and smear negative 
patients representative samples still need to be obtained in order to conduct 
diagnostic tests. To our knowledge, there are currently no published data 












5.2. HYPOTHESIS AND AIM 
Hypothesis 
The Xpert® MTB/RIF assay, when using bronchoalveolar lavage fluid, may 
be a useful rapid tool for tuberculosis diagnosis in sputum-scarce or smear 
negative patients. 
Aim: 
To evaluate the diagnostic utility of the Xpert® MTB/RIF Assay in a group of 
pulmonary TB suspects, who are unable to expectorate sputum (sputum-











5.3. MATERIALS AND METHODS 
5.3.1. Participants and study design 
The subjects for the study were recruited as part of a larger, ongoing parent 
study, which involved the investigation of antigen-specific interferon gamma 
(IFN-y) responses to the RD-l antigens ESAT-6 and CFP-10 (T-SPOT.TB and 
QuantiFERON-TB-Gold-In-Tube), HBHA and PPD, using BAL cells from 91 
consecutively recruited South African patients (Groote Schuur Hospital, 
Cape Town) with suspected pulmonary TB who were unable to expectorate 
sputum (sputum-scarce) or who were smear negative (Dheda et a12009c). Six 
patients were excluded from the parent study analysis, thus evaluable 
samples were obtained for 85 patients. Furthermore, unprocessed (raw) BAL 
fluid stored at -80°C was only available from 59 of the subjects. Thus, the 
present study group comprised 59 pulmonary TB suspects who were unable 
to expectorate sputum (sputum-scarce) or who were smear-negative. 
Archived samples from this group of patients were used. All samples were 
processed at the Lung Infection and Immunity Unit Laboratory (Groote 
Schuur Hospital, H 47 Old Main Building, Observatory, Cape Town. 
Ethical approval was obtained from the University of Cape Town (UCT) 
Health Sciences Faculty Research Ethics Committee. All subjects provided 
informed consent. Detailed clinical and demographic data (including patient 
history, testing for HIV infection, and chest X-ray) was recorded, and 
bronchoscopy was performed, under local anaesthesia and conscious 
sedation, by an experienced pulmonologist. Approximately 150-300 ml of 
sterile saline was used to lavage a radiologically involved lung segment, and 
the aspirate (100-150 ml) was collected in a sterile glass bottle. Aliquots of 
BAL fluid were sent for routine smear microscopy, Gram and fungal 
staining, cell differential count, cytology for malignant cells and 











(MGIT 960). When appropriate, 3-5 trans-bronchial biopsies were performed. 
The study flow diagram is shown in figure 5.1. 
85 South African patients (pulmonaryTS suspects) with potentially evaluable 
SAL and blood samples from the parent study (Dheda et al. Thorax, 2009) 
! 
2xl.5ml aliquotsof unprocessed (raw) BAl fluid 
stored at -80a C for future investigation 
n=S9* 
! 



























*26/85 unprocessed BAl fluid not stored due to limited availability of BAl fluid (the 
investigator was blinded to patient details, thus there was no systematic distribution of the 
groups analysed with respect to clinical background). 
** 1 AlP, 1 anthrosilicosis, 2 asthma, 2 bronchiectasis, 2 carcinoma, 1 cryptococcus, 5 
bacterial infection, 1 infection/lymphoid interstitial pneumonia (UP), 1 UP, 1 metastatic 
breast carcinoma, 1 non small cell lung cancer, 1 small cell lung cancer, 1 NSIP (non-specific 
interstitial pneumonia/fibrosis (NSIP), 1 Pneumocystic Carinii Pneumonia (PCPL 1 
Pneumonia, 1 probable eosinophil pneumonia, 1 pulmonary oedema, 1 respiratory 
bronchiolitis-associated interstitial lung disease (RBllD),l Staphylococcus infection/UP, 1 
renal cell carcinoma, 1 sarcoidosis, 2 squamous cell carcinoma, 1 chronic obstructive 
pulmonary disease (COPD), 4 non TB with no cause identified. 
Figure 5.1. Study flow diagram for the investigation of the diagnostic utility of the 











5.3.2. Laboratory methods: 
The Xpert MTB/RIF test was conducted according to the manufacturer's 
instructions (Xpert® MTB/RIF [Package Insert] 2009). Briefly, the frozen, 
unprocessed samples were thawed and immediately processed. Iml of BAL 
fluid was added to 2mL of the Xpert MTB/RIF Sample Reagent (SR), which 
contains sodium hydroxide and isopropanol. The BAL/SR mixture was 
vigorously shaken and then incubated at room temperature for a total of 
fifteen minutes with a second shake occurring at 10 minutes. 2mL of the 
digested mixture was transferred to the Xpert MTB/RIF cartridge. The 
automated steps of the procedure were initiated by placing the loaded assay 
cartridge into the GeneXpert instrument module and then selecting the "M. 
tuberculosis Xpert-Rif" automated detection test option from the included 
software. The test was started within 30 minutes of adding the sample to the 
cartridge. 
5.3.2.1. The Gene Xpert Dx System: Principle of the procedure 
The Gene Xpert Dx system is a fully integrated, automated system for sample 
processing, nucleic acid amplification, and detection of the target sequences 
(all in a single hands-free step) in simple and complex specimens using a 
combination of real-time peR and reverse transcriptase peR. The system 
consists of the Gene Xpert instrument, which needs to be attached to a 
personal computer and a barcode scanner. 
The pre-loaded software for running the Gene Xpert assay (different import 
assay definition files are available, for example the Xpert MTB/RIF assay) 
and viewing the results is also required. Single-use disposable Gene Xpert 
cartridges (containing the peR reagents for the peR process) for use with the 
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The Xpert MTB/RIF assay includes reagents for the detection of M.tb and 
rifampicin resistance, as well as the following internal controls: i) a sample 
processing control (SPC) to monitor the presence of potential PCR-reaction 
inhibitors and to ensure the correct processing of the target bacteria, and ii) a 
probe check control (PCC) to verify when dehydration of the reagent occurs 
and the PCR tube filling mechanism in the cartridge. The PCC is also 
required to verify dye stability and the integrity of the PCR probes. The 
probes are able to distinguish the conserved wild-type sequence from the 
mutations in the 81 base pair core region (rpoB) of the bacteria that are 
associated with RIF resistance. The primers in the assay are for the 
amplification of the rpoB gene containing the M.tb core region. 
5.3.3. Statistical methods and interpretation of the Gene Xpert results 
Results were obtained using the automated software, and the data analysis 
algorithms identify the following: 1) 'M.tb detected' if the M.tb target DNA 
(rpoB) region is detected, and 2) 'M.tb not detected' if the M.tb target DNA 
(rpoB) region is not detected. If M.tb is detected the results are further 
categorised into 'RIF resistance detected' (if a mutation in the rpoB gene is 
detected) and 'RIF resistance not detected' (if no mutation is detected in the 
rpoB region). 
For analysis purposes, the Xpert MTB/RIF assay results were stratified 
according to diagnosis (patient characterisation definitions outlined in 
chapter 1). Confirmed culture positivity and or/biopsy proven TB was used 
as the reference standard. The sensitivity, specificity, positive and negative 
predictive values of the XpertTM MTB/RIF assay were then calculated using 












The clinical and demographic characteristics of the participants is shown in 
table 5.1. 
Table 5.1. Demographic and clinical characteristics of TB suspects and patients who 
had an unprocessed (raw) BAL fluid sample stored at -80De for further analysis 
(n=59) 
Characteristics 









No BCG vaccination 
Former BCG vaccination 
BCG vaccination status not known 
































* If the culture result was not available, the diagnosis was based on histology in keeping 
with TB (caseous necrosis or acid-fast bacilli with or without granuloma formation) 
There was an almost-equal distribution of males and females (51 % and 49%, 
respectively), and the population was predominantly Black African (54 %). A 











known history of previous TB. The BeG vaccination status was unknown for 
the majority of the group (42/59; 71 %). 
Please refer to table 5.2, which displays the breakdown of the Gene Xpert 
results stratified by confirmed diagnoses. The detailed 2x2 (contingency) 
table is also shown (table 5.3). 
Table 5.2. Gene Xpert results stratified by confirmed diagnoses. There were no 
indeterminate Xpert MTB/RIF results. Hence, all of the results were evaluable 
(n=59). 




Positive 7* 1 1 ** 0 
Negative 5 9 34 2 
12 10 35 2 
* RIF resistance was detected on the Gene Xpert system in the sample 
of1/7 definite T8 cases. 
** 1 Non T8 patient was diagnosed with LIP. However, the gene Xpert 
assay detected RIF resistant M.tb in the patient's sample 




















N=59 Definite TB (n=12) 
Yes No 
MTB/RIF Xpert M.tb detected 7 (TP) 2 (FP) 
M. tb not detected 5 (FN) 45 (TN) 
N=59 Probable TB (n=10) 
Yes No 
MTB/RIF Xpert M.tb detected 1 (TP) 8(FP) 
M. tb not detected 9IFN) 41 (TP) 
N=59 Definite + Probable T8 (n=22) 
Yes No 
MTB/RIF Xpert M. tb detected 8 (TP) 1 (FP) 
M. tb not detected 14(FN) 36 (TP) 
N=59 Non TB (n=35) 
Yes No 
MTB/RIF Xpert M. tb detected 1 (FP) 8 (TP) 
M. tb not detected 34 (TN) 16(FN) 
Key: TP=True positives, TN=True negatives, FP=False positives, FN=False negatives. 
Sensitivity measures the proportion of actual positives which are correctly 
identified as such. Thus, this would be calculated using the definite TB group 
(sensitivity= TP j (TP+ FN). 
Specificity measures the proportion of negatives which are correctly identified as 
such. Thus, this would be calculated using the non TB group 
(spedficity=TNj (TN+FP). 
Positive predictive value (PPV) or precision rate, or post-test probability of 
disease, is the proportion of patients with positive test results who are correctly 
diagnosed: PPV=TPj(TP+FP). 
Negative predictive value (NPV) is the proportion of patients with negative test 











The results revealed a sensitivity of 58% (7/12) in patients with definite TB 
(see table 5.4 below). The remaining 5/12 of these definite TB patients, who 
were found to be Gene Xpert negative (M.tb not detected), had the following 
HIV test results: 1 was HIV-infected, 2 were HIV-uninfected and the HIV 
results were unknown for 2 patients. Furthermore, only 1 had a known 
history of previous TB. However, all had positive QFT -GIT results, 
suggesting LTBI. 
Table 5.4. Sensitivity, Specificity, Positive and Negative Predictive Values for the 
evaluation of the diagnostic utility of the Xpert MTBjRIF assay using BAL fluid. 
Sample Sensitivity Positive Negative Sensitivity in Sensitivity Sensitivity Specificity Sensitivity 
type inDefinite Predictive Predictive Smear+ve inSmear-ve in Clinical in Non-T8 of smear 
T8 Value Value Culture+ve Culture+ve T8 (Definite 
(culture- or + Probable 
biopsy- TB) 
proven) 
BALfluid 58%(7/12) 78%(7/9) 90% 100%(3/3) N/A* 36%(8122) 97%(34/35) 42%(5112) 
(45/50) 
* Not applicable: n=1 
The specificity of the Xpert MTB/RIF assay was high (97%, 34/35). The 
positive and negative predictive values were 78% and 90%, respectively. The 
smear sensitivity in the same cohort was 42% (5/12). However, the difference 
in the sensitivity of the Xpert MTB/RIF assay compared to the sensitivity of 

















The Xpert MTB/RIF Assay offers a promising technical opportunity to 
bridge the gap in time-to-diagnosis of TB suspects, with the added bonus of 
simultaneously detecting drug resistance (Helb et a12009; Pai & Ling 2008). 
In this preliminary study using BAL fluid, the Xpert MTB/RIF Assay 
appears to perform better than smear microscopy (sensitivity of 58% vs. 42%, 
respectively). However, why did Xpert did not detect M.tb in the BAL fluid 
of the 5/12 definite TB patients? It is known that the Xpert® MTB/RIF assay 
was originally optimised for use with sputum, and previous studies have 
reported that the assay has a sensitivity of 90% when using sputum samples 
from definite TB subjects (C Boehme et al. 2010, NEJM In Press). It should 
thus be noted that these data using BAL fluid are preliminary, using stored 
samples, and, moreover, reflect results based on using unprocessed BAL 
fluid only. Further studies are being conducted using more patients to 
evaluate the difference between using unprocessed BAL fluid and a 
centrifuged pellet. We expect the latter to have a higher sensitivity but no 
data are as yet available. The study by Helb et al. included analytic tests of 
M.tb DNA demonstrating a limit of detection (LOD) of 4.5 genomes per 
reaction. Furthermore, experiments using sputum spiked with known 
numbers of M.tb colony forming units (CFU) predicted a clinical LOD of 131 
CFU / mL. (Helb et al 2009) Thus, our future Gene Xpert investigations will 
also include a component where the BAL fluid will be spiked with M.tb to 
determine the LOD (threshold of sensitivity) of the Xpert® MTB/RIF assay. 
Furthermore, we aim to conduct experiments to determine the optimal buffer 
to sample ratios of different biological fluids. 
Although specificity was excellent at 97%, the one subject (1/35) in the non-
TB group who had a positive Gene Xpert result (M.tb detected), had initially 
been diagnosed with lymphoid interstitial pneumonia (LIP) [Table 5.2]. 
Moreover, the M.tb in this subject's sample was detected as being RIF 











of a rapid novel diagnostic assay, such as Xpert MTBjRIF, would prove 
useful. 
As outlined in the literature review (chapter 1, section 1.7), using various in-
house PCR assays, several studies have demonstrated that PCR is more 
sensitive than smear microscopy in detecting M.tb in the BAL fluid of 
sputum-scarce or smear negative patients with active pulmonary TB (Chen et 
al 2002; Liam et al1998; Tan et a11999; Tueller et a12005). The main concern 
in developing countries is the cost and feasibility of new molecular 
technologies. Although in-house PCR assays are less expensive, there is a 
risk that the assay has been poorly standardised and is thus unreliable. On 
the other hand, besides the advantage of obtaining a result in under 2 hours, 
the Gene Xpert system is a controlled, sensitive and reliable automated 
system that eliminates the possibility of cross-contamination of samples 
through the use of the sealed cartridges. Extensive field evaluations in 
different settings are underway and it remains to be seen whether this 
promising new rapid NAAT test will survive the rigors of field evaluation, 











GENERAL CONCLUSIONS AND RECOMMENDATIONS 
IGRAS 
In contrast to low burden settings, there was poor agreement between the 
changes in RDI antigen-specific quantitative T cell responses and culture 
conversion/ reversion in TB patients followed-up after 2 months of anti-TB 
treatment. However, no meaningful cqnclusions could be made about the 
responses at 6 months due to the low sample number. The QFT-GIT test 
appeared to be a he~pful treatment-related response indicator closer to the 
end of treatment completion. HBHA had no discriminatory value. 
Although delayed processing (-24 hours), independent of T-Cell Xtend, 
resulted in significant changes in the median spot counts, there was a high 
agreement between spot counts when samples were processed immediately 
and after the delay. However, although the use of T-Cell Xtend appeared to 
reduce the number of conversions/reversions this reduction was not found 
to be statistically significant. Larger studies in different geographical settings 
and with 3-way parallel sample analyses are now required to clarify the 
efficacy of T-cell Xtend at 32 hours. 
Clearview® LAM ELISA Assay 
The use of the urine LAM ELISA to diagnose unselected TB suspects from a 
primary care high burden setting does not seem to be useful. It is evident, 
though, that a targeted approach to using LAM may be useful in those who 
have advanced HIV infection. However, even in this sub-group, sensitivity is 
modest. Larger targeted studies, especially in the low CD4 count sub-group 
in ambulant and hospitalised TB populations from different geographical 











Xpert® MTBfRIF Assay 
The Xpert MTBjRIF assay appears to be a promising rule-in test, with a 
specificity of 97%, when using BAL fluid from patients with suspected TB. 
However, although the sensitivity (almost 60%) is higher than that of smear 
microscopy, the Xpert MTBjRIF assay in this study did not have incremental 
value over smear (difference between the sensitivities was not statistically 
significant ). It should be emphasized that these are preliminary data, and 
larger studies evaluating BAL and other biological samples for use with the 












(Reference style: 'Ann Rev Medicine') 
T-Cell Xtend™ [mechanism of action], Oxford Immunotec Ltd. 2009. 
http://www.youtube.comlwatch?v= VAsezk74TkE&feature=youtube gdata, 
Retrieved 25/09/2009. 
World Health Organization (2007) "Tuberculosis" Fact sheet N° 104. Retrieved 12 
November 2009. 
<http://who.int/ mediacentrel factsheets I fs1041 enl index.html> 
World Health Organization (2009). II Epidemiology II • Global tuberculosis control: 
epidemiology, strategy, financing. pp. 6-33. Retrieved 12 November 2009. 
<http://who.int/entity/ tbl publications I global reportl 20091 pdf/ ch 
apter1.pdf> 
Aderem A, Underhill DM. 1999. Mechanisms of phagocytosis in 
macrophages. Annual review of immunology 17:593-623 
Aiken AM, Hill PC, Fox A, McAdam KP, Jackson-Sillah D, et al. 2006. 
Reversion of the ELISPOT test after treatment in Gambian tuberculosis 
cases. BMC Infect Dis 6:66 
Al-Attiyah R, Mustafa AS, Abal AT, Madi NM, Andersen P. 2003. 
Restoration of mycobacterial antigen-induced proliferation and 
interferon-gamma responses in peripheral blood mononuclear cells of 
tuberculosis patients upon effective chemotherapy. FEMS Immunol 
Med Microbiol 38:249-56 
Alvarado-Esquivel C, Garcia-Corral N, Carrero-Dominguez D, Enciso-
Moreno JA, Gurrola-Morales T, et al. 2009. Molecular analysis of 
Mycobacterium isolates from extrapulmonary specimens obtained 
from patients in Mexico. BMC Clin Patho19:1 
Arend SM, Andersen P, van Meijgaarden KE, Skjot RL, Subronto YW, et aL 
2000. Detection of active tuberculosis infection by T cell responses to 
early-secreted antigenic target 6-kDa protein and culture filtrate 
protein 10. J Infect Dis 181:1850-4 
Baba K, Sornes S, Hoosen AA, Lekabe JM, Mpe MJ, et al. 2008. Evaluation of 











by the QuantiFERON TB-Gold interferon-gamma assay. BMC Infect 
Dis 8:35 
Barnes PF. 2001. Diagnosing latent tuberculosis infection: The 100-year 
upgrade. American Journal of Respiratory & Critical Care Medicine 
163:807-8 
Blakemore R, Story E, Helb D, Kop J, Banada P, et al. 2010. Evaluation of the 
analytical performance of the Xpert MTB/RIF assay. J Clin Microbiol 
48:2495-501 
Boehme C, Molokova E, Minja F, Geis S, Loscher T, et al. 2005. Detection of 
mycobacterial lipoarabinomannan with an antigen-capture ELISA in 
unprocessed urine of Tanzanian patients with suspected tuberculosis. 
Trans R Soc Trop Med Hyg 99:893-900 
Boehme CCI Nabeta P, Henostroza G, Raqib R, Rahim 2, et al. 2007. 
Operational feasibility of using loop-mediated isothermal 
amplification for diagnosis of pulmonary tuberculosis in microscopy 
centers of developing countries. J Clin MicrobioI45:1936-40 
Bosshard V, Roux-Lombard P, Perneger T, Metzger M, Vivien R, et al. 2009. 
Do results of the T-SPOT.TB interferon-gamma release assay change 
after treatment of tuberculosis? Respir Med 103:30-4 
Brennan PJ, Nikaido H. 1995. The envelope of mycobacteria. Annual review of 
biochemistry 64:29-63 
Brock I, Munk ME, Kok-Jensen A, Andersen P. 2001. Performance of whole 
blood IFN-gamma test for tuberculosis diagnosis based on PPD or the 
specific antigens ESAT-6 and CFP-10. Int J Tuberc Lung Dis 5:462-7 
Brunello F, Favari F, Fontana R. 1999. Comparison of the MB/BacT and 
BACTEC 460 TB systems for recovery of mycobacteria from various 
clinical specimens. J Clin Microbio137:1206-9 
Cardona PJ, Soto CY, Martin C, Giquel B, Agusti G, et aL 2006. Neutral-red 
reaction is related to virulence and cell wall methyl-branched lipids in 












Carrara 5, Vincenti D, Petrosillo N, Amicosante M, Girardi E, Goletti D. 2004. 
Use of a T cell-based assay for monitoring efficacy of antituberculosis 
therapy. Clin Infect Dis 38:754-6 
Cashmore TJ, Peter JG, van Zyl-Smit RN, Semple PL, Maredza A, et al. 2010. 
Feasibility and diagnostic utility of antigen-specific interferon-gamma 
responses for rapid immunodiagnosis of tuberculosis using induced 
sputum. PLoS ONE 5:e10389 
Caviedes L, Moore DA. 2007. Introducing MODS: a low-cost, low-tech tool 
for high-performance detection of tuberculosis and multidrug 
resistant tuberculosis. Indian J Med MicrobioI25:87-8 
Cepheid. 2009. 
Chan J, Fan XD, Hunter SW, Brennan pJ, Bloom BR. 1991. 
Lipoarabinomannan, a possible virulence factor involved in 
persistence of Mycobacterium tuberculosis within macrophages. Infect 
Immun 59:1755-61 
Chapman AL, Munkanta M, Wilkinson KA, Pathan AA, Ewer K, et al. 2002. 
Rapid detection of active and latent tuberculosis infection in HIV-
positive individuals by enumeration of Mycobacterium tuberculosis-
specific T cells. AIDS 16:2285-93 
Chegou NN, Walzl G, Bolliger CT, Diacon AH, van den Heuvel MM. 2008. 
Evaluation of adapted whole-blood interferon-gamma release assays 
for the diagnosis of pleural tuberculosis. Respiration 76:131-8 
Chen NH, Liu YC, Tsao TC, Wu TL, Hsieh MJ, et al. 2002. Combined 
bronchoalveolar lavage and polymerase chain reaction in the 
diagnosis of pulmonary tuberculosis in smear-negative patients. IntJ 
Tuberc Lung Dis 6:350-5 
Clark-Curtiss JE, Haydel SE. 2003. Molecular genetics of Mycobacterium 
tuberculosis pathogenesis. Annual review of microbiology 57:517-49 
Clark SA, Martin SL, Pozniak A, Steel A, Ward B, et al. 2007. Tuberculosis 
antigen-specific immune responses can be detected using enzyme-
linked immunospot technology in human immunodeficiency virus 












Clearview TB ELISA [Package Insert]. Inverness Medical Innovations, 
Waltham, Massachusetts, USA. 2009. 
Comstock GW. 1978. Tuberculosis in twins: a re-analysis of the Prophit 
survey. Am Rev Respir Dis 117:621-4 
Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, et al. 2003. The 
growing burden of tuberculosis: global trends and interactions with 
the HIV epidemic. Archives of internal medicine 163:1009-21 
Cowley D, Govender D, February B, Wolfe M, Steyn L, et al. 2008. Recent and 
rapid emergence of W-Beijing strains of Mycobacterium tuberculosis 
in Cape Town, South Africa. Clin Infect Dis 47:1252-9 
Daffe M, Draper P. 1998. The envelope layers of mycobacteria with reference 
to their pathogenicity. Adv Microb PhysioI39:131-203 
Daley P, Michael JS, Hmar P, Latha A, Chordia P, et al. 2009. Blinded 
evaluation of commercial urinary lipoarabinomannan for active 
tuberculosis: a pilot study. Int J Tuberc Lung Dis 13:989-95 
Daley P, Thomas 5, Pai M. 2007. Nucleic acid amplification tests for the 
diagnosis of tuberculous lymphadenitis: a systematic review. Int J 
Tuberc Lung Dis 11:1166-76 
Das 5, Paramasivan CN, Lowrie DB, Prabhakar R, Narayanan PR. 1995. 
156110 restriction fragment length polymorphism typing of clinical 
isolates of Mycobacterium tuberculosis from patients with pulmonary 
tuberculosis in Madras, south India. Tuber Lung Dis 76:550-4 
Delogu G, Sanguinetti M, Posteraro B, Rocca 5, Zanetti Sf Fadda G. 2006. The 
hbhA gene of Mycobacterium tuberculosis is specifically up regulated 
in the lungs but not in the spleens of aerogenic ally infected mice. Infect 
Immun 74:3006-11 
Dheda K, Davids V, Lenders L, Roberts T, Meldau R, et al. 2010a. Clinical 
utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-
infected patients using urine and sputum samples. PLoS ONE 5:e9848 
Dheda K, Lampe FC, Johnson MA, Lipman Me. 2004a. Outcome of HIV-
associated tuberculosis in the era of highly active antiretroviral 











Dheda K, Pooran A, Pai M, Miller RF, Lesley K, et al. 2007. Interpretation of 
Mycobacterium tuberculosis antigen-specific IFN-gamma release 
assays (T-SPOT.TB) and factors that may modulate test results. J Infect 
Dheda K, Rook G, Zumla A. 2004b. Peripheral T cell interferon-gamma 
responses and latent tuberculosis. Am J Respir Crit Care Med 170:97-8; 
author reply 8 
Dheda K, Schwander SK, Zhu B, van Zyl-Smit RN, Zhang Y. 2010b. The 
immunology of tuberculosis: from bench to bedside. Respirology 
(Carlton, Vic 15:433-50 
Dheda K, Shean K, Zumla A, Badri M, Streicher EM, et al. 2010c. Early 
treatment outcomes and HIV status of patients with extensively drug-
resistant tuberculosis in South Africa: a retrospective cohort study. 
Lancet 375:1798-807 
Dheda K, Smit RZ, Badri M, Pai M. 2009a. T-cell interferon-gamma release 
assays for the rapid immunodiagnosis of tuberculosis: clinical utility 
in high-burden vs. low-burden settings. Current opinion in pulmonary 
medicine 15:188-200 
Dheda K, Udwadia ZF, Huggett JF, Johnson MA, Rook GA. 2005. Utility of 
the antigen-specific interferon-gamma assay for the management of 
tuberculosis. Current opinion in pulmonary medicine 11:195-202 
Dheda K, Van-Zyl Smit RN, Sechi LA, Badri M, Meldau R, et al. 2009b. 
Clinical diagnostic utility of IP-I0 and LAM antigen levels for the 
diagnosis of tuberculous pleural effusions in a high burden setting. 
PLoS ONE 4:e4689 
Dheda K, van Zyl-Smit RN, Meldau R, Meldau S, Symons G, et al. 2009c. 
Quantitative lung T cell responses aid the rapid diagnosis of 
pulmonary tuberculosis. Thorax 64:847-53 
Dheda K, van Zyl-Smit RN, Sechi LA, Badri M, Meldau R, et al. 2009d. Utility 
of quantitative T-cell responses versus unstimulated interferon-
{gamma} for the diagnosis of pleural tuberculosis. Eur Respir J 34:1118-
26 
Diaz-Infantes MS, Ruiz-Serrano MJ, Martinez-Sanchez L, Ortega A, Bouza E. 











susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 
38:1988-9 
Diel R, Loddenkemper R, Meywald-Walter K, Gottschalk R, Nienhaus A. 
2008. Comparative Performance of Tuberculin Skin Test, 
QuantiFERON-TB-Gold In Tube Assay, and T-Spot.TB Test in Contact 
Investigations for Tuberculosis. Chest 
Diel R, Loddenkemper R, Nienhaus A. 2010. Evidence-based comparison of 
commercial interferon-gamma release assays for detecting active TB: a 
metaanalysis. Chest 137:952-68 
Dinnes Jf Deeks J, Kunst H, Gibson A, Cummins E, et al. 2007. A systematic 
review of rapid diagnostic tests for the detection of tuberculosis 
infection. Health technology assessment (Winchester, England) 11:1-314 
Dominguez J, De Souza-Galvao M, Ruiz-Manzano I, Latorre I, Prat C, et al. 
2009. T-cell responses to the Mycobacterium tuberculosis-specific 
antigens in active tuberculosis patients at the beginning, during, and 
after antituberculosis treatment. Diagnostic microbiology and infectious 
disease 63:43-51 
Dominguez J, Ruiz-Manzano J. 2006. [The tuberculin skin test: time for a 
change?]. Archivos de bronconeumologia 42:47-8 
Dormans J, Burger M, Aguilar D, Hernandez-Pando R, Kremer K, et al. 2004. 
Correlation of virulence, lung pathology, bacterial load and delayed 
type hypersensitivity responses after infection with different 
Mycobacterium tuberculosis genotypes in a BALB/c mouse model. 
Clinical and experimental immunology 137:460-8 
Dosanjh DP, Hinks TS, Innes JA, Deeks H, Pasvol G, et al. 2008. Improved 
diagnostic evaluation of suspected tuberculosis. Annals of internal 
medicine 148:325-36 
Drobniewski FA, Caws M, Gibson A, Young D. 2003. Modern laboratory 
diagnosis of tuberculosis. Lancet Infect Dis 3:141-7 
Ernst JD. 1998. Macrophage receptors for Mycobacterium tuberculosis. Infect 
Immun 66:1277-81 
Ferguson JS, Voelker DR, McCormack FX, Schlesinger LS. 1999. Surfactant 











lipoarabinomannan via carbohydrate-lectin interactions resulting in 
reduced phagocytosis of the bacteria by macrophages. ] Immunol 
163:312-21 
Ferrand RA, Bothamley GH, Whelan A, Dockrell HM. 2005. Interferon-
gamma responses to E5AT-6 in tuberculosis patients early into and 
after anti-tuberculosis treatment. Int ] Tuberc Lung Dis 9:1034-9 
Ferrara G, Losi M, D'Amico R, Roversi P, Piro R, et al. 2006. Use in routine 
clinical practice of two commercial blood tests for diagnosis of 
infection with Mycobacterium tuberculosis: a prospective study. 
Lancet 367:1328-34 
Ferrari G, Langen H, Naito M, Pieters J. 1999. A coat protein on phagosomes 
involved in the intracellular survival of mycobacteria. Cell 97:435-47 
Gatfield J, Pieters J. 2000. Essential role for cholesterol in entry of 
mycobacteria into macrophages. Science 288:1647-50 
Gaynor CD, McCormack FX, Voelker DR, McGowan 5E, Schlesinger L5. 
1995. Pulmonary surfactant protein A mediates enhanced 
phagocytosis of Mycobacterium tuberculosis by a direct interaction 
with human macrophages. ] Immunol155:5343-51 
Golden MP, Vikram HR. 2005. Extrapulmonary tuberculosis: an overview. 
Am Fam Physician 72:1761-8 
Goletti D, Carrara 5, Mayanja-Kizza H, Baseke J, Mugerwa MA, et al. 2008. 
Response to M. tuberculosis selected RD1 peptides in Ugandan HIV-
infected patients with smear positive pulmonary tuberculosis: a pilot 
study. BMC Infect Dis 8:11 
Goletti D, Carrara 5, Vincenti D, Girardi E. 2007. T cell responses to 
commercial mycobacterium tuberculosis-specific antigens in HIV-
infected patients. Clin Infect Dis 45:1652-4 
Goletti D, Carrara 5, Vincenti D, 5altini C, Rizzi EB, et al. 2006. Accuracy of 
an immune diagnostic assay based on RD1 selected epitopes for active 












Gordin FM, Slutkin G, Schecter G, Goodman PC, Hopewell Pc. 1989. 
Presumptive diagnosis and treatment of pulmonary tuberculosis 
based on radiographic findings. Am Rev Respir Dis 139:1090-3 
Greco 5, Girardi E, Navarra A, Saltini C. 2006. Current evidence on 
diagnostic accuracy of commercially based nucleic acid amplification 
tests for the diagnosis of pulmonary tuberculosis. Thorax 61:783-90 
Griffith DE, Kerr CM. 1996. Tuberculosis: disease of the past, disease of the 
present. J Penanesth Nurs 11:240-5 
Grzybowski 5, Barnett GD, Styblo K. 1975. Contacts of cases of active 
pulmonary tuberculosis. Bull Int Union Tuberc 50:90-106 
Guyot-Revol V, Innes JA, Hackforth 5, Hinks T, Lalvani A. 2006. Regulatory 
T cells are expanded in blood and disease sites in patients with 
tuberculosis. Am J Respir Cnt Care Med 173:803-10 
Hamasur B, Bruchfeld J, Haile M, Pawlowski A, Bjorvatn B, et al. 2001. Rapid 
diagnosis of tuberculosis by detection of mycobacterial 
lipoarabinomannan in urine. J Microbial Methods 45:41-52 
Harada N, Higuchi K, Yoshiyama T, Kawabe Y, Fujita A, et al. 200B. 
Comparison of the sensitivity and specificity of two whole blood 
interferon-gamma assays for M. tuberculosis infection. J Infect 56:348-
53 
Hawgood BJ. 2007. Albert Calmette (1863-1933) and Camille Guerin (1872-
1961): the C and G of BCG vaccine. Journal of medical biography 15:139-
46 
Helb D, Jones M, Story E, Boehme C, Wallace E, et al. 2009. Rapid detection 
of Mycobacterium tuberculosis and rifampin resistance by use of on-
demand, near-patient technology. J Clin Microbial 48:229-37 
Hellyer TJ, Fletcher TW, Bates JH, Stead WW, Templeton GL, et al. 1996. 
Strand displacement amplification and the polymerase chain reaction 
for monitoring response to treatment in patients with pulmonary 
tuberculosis. J Infect Dis 173:934-41 
Higgins J, Metcalf JA, Stevens RA, Baseler M, Nason MC, et al. 2005. Effects 











CD127 expression on T cells in human immunodeficiency virus-
infected patients. Clinical and diagnostic laboratory immunology 12:228-30 
Hill PC, Fox A, Jeffries DJ, Jackson-5illah D, Lugos MD, et al. 2005. 
Quantitative T cell assay reflects infectious load of Mycobacterium 
tuberculosis in an endemic case contact model. Clin Infect Dis 40:273-8 
Hope JC, Villarreal-Ramos B. 2007. Bovine TB and the development of new 
vaccines. Comp Immunol Microbiol Infect Dis 
Houben EN, Nguyen L, Pieters J. 2006. Interaction of pathogenic 
mycobacteria with the host immune system. Curr Opin Microbiol 9:76-
85 
Hougardy JM, Schepers K, Place 5, Drowart A, Lechevin V, et al. 2007. 
Heparin-Binding-Hemagglutinin-Induced IFN-gamma Release as a 
Diagnostic Tool for Latent Tuberculosis. PLoS ONE 2:e926 
Houghton RL, Lodes MJ, Dillon DC, Reynolds LD, Day CH, et al. 2002. Use 
of multiepitope polyproteins in serodiagnosis of active tuberculosis. 
Clinical and diagnostic laboratory immunology 9:883-91 
Iademarco MF, Castro KG. 2003. Epidemiology of tuberculosis. Semin Respir 
Infect 18:225-40 
Jafari C, Thijsen 5, 50tgiu G, Goletti D, Benitez JA, et al. 2009. 
Bronchoalveolar lavage enzyme-linked immunospot for a rapid 
diagnosis of tuberculosis: a Tuberculosis Network European 
Trialsgroup study. Am J Respir Crit Care Med 180:666-73 
Janeway CA, Jr., Medzhitov R. 2002. Innate immune recognition. Annual 
review of immunology 20:197-216 
Kang YA, Lee HW, Hwang 55, Urn 5W, Han 5K, et al. 2007. Usefulness of 
whole-blood interferon-{gamma} assay and interferon-{gamma} 
enzyme-linked immunospot assay in the diagnosis of active 
pulmonary tuberculosis. Chest 132:959-65 
Kaplan G, Luster AD, Hancock G, Cohn ZA. 1987. The expression of a 
gamma interferon-induced protein (IP-10) in delayed immune 
responses in human skin. J Exp Med 166:1098-108 
Kaul KL. 2001. Molecular detection of Mycobacterium tuberculosis: impact 











Knutson KL, Hmama Z, Herrera-Velit P, Rochford R, Reiner NE. 1998. 
Lipoarabinomannan of Mycobacterium tuberculosis promotes protein 
tyrosine dephosphorylation and inhibition of mitogen-activated 
protein kinase in human mononuclear phagocytes. Role of the Src 
homology 2 containing tyrosine phosphatase 1. J BioI Chem 273:645-52 
Kobashi Y, Mouri K, Yagi 5, Obase Y, Fukuda M, et al. 2008. Usefulness of 
the QuantiFERON TB-2G test for the differential diagnosis of 
pulmonary tuberculosis. Internal medicine (Tokyo, Japan) 47:237-43 
Kobashi Y, Obase Y, Fukuda M, Yoshida K, Miyashita N, et al. 2007. 
Usefulness of QuantiFERON TB-2G, a diagnostic method for latent 
tuberculosis infection, in a contact investigation of health care 
workers. Internal medicine (Tokyo, Japan) 46:1543-9 
Koch MA, Tucker-Heard G, Perdue NR, Killebrew JR, Urdahl KB, Campbell 
DJ. 2009. The transcription factor T-bet controls regulatory T cell 
homeostasis and function during type 1 inflammation. Nature 
immunology 10:595-602 
Kubica G, Wayne L. 1984. Clinical microbiology. The Mycobacteria: a 
Sourcebook, Part A,. pp. 133-75. New York: Marcel Dekker 
Kumar VA, Abul K.; Fausto, Nelson; & Mitchell, Richard N. 2007. Robbins 
Basic Pathology pp. 516-22 Saunders Elsevier. 
Lalvani A. 2007. Diagnosing tuberculosis infection in the 21st century: new 
tools to tackle an old enemy. Chest 131:1898-906 
Lalvani A, Millington KA. 2008. T-cell interferon-gamma release assays: can 
we do better? Eur Respir J 32:1428-30 
Lalvani A, Nagvenkar P, Udwadia Z, Pathan AA, Wilkinson KA, et al. 200la. 
Enumeration of T cells specific for RD1-encoded antigens suggests a 
high prevalence of latent Mycobacterium tuberculosis infection in 
healthy urban Indians. J Infect Dis 183:469-77 
Lalvani A, Pathan AA, McShane H, Wilkinson RJ, Latif M, et al. 200lb. Rapid 
detection of Mycobacterium tuberculosis infection by enumeration of 











Lawn SD, Edwars DJ, Kramer K, Vogt M, Bekker L-G, Wood R. 2009. Urine 
lipoarabinomannan assay for tuberculosis screening prior to ART: 
diagnostic yield and association with immune reconstitution disease. 
Lee RE, Brennan PJ, Besra GS. 1996. Mycobacterium tuberculosis cell 
envelope. Curr Top Microbiol Immunol215:1-27 
Liam CK, Chen YC, Yap SF, Srinivas P, Poi PJ. 1998. Detection of 
Mycobacterium tuberculosis in bronchoalveolar lavage from patients 
with sputum smear-negative pulmonary tuberculosis using a 
polymerase chain reaction assay. Respirology (Carlton, Vic 3:125-9 
Ling DI, Flores LL, Riley LW, Pai M. 2008. Commercial nucleic-acid 
amplification tests for diagnosis of pulmonary tuberculosis in 
respiratory specimens: meta-analysis and meta-regression. PLoS ONE 
3:e1536 
Lipscomb MF, Masten BJ. 2002. Dendritic cells: immune regulators in health 
and disease. Physiological reviews 82:97-130 
Liu XQ, Dosanjh D, Varia H, Ewer K, Cockle P, et al. 2004. Evaluation of T-
cell responses to novel RD1- and RD2-encoded Mycobacterium 
tuberculosis gene products for specific detection of human 
tuberculosis infection. Infect Immun 72:2574-81 
Lyashchenko K, Colangeli R, Houde M, Al Jahdali H, Menzies D, Gennaro 
ML. 1998. Heterogeneous antibody responses in tuberculosis. Infect 
Immun 66:3936-40 
Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, et al. 2009. LTBI: latent 
tuberculosis infection or lasting immune responses to M. tuberculosis? 
A TBNET consensus statement. Eur Respir ] 33:956-73 
Malik AN, Godfrey-Faussett P. 2005. Effects of genetic variability of 
Mycobacterium tuberculosis strains on the presentation of disease. The 
Lancet infectious diseases 5:174-83 
McKenna KC, Beatty KM, Vicetti Miguel R, Bilonick RA. 2008. Delayed 
processing of blood increases the frequency of activated CD11 b+ 
CD15+ granulocytes which inhibit T cell function. ] Immunol Methods 
Meier T, Eulenbruch HP, Wrighton-Smith P, Enders G, Regnath T. 2005. 











SPOT -TB) for diagnosis of tuberculosis in clinical practice. Eur J Clin 
Microbial Infect Dis 24:529-36 
Menozzi FDf Rouse JH, Alavi M, Laude-Sharp M, Muller J, et al. 1996. 
Identification of a heparin-binding hemagglutinin present in 
mycobacteria. J Exp Med 184:993-1001 
Menzies D. 2008. Using tests for latent tuberculous infection to diagnose 
active tuberculosis: can we eat our cake and have it too? Annals of 
internal medicine 148:398-9 
Menzies D, Pai M, Comstock G. 2007. Meta-analysis: new tests for the 
diagnosis of latent tuberculosis infection: areas of uncertainty and 
recommendations for research. Annals of internal medicine 146:340-54 
Mol CJ, Koethe SM. 2006. QuantiFERON-TB GOLD--An innovation in 
tuberculosis screening. Aaohn J 54:245-7 
Monkongdee P, McCarthy KD, Cain KP, Tasaneeyapan T, Nguyen HD, et al. 
2009. Yield of acid-fast smear and mycobacterial culture for 
tuberculosis diagnosis in people with human immunodeficiency virus. 
Am J Respir Crit Care Med 180:903-8 
Moore DA, Evans CA, Gilman RH, Caviedes L, Coronel J, et al. 2006. 
Microscopic-observation drug-susceptibility assay for the diagnosis of 
TB. N Engl J Med 355:1539-50 
Moore DA, Roper MH. 2007. Diagnosis of smear-negative tuberculosis in 
people with HIV / AIDS. Lancet 370:1033-4 
Mortier E, Pouchot J, Girard L, Boussougant Y, Vinceneux P. 1996. 
Assessment of urine analysis for the diagnosis of tuberculosis. BMJ 
312:27-8 
Mutetwa R, Boehme C, Dimairo M, Mangwanya D, Munyati S, et al. 2009. 
Diagnostic accuracy of commercial urinary 
lipoarabinomannandetection in African TB suspects and patients. The 
International Journal of Tuberculosis and Lung Disease 
Nathan C, Shiloh MU. 2000. Reactive oxygen and nitrogen intermediates in 
the relationship between mammalian hosts and microbial pathogens. 












Ng VH, Cox JS, Sousa AO, MacMicking JD, McKinney JD. 2004. Role of KatG 
catalase-peroxidase in mycobacterial pathogenesis: countering the 
phagocyte oxidative burst. Molecular microbiology 52:1291-302 
Nguyen L, Pieters J. 2006. Battle for survival: interplay between pathogenic 
mycobacteria and the host immune system. Discov Med 6:82-6 
Noss EH, Pai RK, Sellati TJ, Radolf JD, Belisle J, et al. 2001. Toll-like receptor 
2-dependent inhibition of macrophage class II MHC expression and 
antigen processing by 19-kDa lipoprotein of Mycobacterium 
tuberculosis. J ImmunoI167:910-8 
Nour EM, Cherian BP, Quantrill SJ. 2007. Diagnostic yield of early morning 
urine samples in the diagnosis of tuberculosis. QJM 100:464-5 
O'Connor TM, Sheehan 5, Cryan B, Brennan N, Bredin CPo 2000. The ligase 
chain reaction as a primary screening tool for the detection of culture 
positive tuberculosis. Thorax 55:955-7 
Okamoto M, Kawabe T, Iwasaki Y, Hara T, Hashimoto N, et al. 2005. 
Evaluation of interferon-gamma, interferon-gamma-inducing 
cytokines, and interferon-gamma-inducible chemokines in 
tuberculous pleural effusions. J Lab Clin Med 145:88-93 
Onyebujoh P, Rook GA. 2004. Tuberculosis. Nat Rev Microbiol 2:930-2 
Orme I. 2004. Adaptive immunity to mycobacteria. Curr Opin Microbiol 7:58-
61 
Oxford Immunotec Ltd. 2009. T-Cell Xtend™ [mechanism of action}, 
http://www.youtube.comlwatch?v=VAsezk74TkE&{eature=youtube...gdata, 
Retrieved 25/09/2009. 
Pai M, Flores LL, Hubbard A, Riley LW, Colford JM, Jr. 2004. Nucleic acid 
amplification tests in the diagnosis of tuberculous pleuritis: a 
systematic review and meta-analysis. BMC Infect Dis 4:6 
Pai M, Flores LL, Pai N, Hubbard A, Riley LW, Colford JM, Jr. 2003. 
Diagnostic accuracy of nucleic acid amplification tests for tuberculous 












Pai M, Gardam M, Haldane D. 2008a. Canadian Tuberculosis Committee: 
Updated recommendations on interferon gamma release assays for 
latent tuberculosis infection. Can Commun Dis Rep 2008., pp. 1-12 
Pai M, Joshi R, Dogra 5, Mendiratta DK, Narang P, et al. 2006a. Persistently 
elevated T cell interferon-gamma responses after treatment for latent 
tuberculosis infection among health care workers in India: a 
preliminary report. J Occup Med Toxicol1:7 
Pai M, Joshi R, Dogra 5, Mendiratta DK, Narang P, et al. 2006b. Serial testing 
of health care workers for tuberculosis using interferon-gamma assay. 
Am J Respir Crit Care Med 174:349-55 
Pai M, Kalantri 5, Dheda K. 2006c. New tools and emerging technologies for 
the diagnosis of tuberculosis: part II. Active tuberculosis and drug 
resistance. Expert Rev Mol Diagn 6:423-32 
Pai M, Kalantri 5, Menzies D. 2006d. Discordance between tuberculin skin 
test and interferon-gamma assays. Int J Tuberc Lung Dis 10:942-3 
Pai M, Ling D1. 2008. Rapid diagnosis of extra ulmonary tuberculosis using 
nucleic acid amplification tests: what is the evidence? Future 
microbiology 3:1-4 
Pai M, Menzies D. 2007a. Interferon-gamma release assays: what is their role 
in the diagnosis of active tuberculosis? . Clin Infect Dis 44:74-7 
Pai M, Menzies D. 2007b. The New IGRA and the Old TST: Making Good 
Use of Disagreement. Am J Respir Crit Care Med 175:529-31 
Pai M, Minion J, Sohn H, Zwerling A, Perkins MD. 2009. Novel and 
improved technologies for tuberculosis diagnosis: progress and 
challenges. Clinics in chest medicine 30:701-16, viii 
Pai M, O'Brien R. 2007. Serial Testing for Tuberculosis: Can We Make Sense 
of T Cell Assay Conversions and Reversions? PLoS Med 4:e208 
Pai M, Zwerling AI Menzies D. 2008b. Systematic review: T-cell-based assays 
for the diagnosis of latent tuberculosis infection: an update. Annals of 
internal medicine 149:177-84 
Patel VB, Singh R, Connolly C, Coovadia Y, Peer AKI et al. 2010. 











Meningitis in a HIV and TB Endemic Population. Am J Respir Crit Care 
Med 
Pathan AA, Wilkinson KA, Klenerman P, McShane H, Davidson RN, et al. 
2001. Direct ex vivo analysis of antigen-specific IFN-gamma-secreting 
CD4 T cells in Mycobacterium tuberculosis-infected individuals: 
associations with clinical disease state and effect of treatment. J 
ImmunoI167:5217-25 
Pereira Arias-Bouda LM, Nguyen LN, Ho LM, Kuijper 5, Jansen HM, Kolk 
AH. 2000. Development of antigen detection assay for diagnosis of 
tuberculosis using sputum samples. J Clin MicrobioI38:2278-83 
Perkins MD, Roscigno G, Zumla A. 2006. Progress towards improved 
tuberculosis diagnostics for developing countries. Lancet 367:942-3 
Peter J, Green C, Hoelscher M, Mwaba P, Zumla A, Dheda K. 2010. Urine for 
the diagnosis of tuberculosis: current approaches, clinical 
applicability, and new developments. Current opinion in pulmonary 
medicine 16:262-70 
Pethe K, Alonso 5, Biet F, Delogu G, Brennan MJ, et al. 2001. The heparin-
binding haemagglutinin of M. tuberculosis is required for 
extrapulmonary dissemination. Nature 412:190-4 
Pfyffer GE, Cieslak C, Welscher HM, Kissling P, Rusch-Gerdes 5.1997. Rapid 
detection of mycobacteria in clinical specimens by using the 
automated BACTEC 9000 MB system and comparison with 
radiometric and solid-culture systems. J Clin Microbiol 35:2229-34 
Piersimoni C, Scarparo C. 2003. Relevance of commercial amplification 
methods for direct detection of Mycobacterium tuberculosis complex 
in clinical samples. J Clin MicrobioI41:5355-65 
Prescott L, Harley J, Klein D. 2005. Microbiology 6th edition. pp. 8t, 674-702 and 
882-4. New York: McGraw-Hill. 
QuantiFERON®-TB Gold In-Tube [Package Insert], Cellestis Ltd., Australia. 
2007. 
Raby E, Moyo M, Devendra A, Banda J, De Haas P, et al. 2008. The effects of 
HIV on the sensitivity of a whole blood IFN-gamma release assay in 











Rangaka MX, Diwakar L, Seldon R, van Cutsem G, Mein~es GA, et al. 2007. 
Clinical, immunological, and epidemiological importance of 
antituberculosis T cell responses in HIV-infected Africans. Clin Infect 
Dis 44:1639-46 
Rantakokko-Jalava K, Marjamaki M, Marttila H, Makela L, Valtonen V, 
Viljanen MK. 2001. LCx Mycobacterium tuberculosis assay is valuable 
with respiratory specimens, but provides little help in the diagnosis of 
extra pulmonary tuberculosis. Ann Med 33:55-62 
Read SW, Rupert A, Stevens R, O'Shea A, Sereti 1. 2006. Delayed sample 
processing leads to marked decreases in measured plasma IL-7Ievels. 
J Acquir Immune Defic Syndr 42:511-2 
Reither K, Saathoff E, Jung J, Minja L, Kroidl I, et al. 2009. Low sensitivity of a 
urine LAM-ELISA in the diagnosis of pulmonary tuberculosis. 
Ribeiro S, Dooley K, Hackman J, Loredo C, Efron A, et al. 2009. T-SPOT.TB 
responses during treatment of pulmonary tuberculosis. BMC Infect Dis 
9:23 
Richeldi L, Ewer K, Losi M, Hansell DM, Roversi P, et al. 2004. Early 
diagnosis of subclinical multidrug-resistant tuberculosis. Annals of 
internal medicine 140:709-13 
Romani L, Puccetti P, Bistoni F. 1997. Interleukin-12 in infectious diseases. 
Clinical microbiology reviews 10:611-36 
Rothel JS, Andersen P. 2005. Diagnosis of latent Mycobacterium tuberculosis 
infection: is the demise of the Mantoux test imminent? Expert review of 
anti-infective therapy 3:981-93 
Ruhwald M, Bjerregaard-Andersen M, Rabna P, Kofoed K, Eugen-Olsen J, 
Ravn P. 2007. CXCL10jIP-10 release is induced by incubation of 
whole blood from tuberculosis patients with ESAT-6, CFP10 and 
TB7.7. Microbes and infection /Institut Pasteur 9:806-12 
Russell DG. 2001. Mycobacterium tuberculosis: here today, and here 
tomorrow. Nat Rev Mol Cell BioI 2:569-77 
Sada E, Brennan PJ, Herrera T, Torres M. 1990. Evaluation of 












Sarmiento OL, Weigle KA, Alexander J, Weber DJ, Miller We. 2003. 
Assessment by meta-analysis of PCR for diagnosis of smear-negative 
pulmonary tuberculosis. J Clin MicrobioI41:3233-40 
Schlesinger LS. 1993. Macrophage phagocytosis of virulent but not 
attenuated strains of Mycobacterium tuberculosis is mediated by 
mannose receptors in addition to complement receptors. J Immunol 
150:2920-30 
Shah M, Variava E, Holmes CB, Coppin A, Golub JE, et al. 2009. Diagnostic 
Accuracy of a Urine Lipoarabinomannan Test for Tuberculosis in 
Hospitalized Patients in a High HIV Prevalence Setting. J Acquir 
Immune Defic Syndr 
Shin AR, Lee KS, Lee JS, Kim SY, Song CH, et al. 2006. Mycobacterium 
tuberculosis HBHA protein reacts strongly with the serum 
immunoglobulin M of tuberculosis patients. Clin Vaccine Immunol 
13:869-75 
Sittampalam GS, Smith WC, Miyakawa TW, Smith DR, McMorris e. 1996. 
Application of experimental design techniques to optimize a 
competitive ELISA. J Immunol Methods 190:151-61 
Smith L 2003. Mycobacterium tuberculosis pathogenesis and molecular 
determinants of virulence. Clinical microbiology reviews 16:463-96 
Steingart KR, Henry M, Ng V, Hopewell PC, Ramsay A, et al. 2006. 
Fluorescence versus conventional sputum smear microscopy for 
tuberculosis: a systematic review. Lancet Infect Dis 6:570-81 
T-cell XtendTM [package insert], Oxford Immunotec Ltd. Oxford, England. 
2008. 
T-SPOT®.TB [package insert], Oxford Immunotec Ltd. Oxford, England. 2008. 
Tan YK, Lee AS, Khoo KL, Ong SY, Wong SY, Ong YY. 1999. Rapid 
mycobacterial tuberculosis detection in bronchoalveolar lavage 
samples by polymerase chain reaction in patients with upper lobe 
infiltrates and bronchiectasis. Ann Acad Med Singapore 28:205-8 
Temmerman S, Pethe K, Parra M, Alonso S, Rouanet C, et al. 2004. 
Methylation-dependent T cell immunity to Mycobacterium 











Tessema TA, Hamasur B, Bjun G, Svenson S, Bjorvatn B. 2001. Diagnostic 
evaluation of urinary lipoarabinomannan at an Ethiopian tuberculosis 
centre. Scand J Infect Dis 33:279-84 
Thoen C, Lobue P, de Kantor I. 2006. The importance of Mycobacterium 
bovis as a zoonosis. Vet MicrobioI112:339-45 
Thomas MM, Hinks TS, Raghuraman S, Ramalingam N, Ernst M, et al. 2008. 
Rapid diagnosis of Mycobacterium tuberculosis meningitis by 
enumeration of cerebrospinal fluid antigen-specific T -cells. Int J Tuberc 
Lung Dis 12:651-7 
Todd B. 2006. The QuantiFERON-TB Gold Test: a new blood assay offers a 
promising alternative in tuberculosis testing. Am J Nurs 106:33-4, 7 
Tueller C, Chhajed PN, Buitrago-Tellez C, Frei R, Frey M, Tamm M. 2005. 
Value of smear and PCR in bronchoalveolar lavage fluid in culture 
positive pulmonary tuberculosis. Eur Respir J 26:767-72 
Turner J, Corrah T, Sabbally S, Whittle H, Dockrell HM. 2000. A longitudinal 
study of in vitro IFNgamma production and cytotoxic T cell responses 
of tuberculosis patients in the gambia. Tuber Lung Dis 80:161-9 
Ulrichs T, Anding P, Porcelli S, Kaufmann SH, Munk ME. 2000a. Increased 
numbers of ESAT -6- and purified protein derivative-specific gamma 
interferon-producing cells in subclinical and active tuberculosis 
infection. Infect Immun 68:6073-6 
Ulrichs T, Anding R, Kaufmann SH, Munk ME. 2000b. Numbers of IFN-
gamma-producing cells against ESAT-6 increase in tuberculosis 
patients during chemotherapy. Int J Tuberc Lung Dis 4:1181-3 
van Zyl-Smit RN, Pai M, Peprah K, Meldau R, Kieck J, et al. 2009. Within-
subject variability and boosting of T-cell interferon-gamma responses 
after tuberculin skin testing. Am J Respir Crit Care Med 180:49-58 
Vaneechoutte M, Van Eldere J. 1997. The possibilities and limitations of 
nucleic add amplification technology in diagnostic microbiology. 
Journal of medical microbiology 46:188-94 
Vincenti D, Carrara 5, Butera 0, Bizzoni P, Casetti R, et al. 2007. Response to 
region of difference 1 (RD1) epitopes in human immunodeficiency 











tuberculosis: a pilot study. Clinical and experimental immunology 150:91-
8 
Wagstaff AJ, Zellweger JP. 2006. T-SPOT.TB: an in vitro diagnostic assay 
measuring T-cell reaction to Mycobacterium tuberculosis-specific 
antigens. Mol Diagn Ther 10:57-63; discussion 4-5 
Walzl G, Ronacher K, Djoba Siawaya JF, Dockrell HM. 2008. Biomarkers for 
TB treatment response: challenges and future strategies. J Infect 57:103-
9 
Wilkinson KA, Kon OM, Newton SM, Meintjes G, Davidson RN, et al. 2006. 
Effect of Treatment of Latent Tuberculosis Infection on the T Cell 
Response to Mycobacterium tuberculosis Antigens. J Infect Dis 
193:354-9 
Wilkinson KA, Wilkinson RJ, Pathan A, Ewer K, Prakash M, et al. 2005. Ex 
vivo characterization of early secretory antigenic target 6-specific T 
cells at sites of active disease in pleural tuberculosis. Clin Infect Dis 
40:184-7 
Wilson D, Nachega J, Morroni C, Chaisson R, Maartens G. 2006. Diagnosing 
smear-negative tuberculosis using case definitions and treatment 
response in HIV-infected adults. Int J Tuberc Lung Dis 10:31-8 
Xpert® MTBjRIF [Package Insert], Cepheid. Sunnyvale CA, VS. 2009. 
Zink A, Haas CJ, Reischl V, Szeimies V, Nerlich AG. 2001. Molecular analysis 
of skeletal tuberculosis in an ancient Egyptian population. Journal of 
medical microbiology 50:355-66 
145 
